<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000028.pub2" GROUP_ID="HTN" ID="952099102611370642" MERGED_FROM="" MODIFIED="2010-11-10 05:32:00 +0100" MODIFIED_BY="Ciprian Jauca" REVIEW_NO="A001" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="14.0">
<COVER_SHEET MODIFIED="2010-11-10 05:32:00 +0100" MODIFIED_BY="Ciprian Jauca">
<TITLE>Pharmacotherapy for hypertension in the elderly</TITLE>
<CONTACT MODIFIED="2010-11-10 05:32:00 +0100" MODIFIED_BY="Ciprian Jauca"><PERSON ID="14182" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vijaya</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Musini</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>vijaya@ti.ubc.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anesthesiology, Pharmacology and Therapeutics</DEPARTMENT><ORGANISATION>University of British Columbia</ORGANISATION><ADDRESS_1>2176 Health Science Mall</ADDRESS_1><CITY>Vancouver</CITY><ZIP>V6T 1Z3</ZIP><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 604 827 3655</PHONE_1><PHONE_2>+1 604 822 0700</PHONE_2><FAX_1>+1 604 822 0701</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-11-10 05:32:00 +0100" MODIFIED_BY="Ciprian Jauca"><PERSON ID="14182" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vijaya</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Musini</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>vijaya@ti.ubc.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anesthesiology, Pharmacology and Therapeutics</DEPARTMENT><ORGANISATION>University of British Columbia</ORGANISATION><ADDRESS_1>2176 Health Science Mall</ADDRESS_1><CITY>Vancouver</CITY><ZIP>V6T 1Z3</ZIP><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 604 827 3655</PHONE_1><PHONE_2>+1 604 822 0700</PHONE_2><FAX_1>+1 604 822 0701</FAX_1></ADDRESS></PERSON><PERSON ID="ED920D7A82E26AA20107072394F68C15" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Aaron</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Tejani</LAST_NAME><POSITION>Coordinator, drug information and clinical research</POSITION><EMAIL_1>Aaron.Tejani@fraserhealth.ca</EMAIL_1><MOBILE_PHONE>+1 (604) 614-3443</MOBILE_PHONE><ADDRESS><DEPARTMENT>Pharmacy Services</DEPARTMENT><ORGANISATION>Fraser Health Authority</ORGANISATION><ADDRESS_1>3935 Kincaid Street</ADDRESS_1><CITY>Burnaby</CITY><ZIP>V5G 2X6</ZIP><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+16044312875</PHONE_1><FAX_1>+16044126187</FAX_1></ADDRESS></PERSON><PERSON ID="14156" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ken</FIRST_NAME><LAST_NAME>Bassett</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>bassett@chspr.ubc.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anesthesiology, Pharmacology and Therapeutics</DEPARTMENT><ORGANISATION>University of British Columbia</ORGANISATION><ADDRESS_1>2176 Health Sciences Mall</ADDRESS_1><CITY>Vancouver</CITY><ZIP>V6T 1Z3</ZIP><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1-604-822-3130</PHONE_1><PHONE_2>+1-604-822-0700</PHONE_2><FAX_1>+1-604-822-0701</FAX_1></ADDRESS></PERSON><PERSON ID="5489" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Wright</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>jim.wright@ti.ubc.ca</EMAIL_1><URL>http://hypertension.cochrane.org/James-Wright</URL><ADDRESS><DEPARTMENT>Department of Anesthesiology, Pharmacology and Therapeutics</DEPARTMENT><ORGANISATION>University of British Columbia</ORGANISATION><ADDRESS_1>2176 Health Sciences Mall</ADDRESS_1><CITY>Vancouver</CITY><ZIP>V6T 1Z3</ZIP><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1-604-822-4270</PHONE_1><PHONE_2>+1-604-822-0700</PHONE_2><FAX_1>+1-604-822-0701</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-10-26 18:10:44 -0700" MODIFIED_BY="Vijaya Musini">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="12" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="5" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2010-11-01 12:37:48 -0700" MODIFIED_BY="Vijaya M Musini">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-01 12:37:48 -0700" MODIFIED_BY="Vijaya M Musini">
<DATE DAY="1" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Added links to Figures in the result section (to the Forest plots of the primary and secondary outcome measures) which were initially refered to as links in the Data and Analysis section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-27 00:02:14 -0700" MODIFIED_BY="Vijaya M Musini">
<DATE DAY="27" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Corrected denominator of the STOP trial for total mortality from 22 to 122 in the hypertension in very elderly subgroup</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-11-11 20:15:52 -0800" MODIFIED_BY="Ciprian D Jauca">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-08-11 15:55:10 -0700" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="11" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Excluded HDFP trial since it is a multi-interventional study.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-11-11 20:15:52 -0800" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="11" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>substantive update, authors and conclusions have changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-08-11 13:19:16 -0700" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="28" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>New feedback received 28 October 2008.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 15:10:20 -0800" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-08-13 02:38:59 -0700" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="5" MONTH="6" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-08-13 02:38:04 -0700" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="17" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-06-30 13:53:52 -0700" MODIFIED_BY="James M Wright">
<INTERNAL_SOURCES MODIFIED="2009-06-30 13:53:05 -0700" MODIFIED_BY="James M Wright">
<SOURCE MODIFIED="2009-06-30 13:50:59 -0700" MODIFIED_BY="James M Wright">
<NAME>Department of Anesthesiology, Pharmacology &amp; Therapeutics, University of BC</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P>Office space</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-06-30 13:53:52 -0700" MODIFIED_BY="James M Wright">
<SOURCE MODIFIED="2009-06-30 13:53:52 -0700" MODIFIED_BY="James M Wright">
<NAME>CIHR grant to the Hypertension Review Group</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P>Infrastructure</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-11-08 21:30:02 -0800" MODIFIED_BY="James M Wright">
<SUMMARY MODIFIED="2009-07-13 09:49:19 -0700" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-07-13 09:49:19 -0700" MODIFIED_BY="[Empty name]">Blood pressure lowering drugs reduce stroke and heart attack in elderly people with hypertension</TITLE>
<SUMMARY_BODY MODIFIED="2009-07-12 09:18:02 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Hypertension (high blood pressure) is common among elderly people and increases the risk of heart attack and stroke. An assessment of all the trials of blood pressure lowering therapy in people with hypertension 60 years and over showed that treatment reduced death, strokes and heart attacks. The benefit was similar if both the upper and lower number was elevated or only the upper number. In people 80 and over treatment did not reduce death but did reduce stroke. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-11 10:53:53 -0700" MODIFIED_BY="James M Wright">
<ABS_BACKGROUND MODIFIED="2009-07-14 14:14:08 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Elevated blood pressure (known as hypertension) increases with age, and most rapidly over age 60.  Systolic hypertension is more strongly associated with cardiovascular disease than diastolic hypertension, and occurs more commonly in older people.  It is important to know the benefits and harms of antihypertensive treatment of hypertension in this age group.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-08-11 09:40:25 -0700" MODIFIED_BY="James M Wright">
<P>To quantify antihypertensive drug effect on overall mortality, cardiovascular mortality and morbidity and withdrawal due to adverse effects in people 60 years and older with mild to moderate systolic or diastolic hypertension.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-11 09:40:49 -0700" MODIFIED_BY="James M Wright">
<P>Updated search of electronic database of EMBASE, CENTRAL, MEDLINE until Dec 2008; previous search of two Japanese databases (1973-1995) and WHO-ISH Collaboration register (August 1997); references from reviews, trials and previously published meta-analyses; and experts.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-14 14:12:01 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Randomized controlled trials of at least one year duration in hypertensive elders (at least 60 years old) comparing antihypertensive drug therapy with placebo or no treatment and providing morbidity and mortality data.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-11 09:41:45 -0700" MODIFIED_BY="James M Wright">
<P>Outcomes assessed were total mortality<B> </B>(including cardiovascular, coronary heart disease and cerebrovascular mortality); total cardiovascular morbidity and mortality (representing combined coronary heart disease and cerebrovascular morbidity and mortality); and withdrawal due to adverse events.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-11 10:53:53 -0700" MODIFIED_BY="James M Wright">
<P>Fifteen trials (24,055 subjects &#8805; 60 years) with moderate to severe hypertension were identified.  These trials mostly evaluated first-line thiazide diuretic therapy for a mean duration of treatment of 4.5 years. Treatment reduced total mortality, RR 0.90 (0.84, 0.97); event rates per 1000 participants reduced from 116 to 104.  Treatment also reduced total cardiovascular morbidity and mortality, RR 0.72 (0.68, 0.77); event rates per 1000 participants reduced from 149 to 106. In the three trials restricted to persons with isolated systolic hypertension the benefit was similar. In very elderly patients &#8805; 80 years the reduction in total cardiovascular mortality and morbidity was similar RR 0.75 [0.65, 0.87] however, there was no reduction in total mortality, RR 1.01 [0.90, 1.13].  Withdrawals due to adverse effects were increased with treatment, RR 1.71 [1.45, 2.00].</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-08-11 09:42:22 -0700" MODIFIED_BY="James M Wright">
<P>Treating healthy persons (60 years or older) with moderate to severe systolic and/or diastolic hypertension reduces all cause mortality and cardiovascular morbidity and mortality. The decrease in all cause mortality was limited to persons 60 to 80 years of age.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-08 21:30:02 -0800" MODIFIED_BY="James M Wright">
<BACKGROUND MODIFIED="2009-08-11 16:02:12 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Blood pressure increases with age, and the rate of rise is greater over age 60. As a result the number of people with elevated blood pressure (known as hypertension) increases with age. Systolic blood pressure is more strongly associated with cardiovascular disease than diastolic blood pressure particularly in older people. Isolated systolic hypertension occurs more commonly in older people. Older people also accumulate higher rates of other risk factors for cardiovascular disease including obesity, left ventricular hypertrophy, sedentary life style, hyperlipidemia, and diabetes.</P>
<P>Most of the early trials evaluating antihypertensive drug therapy were conducted in lower risk people under age 60.  The first definitive clinical trial evidence supporting blood pressure lowering treatment was produced in the mid-1980s. Before that time, policymakers and clinicians were reluctant to recommend treatment particularly in the elderly; some regarded systolic hypertension as a natural feature of aging, while others feared excessive harm from blood pressure lowering in this age group.</P>
<P>Since 1985, several large trials have been conducted, and several meta-analyses have summarized their results (<LINK REF="REF-Davidson-1987" TYPE="REFERENCE">Davidson 1987</LINK>, <LINK REF="REF-Staessen-1988" TYPE="REFERENCE">Staessen 1988</LINK>, <LINK REF="REF-Staessen-1990a" TYPE="REFERENCE">Staessen 1990a</LINK>, <LINK REF="REF-Staessen-1990b" TYPE="REFERENCE">Staessen 1990b</LINK>, <LINK REF="REF-Leonetti-1992" TYPE="REFERENCE">Leonetti 1992</LINK>, <LINK REF="REF-Thijs-1992" TYPE="REFERENCE">Thijs 1992</LINK>, <LINK REF="REF-Celis-1993" TYPE="REFERENCE">Celis 1993</LINK>, <LINK REF="REF-MacMahon-1993" TYPE="REFERENCE">MacMahon 1993</LINK>, <LINK REF="REF-Thijs-1994" TYPE="REFERENCE">Thijs 1994</LINK>, <LINK REF="REF-Insua-1994" TYPE="REFERENCE">Insua 1994</LINK>, <LINK REF="REF-Pearce-1995" TYPE="REFERENCE">Pearce 1995</LINK>, <LINK REF="REF-Wright-JM-1999" TYPE="REFERENCE">Wright JM 1999</LINK>, <LINK REF="REF-Gueyffier-F-1999" TYPE="REFERENCE">Gueyffier F 1999</LINK>, <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>, <LINK REF="REF-Musini-VM-2008" TYPE="REFERENCE">Musini VM 2008</LINK>). The purpose of this systematic review is to summarize all the available evidence for the benefits and harms of antihypertensive treatment for people aged 60 and above.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-08-11 13:30:45 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>
<B>Primary:</B>
</P>
<P>1. To quantify antihypertensive drug effect on overall mortality in people 60 years and older with mild to moderate systolic or diastolic hypertension.</P>
<P>
<B>Secondar</B>y:</P>
<P>2. To quantify antihypertensive drug effect on cardiovascular specific morbidity and mortality in people 60 years and older with mild to moderate systolic or diastolic hypertension.</P>
<P>3. To quantify withdrawal due adverse events.</P>
<P>Planned subgroup analyses included patients with isolated systolic hypertension and the very elderly people 80 years or older.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-11 16:07:43 -0700" MODIFIED_BY="Ciprian D Jauca">
<SELECTION_CRITERIA MODIFIED="2009-08-11 16:02:48 -0700" MODIFIED_BY="Ciprian D Jauca">
<CRIT_STUDIES MODIFIED="2009-07-12 09:24:04 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Only randomized controlled trials of at least one year duration were included. Trials must have included a control group that either received a placebo or received no anti-hypertensive therapy. Trials that compared two specific antihypertensive therapies were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-12 09:24:02 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Trials must include only people 60 or older or separately report outcomes for people 60 or older. Participants must have a systolic blood pressure of at least 140 mmHg and/or a diastolic blood pressure of at least 90 mmHg at baseline.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-12 09:34:54 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Acceptable anti-hypertensive drug therapies include: angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, beta adrenergic blockers, combined alpha and beta blockers, calcium-channel blockers, diuretics, alpha adrenergic blockers, central sympatholytics, direct vasodilators or peripheral adrenergic antagonists. Drugs could have been administered alone or in combination or in fixed or stepped up regimens.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-08-11 16:02:48 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Morbidity and mortality were defined as follows:</P>
<UL>
<LI>Total mortality means deaths from all causes.</LI>
<LI>Coronary heart disease (CHD) mortality includes fatal myocardial infarctions and sudden or rapid cardiac death.</LI>
<LI>Cerebrovascular mortality includes fatal strokes.</LI>
<LI>Cardiovascular mortality sums coronary heart disease mortality and cerebrovascular mortality.</LI>
<LI>CHD morbidity and mortality includes fatal and non fatal myocardial infarctions and sudden or rapid cardiac death.</LI>
<LI>Cerebrovascular morbidity and mortality includes fatal and nonfatal strokes.</LI>
<LI>Cardiovascular morbidity and mortality includes CHD plus cerebrovascular morbidity and mortality plus aneurysms, congestive heart failure and transient ischemic attacks.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawal due to adverse effects</HEADING>
<P>When the primary trials did not report outcomes with exact definitions as listed above, the review authors categorized data to minimize missing data while maintaining the intended study measures. For example, the Medical Research Council Trial of Treatment of Hypertension in Older Adults (MRCOA) includes "deaths due to hypertension" in its definition of "cardiovascular events". The broad label "deaths due to hypertension" is not included in the standard definition for "cardiovascular morbidity and mortality" listed above. We include MRCOA's results in the cardiovascular morbidity and mortality outcome measure because "deaths due to hypertension" was congruous with the concept of cardiovascular morbidity and mortality. The alternative, omitting MRCOA's data, would result in a more reliable measure but at the expense of accuracy of the effect estimate. The number of differences in definitions was small and is unlikely to affect results. Supporting this assumption, previous meta-analyses found homogeneity of risk reduction among outcome measures suggesting differences in outcome definition were unlikely causes of bias.</P>
<P>One of the new trials included in the update (<LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK>) was not conducted according to the standards of Good Clinical Practice Guidelines and did not collect data on serious adverse events, non-fatal MI or heart failure (personal communication with the author). However, data on cardiovascular mortality and morbidity was reported in the trial and is included in the meta-analysis.</P>
<P>The actual endpoints represented by each outcome measure for each study are listed under the "Outcomes" heading of the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. Within each study the definition of endpoints for each outcome measure are identical between the treatment and control groups. The individual non-fatal outcomes included in the composite endpoint were included as counted by the trialist of each study. Many trials did not report on how events were counted after patients were censored. Refer to personal communication with author of HYVET 2008 trial in the risk of bias table to find out how events were counted in that trial.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-11 13:40:19 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>The following sources were searched:</P>
<P>Updated search of MEDLINE up to Dec. 2008, EMBASE (up to Dec. 2008), CENTRAL (up to Dec. 2008, issue 4). The previous version of this review included search of two Japanese databases: JMEDICINE was searched in the previous review from 1981-1995 and JAPIC-DOC from 1973-1995 with the keywords Hikaku-Shiken (comparative studies), Nijuu-Mouken-Ho (double-blind method) and Hontaisei-Koketsuatsu (hypertension). This search produced 46 articles of which 34 were reports of randomized controlled trials. Titles of the 34 RCTs were translated into English by S Lee-Borges. The abstracts of three possibly relevant trials were translated into English. None met the inclusion criteria of this review.</P>
<P>Thirteen other meta-analyses on antihypertensive drug therapy in the elderly have also been published (<LINK REF="REF-Davidson-1987" TYPE="REFERENCE">Davidson 1987</LINK>, <LINK REF="REF-Staessen-1988" TYPE="REFERENCE">Staessen 1988</LINK>, <LINK REF="REF-Staessen-1990a" TYPE="REFERENCE">Staessen 1990a</LINK>, <LINK REF="REF-Staessen-1990b" TYPE="REFERENCE">Staessen 1990b</LINK>, <LINK REF="REF-Leonetti-1992" TYPE="REFERENCE">Leonetti 1992</LINK>, <LINK REF="REF-Thijs-1992" TYPE="REFERENCE">Thijs 1992</LINK>, <LINK REF="REF-Celis-1993" TYPE="REFERENCE">Celis 1993</LINK>, <LINK REF="REF-MacMahon-1993" TYPE="REFERENCE">MacMahon 1993</LINK>, <LINK REF="REF-Thijs-1994" TYPE="REFERENCE">Thijs 1994</LINK>, <LINK REF="REF-Pearce-1995" TYPE="REFERENCE">Pearce 1995</LINK>, <LINK REF="REF-Wright-JM-1999" TYPE="REFERENCE">Wright JM 1999</LINK>, <LINK REF="REF-Gueyffier-F-1999" TYPE="REFERENCE">Gueyffier F 1999</LINK>, <LINK REF="REF-Musini-VM-2008" TYPE="REFERENCE">Musini VM 2008</LINK>). A review of the reference lists in these review did not identify any additional studies which met the inclusion criteria for this review.</P>
<P>The MEDLINE search has been updated by searching from 1994 through December 2008. The search strategy (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) is designed to identify pharmacological treatment of hypertension. (A "/" at the end of a term indicates that it is a Medical Subject Heading (MeSH) term; "exp" indicates that the term is exploded meaning that all MeSH terms nested under the exploded MeSH term are included in the search; "tw" indicates that the term is a text word meaning the title, abstract and MeSH terms are searched for the term; hypertension/dt returns references coded as Drug Treatment for hypertension; "pt" indicates a publication type; "ti.ab" indicates a search for the text word in the title and abstract but not the MeSH terms; the symbols "$" and "?" are wildcard characters used to search for multiple forms of a word; the search modifier "adj" plus a number between any two terms returns records which contain the two terms within the specified number of words of each other.)</P>
<P>The updated search of Medline up to December 2008 identified 162 citations. The titles and abstracts of this list were screened independently by two reviewers (VM and AT) for inclusion which resulted in the retreival of 31 full papers. One reviewer then screened the 31 full papers and a further 3 RCTS were considered for potential inclusion into the review (<LINK REF="STD-Jikei-2007" TYPE="STUDY">Jikei 2007</LINK>, <LINK REF="STD-ADVANCE-2007" TYPE="STUDY">ADVANCE 2007</LINK>, <LINK REF="STD-SCOPE-2003" TYPE="STUDY">SCOPE 2003</LINK>). Three reviewers discussed and reached consensus that the 3 RCTS did not meet the inclusion criteria and were excluded. A search of CENTRAL up to June 2009 identified only 1 additional citation (<LINK REF="STD-HYVET_x002d_Cog-2008" TYPE="STUDY">HYVET-Cog 2008</LINK>) that was not identified in the Medline search. The <LINK REF="STD-HYVET_x002d_Cog-2008" TYPE="STUDY">HYVET-Cog 2008</LINK> was retrieved however it was concluded that this substudy of the <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> trial did not provide any additional data for analysis. A search of EMBASE was conducted up to December 2008 which identified 6 new citations however none of these met inclusion criteria based on a review of titles and abstracts.</P>
<P>Bibliographies of newly identified meta-analyses, reviews and trials were examined for references to other trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-11 16:07:43 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>
<B>Data abstraction</B>
</P>
<P>This review is based on five previously published meta-analyses on the same topic (<LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>, <LINK REF="REF-Mulrow-1998" TYPE="REFERENCE">Mulrow 1998</LINK>, <LINK REF="REF-Wright-JM-1999" TYPE="REFERENCE">Wright JM 1999</LINK>, <LINK REF="REF-Gueyffier-F-1999" TYPE="REFERENCE">Gueyffier F 1999</LINK>, <LINK REF="REF-Musini-VM-2008" TYPE="REFERENCE">Musini VM 2008</LINK>). Data was abstracted using a standard data abstraction form; dual abstraction of data from the original reports of trial results by two independent reviewers; and disagreements were resolved by discussion. The published results of these meta-analyses as well as data from additional trials included in the updated review were compared by two reviewers (VM and AT). Any disagreements were resolved by consensus (JMW and KB) .</P>
<P>
<B>Risk of Bias table </B>
</P>
<P>A quality scoring scheme was not used, but instead key trial characteristics are detailed in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Potential parameters of methodological quality listed in the table include: whether randomization was completed in an appropriate and blinded manner; whether patients, providers and/or outcome assessors were blinded to assigned therapy; whether the control group received a placebo; percent of participants who did not complete follow-up (dropouts); and the percent of participants not on assigned active or placebo therapy at study completion (cross-over).</P>
<P>The updated review uses the Risk of Bias tool to assess each trial according to the Cochrane Handbook guidelines.</P>
<P>
<B>Analyses</B>
</P>
<P>Quantitative analyses of outcomes are based on intention-to-treat results. Our measure of effect for each study was the Relative-Risk (RR) with 95% CI. Chi-square tests for heterogeneity were used to assess outcome data for compatibility with the assumption of a uniform relative risk (P&gt;0.10). Pooled risk differences are converted to numbers needed to treat (NNTs) with the formula NNT = 1/risk difference. NNTs are the number of patients who must be treated to prevent one adverse outcome.</P>
<P>To test for robustness of results, several sensitivity analyses were performed. Data were analysed using both fixed effect and random effects models. As further tests of sensitivity, trials that were not blinded and placebo controlled were analysed separately from blinded (subject and/or provider), placebo controlled trials. Results were also analysed with and without those trials restricted to persons who had previously suffered a stroke. Results of trials restricted to persons with isolated systolic hypertension were analysed both as a separate group and combined with trials also assessing persons with both systolic and diastolic hypertension. Analyses in the very elderly (80 year or older) were planned because a subgroup meta-analysis from earlier trials by <LINK REF="REF-Gueyffier-F-1999" TYPE="REFERENCE">Gueyffier F 1999</LINK> showed a trend towards increased mortality. Furthermore, two recent randomised trials <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> and <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> were specifically done in the very elderly group of patients.</P>
<P>Individual differences in patient characteristics or disease severity are associated with different levels of risk to experience an adverse event. In the aggregate, these individual differences contribute to the proportion of patients we expect to experience an event within a population. Variation in level of risk in different patient populations, both within and between clinical trials, is often associated with variability in treatment outcomes (<LINK REF="REF-Ioannidis-1997" TYPE="REFERENCE">Ioannidis 1997</LINK>, <LINK REF="REF-Schmid-1998" TYPE="REFERENCE">Schmid 1998</LINK>). This average population risk is unknown, but contributes to the proportion of events experienced by a placebo control group in a randomised trial. We use the term control rate to describe the probability that a member within the control group experiences the adverse event, and we use this sample value to estimate the aggregate population risk for patients enrolled in a clinical trial.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-08 21:26:56 -0800" MODIFIED_BY="James M Wright">
<STUDY_DESCRIPTION MODIFIED="2009-08-11 14:08:38 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Two new randomised controlled trials met the inclusion criteria (<LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> and <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK>). Two RCTs included in the previous version were excluded in the update since the control group was not an untreated or placebo control group. The <LINK REF="STD-HDFP-1982" TYPE="STUDY">HDFP 1982</LINK> study was excluded since it is a multifactorial intervention (<LINK REF="REF-Ebrahim-2006" TYPE="REFERENCE">Ebrahim 2006</LINK>). <LINK REF="STD-CASTEL-1994" TYPE="STUDY">CASTEL 1994</LINK> was excluded since the control group was receiving non-specific anti-hypertensive therapy from their personal physician. </P>
<P>Fifteen trials including 24,005 people age 60 or over<B> </B>were identified<B>. </B>For most subjects included in this review the mean age ranged from 63 to 84 years. Three trials (<LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>, <LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK>) did not report mean age. Most trials were conducted in Western, industrialized countries and evaluated first-line diuretics (<LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>, <LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>, <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK>, <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK>, <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>, <LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK>). Two trials evaluated beta-blocker therapies (<LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK>, <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>). Four of these trials (<LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK>, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>, <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>) originally included both younger and older persons. Only data on those older than 60 is reported. The average age across trials was 73.8 years. The Swedish Trial in Old Patients with Hypertension (<LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>) specifically evaluated people over age 70. The <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> and <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> trials included patients 80 years or older.</P>
<P>Participants were recruited from industrialized countries: USA (36%), UK (25%), European multi-site trials (25%), Sweden (7%), Italy (3%), Australia (3%) and Japan (&lt;1%). <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> trial recruited patients from Bulgaria (88%), Spain (3%), Romania (3%), UK (2.5%) and Poland (1.5%) and from other countries in smaller numbers (Finland, Lithuania, Ireland, Greece and Serbia). <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> trial recruited patients from Western Europe (2.2%), Eastern Europe (55.8%), China (39.6%), Australasia (0.5%) and Tunisia (1.9%).</P>
<P>14,663 (59.5%) percent of the subjects were female. The four trials based in the USA reported ethnicity African-American: <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> (14%), <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK> (18% non-white), <LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK> (41%), <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> (78%). The ethnicity data from VA Coop 1970 and HTN Coop 1974 refer to the entire study population, not the &gt;60 year old sub-group. All subjects in <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> and <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> were white. Nine<B> </B>trials including <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> and <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> did not report ethnicity.</P>
<P>Study populations predominantly consisted of ambulatory patients recruited from the community or primary care facilities. A small proportion (6%) were recruited from hospitals or homes for the aged. Studies did not consistently report data on pre-existing conditions for subjects; available data follows. Two small studies were limited to stroke survivors (<LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>). Six other trials reported the baseline prevalence of stroke. The sample-size-based weighted average prevalence across those six trials was 3.6%<I>:</I> <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK> (1%), <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> (1.4%), <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK> (3.5%), <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK> (11.3%), <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> (4.5%) and <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> (6.8%). Six trials reported the baseline prevalence of myocardial infarctions. The average prevalence across trials was 2.3%:<I> </I>
<LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> (0.5%),<I> </I>
<LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK> (1.2%), <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK> (4%), <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> (4.9%),<B> </B>
<LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> (3.0%), and <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> (3.1%).<B> </B>Two studies excluded patients with diabetes (<LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>, <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>), while three other trials reported the baseline prevalence. The average prevalence across trials was 9.2%: <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> (6.8%), <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> (10.1%), <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> (36%). Two trials reported the baseline prevalence of hyperlipidemia:<I> </I>
<LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> (22%) and <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> (62.2%). Ten trials reported the baseline prevalence of smoking. The average prevalence across trials was 12.1%: <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> (4.2%), <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> (6.6%), <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>(7.3%), <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK> (11%), <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>(12.7%), <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> (16.4%), <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> (17.5%), <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> (17.5%), <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK> (24%), and <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> (60%). Only <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> reported data on prevalence of obesity (29%).</P>
<P>Entry diastolic blood pressure criteria also have varied somewhat from trial to trial. However, trials in older persons have not routinely included patients with higher diastolic blood pressures than trials in younger persons.</P>
<P>All trials except <LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK> reported the mean SBP and DBP at baseline. <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> and <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK> restricted recruitment to persons with isolated systolic hypertension; defined as SBP 160-219 mm Hg and DBP &lt;90 mm Hg (<LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>) or DBP &lt; 95 mm Hg (<LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>). Mean blood pressure at entry in the 3 isolated systolic hypertension trials was 172/81 mmHg. Two studies (<LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK>) recruited persons with isolated systolic hypertension, diastolic hypertension or systo-diastolic hypertension. <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK> and <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> recruited patients with either isolated systolic hypertension or systo-diastolic hypertension. <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> recruited patients with systolic and/or diastolic hypertension (SBP &gt; 140 mmHg and DBP 90-109 mmHg). <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> recruited patients with persistent hypertension defined as SBP of 160-199 mmHg and a DBP &lt; 110mmHg.<B> </B>32.5% of patients in <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> had isolated systolic hypertension. The remainder of the studies required that subjects' DBP be at least 90 mm Hg. Mean BP at entry in these 11 other trials was 182/95 mmHg.</P>
<P>See the "Participants" heading in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for a complete description of each study's blood pressure inclusion criteria. The mean sitting SBP/DBP in <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> was 182/99.6 mmHg and in <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> was 173/90.8 mmHg.</P>
<P>Twelve of the 15 trials instituted a stepped care approach to hypertension treatment. In over 70% of trials a thiazide diuretic was the first line drug in the treatment group.<B> </B>Seven trials (<LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>, <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK>, <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>, <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>) started the treatment group exclusively on a thiazide diuretic. <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK> and <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> started the treatment group on either a diuretic or beta-blocker. <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> randomized the treatment group to two arms, one initially receiving diuretics and the other initially receiving a beta-blocker. <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK> started the treatment group on a calcium channel blocker. <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> started one treatment arm on a diuretic and other treatment arm with an ACE inhibitor. Second and third line drugs included diuretics, beta-blockers, central acting anti adrenergic agents, peripheral acting anti adrenergic agents, vasodilators, converting-enzyme inhibitors and calcium channel blockers. See the "Interventions" heading in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for a complete description of each study's drug treatment protocol.</P>
<P>Three trials maintained subjects on a particular therapeutic regimen (i.e. not stepped care) throughout the study. <LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK> treated subjects with a combination diuretic - central acting anti adrenergic agent (hydrochlorothiazide/reserpine) plus a vasodilator (hydralazine). <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> treated subjects with a diuretic (methyclothiazide) and peripheral acting anti adrenergic agent (deserpidine). <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK> treated subjects with a central acting anti adrenergic agent (methyldopa).</P>
<P>
<LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> trial randomized patients to three groups: no treatment, diuretic based treatment (usually bendrofluazide 2.5mg) and an ACE-inhibitor based regimen (usually lisinopril 2.5mg). To attain target blood pressure (sitting SBP &lt; 150 mmHg and sitting DBP &lt; 80 mmHg) in the actively treated groups, the dose of diuretic or ACEI could be doubled (step 2), diltiazem slow release 120 mg could be added (step 3) and diltiazem slow release 240mg could be added as (Step 4). </P>
<P>
<LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> trial randomized patients to either indapamide sustained release 1.5 mg or matching placebo. In order to reach target blood pressure (SBP &lt; 150 mmHg and DBP &lt; 80 mmHg) perindropil 2 mg or 4 mg or matching placebo could be added.</P>
<P>Length of study follow up ranged from relatively short: 1 year (<LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK>) or 2 years (<LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>, <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>), to relatively long: the rest of the trials lasting 3 to 6 years. All of the trials were multi site studies except for <LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK> and <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK>. The mean duration of treatment was 4.5 years in elderly (60 years or older) and 2.2 years in very elderly patients<B> </B>(80 years or older) and 3.2 years in trials with isolated systolic hypertension in the elderly.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-08 20:19:48 -0800" MODIFIED_BY="James M Wright">
<P>Twelve of the 15 trials employed some method of blinding. Twelve blinded subjects to therapy (<LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK>, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>, <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>, <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK>, <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK>, <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>, <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>, <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>, <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>). Of these, eleven (all but <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>) also blinded providers to therapy. Eight trials specifically reported blinding outcome assessors (<LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK>, <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>, <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>, <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>, <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>).</P>
<P>Eleven trials were placebo controlled (<LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK>, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>, <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>, <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK>, <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>, <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>, <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>, <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008)</LINK>. Four trials were no treatment controlled without placebo (<LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK>, <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK>, <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK>).</P>
<P>In nine<B> </B>of the trials the method of randomization is described while in the remaining six trials randomization is mentioned, but not described. See the "Method" heading in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for a description of each study's method of randomization and stratification, if any.</P>
<P>Nine studies<B> </B>reported loss to follow-up figures of less than 5% (<LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>, <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK>, <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>, <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>, <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>). Three studies reported loss to follow-up figures of 13-15% (<LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK>, <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK>, <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK>). <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> experienced a loss to follow-up of 25%. The remainder (<LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>, <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK>) did not report data on numbers lost to follow-up.</P>
<P>Studies included in this review allowed subjects in the control group to receive antihypertensive therapy because their blood pressure exceeded pre-set "escape" criteria. Also, a portion of the subjects assigned to the treatment group stopped taking their assigned medication because of adverse drug effects or because they achieved normal blood pressures. The degree to which subjects cross over from one group to the other dilutes the results of the study. The percent of patients assigned to the control group which were receiving antihypertensive medication by the end of the trial were as follows: <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK> (9%), <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK> (17%), <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> (23%), <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK> (27%), <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> (35%), <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK> (40%), <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> (44%), <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> (53%), and <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> (&gt;35%), <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> (0.8%) and <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> (0.6%). The remaining four trials did not report such data. The percent of patients assigned to the treatment group which had ceased taking antihypertensive medication by the end of the trial were: <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> (4%), <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> (0.5%), <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK> (5%), <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> (10%), <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> (16%), <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK> (18%), <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK> (30%), <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> (33%), <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> - diuretic arm (48%), <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> - beta-blocker arm (63%), and <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> (&gt;35%). The remaining<B> </B>five trials did not report such data.</P>
<P>
<LINK REF="FIG-24" TYPE="FIGURE">Figure 24</LINK> and <LINK REF="FIG-25" TYPE="FIGURE">Figure 25</LINK> show a summary of the Risk of Bias assessment.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-08 21:26:56 -0800" MODIFIED_BY="James M Wright">
<P>Analyses were performed on the combined results of all 15 studies. The three trials that included only people with isolated systolic hypertension (<LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>) were included in the overall analyses and were also analysed separately. <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> reported intention-to-treat data for mortality only; the morbidity data reported from <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> is not intention-to-treat and is not included in the analysis. The occurrence of any trial endpoint in <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> participants terminated their participation in the study. Thus, true intention-to-treat data for <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> is only available for combined cardiovascular morbidity and mortality.</P>
<P>Results were analysed with and without the two small trials that were restricted to stroke survivors (<LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK>, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>). Removing these two trials from the analysis did not appreciably affect the results. The relative risk point estimates and confidence intervals did not shift by more than 0.01. Thus, all results reported below include these two trials.</P>
<P>There was homogeneity across studies with respect to all outcomes except cardiovascular morbidity and mortality. Point estimates for the pooled log relative risk ratios were nearly identical between the random and fixed effect analyses. Thus, all results are reported using the fixed effects model. In the very elderly patients there was homogeneity across studies for all outcomes except total mortality.</P>
<P>
<B>
<U>Total mortality:</U> </B>The combined results of the 12 trials reporting total mortality data in people 60 years or older show a significant benefit (RR=0.90, 95% CI 0.84 to 0.97; NNT=84) with event rates per 1000 participants reduced from 116 to 104 events with 95% CI of the difference (3 to 19) for a mean duration of treatment of 4.5 years, see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> and <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> independently reached a statistically significant mortality benefit.</P>
<P>Analysis of trials in very elderly (80 years or older) showed no reduction in total mortality for a mean duration of treatment of 2.2 years (RR = 0.98 95% CI 0.87 to 1.10; p = 0.72), see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> . There was significant heterogeneity between trials (RR = 1.06 95% CI 0.88 to 1.28 using random effects model).</P>
<P>The three trials with isolated systolic hypertension did not achieve a statistically significant reduction in mortality for a mean duration of treatment of 3.2 years<B> </B>(RR=0.88, 95% CI 0.77 to 1.01; p =0.07), see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>
<B>
<U>Cardiovascular mortality:</U>
</B> The combined results of the 10 trials reporting cardiovascular mortality data in people 60 years or older indicated a significant reduction (RR=0.77, 95% CI 0.68 to 0.86; ARR= 1.5%, NNT = 67), see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> and <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> independently reached statistical significance. Non-cardiovascular mortality was not affected, RR with 95% CI 1.02(0.92, 1.14 p = 0.65), see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
<P>Combined results of the three trials with isolated systolic hypertension showed a significant reduction in cardiovascular mortality (RR=0.77, 95% CI 0.63 to 0.95), see <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>. Analysis of trials in very elderly (80 years or older) showed no significant difference (RR = 0.98 95% CI 0.81 to 1.19; p = 0.86), see <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>.</P>
<P>
<B>
<U>Cerebrovascular mortality:</U>
</B> In people 60 years or older there was a significant reduction (RR=0.66, 95% CI 0.53 to 0.82), see <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>. <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> and <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK> independently reached statistical significance.</P>
<P>In the three trials with isolated systolic hypertension the reduction was not statistically significant (RR=0.68 95% CI 0.42 to 1.11; p = 0.13), see <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>.</P>
<P>In the very elderly (80 years or older) there was also no significant difference (RR = 0.80 95% CI 0.58 to 1.11; p = 0.18), see <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>.</P>
<P>
<B>
<U>Coronary heart disease (CHD) mortality:</U> </B>In the 9 trials reporting CHD mortality in people 60 years or older treatment reduced CHD mortality (RR=0.77, 95% CI 0.65 to 0.90), see <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>. <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> independently reached statistical significance.</P>
<P>In the very elderly (80 years or older) there was no reduction (RR = 0.98 95% CI 0.69 to 1.40; p = 0.93), see <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>.</P>
<P>In the three trials with isolated systolic hypertension the reduction was not statistically significant (RR=0.78, 95% CI 0.60 to 1.02; p = 0.06), see <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>.</P>
<P>
<B>
<U>Cardiovascular mortality and morbidity (M&amp;M):</U> </B>In the 13 trials reporting cardiovascular mortality and morbidity data in people 60 years or older, treatment caused a significant reduction (RR=0.72, 95% CI 0.68 to 0.77), see <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>. <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>, <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>, <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>, <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK> and <LINK REF="STD-VA-Coop-1962" TYPE="STUDY">VA Coop 1962</LINK> independently reached statistical significance. The significant heterogeneity between trials was no longer evident when the unblinded <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK> and <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK> trials were excluded from the analysis (RR = 0.71 95% CI 0.66 to 0.78 with I<SUP>2</SUP> reduced from 70% with p &lt; 0.0001 to I<SUP>2</SUP> = 32% with p = 0.14).</P>
<P>Excluding <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> because it used a different definition for the cardiovascular morbidity and mortality outcome did not affect the estimate (RR=0.69, 95% CI 0.65 to 0.75).</P>
<P>Cardiovascular mortality and morbidity was significantly reduced in elderly patients due to reduction in both cerebrovascular as well as CHD mortality and morbidity, see <LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK> and <LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK> respectively.</P>
<P>In the very elderly patients (80 years or older) and in elderly patients with isolated systolic hypertension, treatment caused a significant reduction in cardiovascular mortality and morbidity (RR = 0.75 95% CI 0.65 to 0.87 p = 0.0001), see <LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK>, and (RR=0.68, 95% CI 0.61 to 0.75) see <LINK REF="FIG-18" TYPE="FIGURE">Figure 18</LINK> respectively.</P>
<P>Cerebrovascular mortality and morbidity was significantly reduced in the very elderly <LINK REF="FIG-19" TYPE="FIGURE">Figure 19</LINK> but there was no significant difference observed in coronary heart disease mortality and morbidity (<LINK REF="FIG-20" TYPE="FIGURE">Figure 20</LINK>).</P>
<P>Cerebrovascular mortality and morbidity (<LINK REF="FIG-21" TYPE="FIGURE">Figure 21</LINK>) as well as coronary heart disease mortality and morbidity (<LINK REF="FIG-22" TYPE="FIGURE">Figure 22</LINK>) were significantly reduced in the elderly patients with isolated systolic hypertension.</P>
<P>
<B>
<U>Withdrawals due to adverse effects:</U> </B>Numbers of participants who dropped out of trials due to adverse drug effects were often not reported. The three trials that did report this data showed a significant increase in withdrawals due to adverse effects, RR=1.71, 95% CI 1.45 to 2.00, see <LINK REF="FIG-23" TYPE="FIGURE">Figure 23</LINK>, with event rates per 1000 participants increased from 65 to 111 events, absolute risk increase of 46 (95% CI 29 to 65).</P>
<P>The number of people withdrawing from therapy due to adverse effects varied significantly from study to study. On average, treating 17 subjects in <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> resulted in one withdrawal, whereas in <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> treating 9 subjects with a diuretic and 4 subjects with a beta-blocker resulted in one withdrawal in each treatment arm. In <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>, un-blinded physicians made decisions regarding severity of side effects and continuation of therapy; 176 subjects in the beta-blocker group were withdrawn because of bradycardia.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-11-08 21:30:02 -0800" MODIFIED_BY="James M Wright">
<P>This systematic review provides the best available evidence for antihypertensive treatment for people with elevated blood pressure who are at least 60 years of age. It is important to appreciate that this represents a group of people with relatively high systolic blood pressures: an average of 172/81 mmHg in the isolated systolic hypertension trials and an average of 182/95 mmHg in the 11 other trials. The reason that the diastolic pressure is lower than expected is because only 6 of these trials ensured the presence of diastolic hypertension, i.e. &gt; 90 mmHg diastolic (<LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>, <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK>, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>, <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK>, <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>, <LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK>). In these trials the average diastolic BP was &gt;100 mmHg.</P>
<P>In this population antihypertensive drug treatment was associated with a modest reduction in total mortality, RR 0.90 (0.84 - 0.97). This represents an absolute reduction in deaths of 12, from 116 to 104 events per 1000 participants, over an average duration of 4.5 years, see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. However, the 95% CI range from 3 to 19 deaths per 1000 participants, so we cannot be very confident in this result. This absolute reduction is explained by 6 less deaths due to stroke and 6 less deaths due to coronary heart disease. Most importantly when we limited the analysis to people 80 years old and over there was no reduction in total mortality, RR 0.98 (0.87 - 1.10). Thus trials with longer duration of treatment in the very elderly are warranted.</P>
<P>Cardiovascular mortality and morbidity was significantly reduced, RR 0.72 (0.68 - 0.77). This represents an absolute reduction of 43 (35 - 49), from 153 to 110 events per 1000 participants for a mean duration of treatment of 4.5 years, see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. This was due to a reduction of 20 cerebrovascular disease mortality and morbidity events as well as 10 coronary heart disease mortality and morbidity events. In the very elderly a similar reduction of 18 cerebrovascular mortality and morbidity events per 1000 participants was present, but there was no significant reduction in coronary heart disease mortality and morbidity.</P>
<P>The magnitude of benefit depends on multiple factors including their baseline risk of cardiovascular complications of hypertension (<LINK REF="REF-Gueyffier-1997" TYPE="REFERENCE">Gueyffier 1997</LINK>).  People with more cardiovascular risk factors (e.g. diabetes, family history of heart disease, left ventricular hypertrophy, etc.) have greater likelihood of a reduction in cardiovascular events by antihypertensive therapy.</P>
<P>The five-year absolute morbidity and mortality benefit of antihypertensive therapy is greater for older than younger adults (<LINK REF="REF-Collins-1990" TYPE="REFERENCE">Collins 1990</LINK>, <LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>). Several reasons could explain this greater absolute benefit. First, older people are at higher immediate absolute risk of a cardiovascular event than younger people (<LINK REF="REF-Alderman-1981" TYPE="REFERENCE">Alderman 1981</LINK>, <LINK REF="REF-Browner-1989" TYPE="REFERENCE">Browner 1989</LINK>, <LINK REF="REF-Alderman-1993" TYPE="REFERENCE">Alderman 1993</LINK>). The risk factors include pre-existing cardiovascular disease and systolic hypertension (<LINK REF="REF-Applegate-1992" TYPE="REFERENCE">Applegate 1992</LINK>, <LINK REF="REF-Mann-1992" TYPE="REFERENCE">Mann 1992</LINK>). Lowering of blood pressure results in similar relative but higher absolute effect in these people at high risk. The subgroup analysis of treatment in the very elderly patients (80 years or older) showed no significant benefit in terms of all cause mortality including cardiovascular, coronary heart disease or cerebrovascular disease mortality. However, a higher absolute risk reduction was observed in cardiovascular mortality and morbidity from 115 to 86 (75 to 100) events per 1000 participants, which was mostly due to a decrease in cerebrovascular mortality and morbidity for a mean duration of 2.0 years, see<B> </B>
<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
<P>Trials involving older people could have varied systematically from those in younger people. Except for <LINK REF="STD-TOMHS-1995" TYPE="STUDY">TOMHS 1995</LINK>, trials that included younger people were published before 1987(<LINK REF="STD-VA-Coop-1962" TYPE="STUDY">VA Coop 1962</LINK>, <LINK REF="STD-Wolf-1966" TYPE="STUDY">Wolf 1966</LINK>, <LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK>, <LINK REF="STD-Barraclough-1973" TYPE="STUDY">Barraclough 1973</LINK>, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK>, <LINK REF="STD-USPHS-Coop-1977" TYPE="STUDY">USPHS Coop 1977</LINK>, <LINK REF="STD-VA_x002f_NHLBI-1978" TYPE="STUDY">VA/NHLBI 1978</LINK>, <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK>, <LINK REF="STD-Oslo--1986" TYPE="STUDY">Oslo 1986</LINK>). Six large trials involving older people were published after 1990 (<LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK>, <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK>, <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK>, <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK>, <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK>, <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>). While first-line beta-blockers and thiazide diuretics were used in most trials, the recent large trials in older people have usually used either lower doses of thiazides or combinations with potassium sparing agents. As a result they  may be associated with less toxic adverse effects. The most recent trial in very elderly (<LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>) used<B> </B>indapamide sustained release 1.5 mg or matching placebo. If blood pressure remained above SBP=150 mmHg and DBP=80 mmHg, perindopril 2 mg or 4 mg or matching placebo could be added. Thus, this trial showed a significant reduction in mortality, RR 0.82 (0.69 - 0.99), ARR = 2.2%, NNT= 48 for 2 years, and in total cardiovascular events, RR 0.71 (0.57 - 0.87) with low doses of two antihypertensive drugs. The other trials in the very elderly used higher doses of more antihypertensive drugs and showed a trend towards increased total mortality. These observations suggest that less aggressive treatment is probably a good approach in the very elderly, but this needs to be validated with RCTs testing different approaches to BP control in this patient population.</P>
<P>Numbers of participants who dropped out of trials due to adverse drug effects were often not reported. The three trials that did report this data showed a significant increase in withdrawals due to adverse effects from 65 to 111 events per 1000 participants, absolute increase of 46 (29 - 65) per 1000 patients. Separate data for withdrawals due to adverse effects was not available in the very elderly patients.</P>
<P>
<B>Control rates</B>
</P>
<P>Control rates provide insight regarding baseline risk of study populations and can explain the differences in outcomes between individual trials. Total mortality rates in the control groups ranged from 3 to 71%. Trials with relatively low rates included <LINK REF="STD-ANBP-1981" TYPE="STUDY">ANBP 1981</LINK> (3%), <LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> (5.2%), <LINK REF="STD-Syst_x002d_Eur-1991" TYPE="STUDY">Syst-Eur 1991</LINK> (6%), <LINK REF="STD-SHEP_x002d_PS-1986" TYPE="STUDY">SHEP-PS 1986</LINK> (6.5%), <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> (7.7%), and <LINK REF="STD-SHEP-1991" TYPE="STUDY">SHEP 1991</LINK> (10.2%). Trials with moderate rates included <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> (12.3%), <LINK REF="STD-MRCOA-1992" TYPE="STUDY">MRCOA 1992</LINK> (14.2%), <LINK REF="STD-HEP-1986" TYPE="STUDY">HEP 1986</LINK> (14.8%), and <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK> (14.9%). Trials with relatively high rates included <LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK> (34.6%), <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> (35.1%), and <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK> (71%). <LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK> and <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> did not report total mortality, but reported the second and third highest event rates (behind <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK>) in cardiovascular morbidity and mortality (<LINK REF="STD-VA-Coop-1970" TYPE="STUDY">VA Coop 1970</LINK> 58.1%, <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> 34.3% and <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK> 83.9%).</P>
<P>The 95% CI of the RR of total mortality for <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK>, 1.11 (0.90 to 1.36), did not overlap with the 95% CI of the <LINK REF="STD-STOP-1991" TYPE="STUDY">STOP 1991</LINK> trial, 0.57 (0.39 to 0.85). Differences in control rates may in part be due to differing baseline characteristics in recruited subjects. For example, the subjects in <LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK> and <LINK REF="STD-HTN-Coop-1974" TYPE="STUDY">HTN Coop 1974</LINK> were all stroke survivors. Subjects in <LINK REF="STD-Sprackling-1981" TYPE="STUDY">Sprackling 1981</LINK> and <LINK REF="STD-Kuramoto-1981" TYPE="STUDY">Kuramoto 1981</LINK> resided in a home for the aged. Subjects in <LINK REF="STD-Carter-1970" TYPE="STUDY">Carter 1970</LINK> and <LINK REF="STD-VA-Coop-1962" TYPE="STUDY">VA Coop 1962</LINK> were recruited from hospitals (though followed up in clinics) and subjects in <LINK REF="STD-EWPHE-1989" TYPE="STUDY">EWPHE 1989</LINK> were recruited from geriatric hospitals, physician's offices and homes for the aged.</P>
<P>Additional explanations of differing control rates include variations in definitions of trial end-points, cross-over rates and follow-up durations. Although we attempted to standardize outcome definitions as much as possible (see <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section), truly uniform definitions between trials were not possible. Trials had cross-over rates ranging from 9% to 62% (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and follow-up durations ranging from 1 to 6 years.</P>
<P>Since most data is based on a small percentage of randomized patients with stroke or MI at baseline, patients with significant competing comorbidity and complicated medical regimens may also have poorer compliance, less benefit, and more adverse effects compared to participants in trials. </P>
<P>
<B>Risk of Bias </B>
</P>
<P>Risk of bias was assessed using the Cochrane Risk of Bias tool and demonstrated that approximately 40% of trials had evidence of selective reporting bias and approximately 30% of trials did not deal with missing or incomplete outcome data appropriately. In other words, 40% of trials could have censored outcome data for patients after they had had their first event. In addition, in 30% of the trials, when outcome data wasn't available it appeared the assumption was that an event did not occur in that patient. See <LINK REF="FIG-24" TYPE="FIGURE">Figure 24</LINK>; and <LINK REF="FIG-25" TYPE="FIGURE">Figure 25</LINK>. The implications are that the available outcome data used in the meta-analyses may be incomplete. It is difficult to determine whether this bias would favour treatment or control. What can be said is that reported event rates are underestimates and the calculated effect sizes for outcomes (other than death as the first event) may be inaccurate.</P>
<P>
<B>Limitations and generalizability</B>
</P>
<P>The most appropriate way to match expected magnitude of benefits to patients with particular constellations of risk factors is to perform individual patient based meta-analyses (<LINK REF="REF-Gueyffier-1997" TYPE="REFERENCE">Gueyffier 1997</LINK>), which was not possible in this review. Moreover, our aggregate results only refer to generally expected benefits for elderly hypertensive patients, and are not tailored specifically to patients with particular risk factors. Our average results refer primarily to a primary prevention population with moderate to severe systolic or systodiastolic hypertension treated with a first-line thiazide. Data for other first-line drugs is insufficient, and the objective of this review was not to compare different first-line drugs, which has been done by other systematic reviews (<LINK REF="REF-Psaty-1997" TYPE="REFERENCE">Psaty 1997</LINK>, <LINK REF="REF-Wright-JM-1999" TYPE="REFERENCE">Wright JM 1999</LINK>, <LINK REF="REF-Psaty-2003" TYPE="REFERENCE">Psaty 2003</LINK>, <LINK REF="REF-Wright-JM-2009" TYPE="REFERENCE">Wright JM 2009</LINK>).</P>
<P>Actual estimates of benefits and harms of treating elderly persons with hypertension derived from trials with highly selected subjects are not readily generalizable to clinical practice. Many patients either would not meet eligibility criteria or, if offered the chance, would not have enrolled in a clinical trial. Strictly speaking, trial results cannot be generalized to such patients. In practice, clinicians are of course willing to offer treatment to patients who may not have been eligible for a trial or who, if eligible, would have refused participation; but we should approach these generalizations with forethought. Without extra care and visits provided in many trials, even our "eligible" patients may be less compliant than trial participants. Patients with significant competing comorbidities and complicated medical regimens may also have poorer compliance, less benefit, and more adverse effects compared to participants in trials. For example in an octagenarian with orthostasis and recurring falls related to antihypertensive therapy, the harms likely exceed benefits. On the other hand, clinicians should not always assume that less benefit would be seen in "real life" clinical settings. A person who is at high immediate risk of suffering a cardiovascular event and does not have other competing illnesses may have a higher benefit-to-harm ratio than the average trial participant.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-08-11 15:43:45 -0700" MODIFIED_BY="Ciprian D Jauca">
<IMPLICATIONS_PRACTICE MODIFIED="2009-08-11 15:42:56 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Antihypertensive treatment of people aged 60 and older with moderate to severe systolic and/or diastolic hypertension reduces total mortality and total cardiovascular morbidity and mortality. The absolute risk reduction in cerebrovascular mortality and morbidity over 4.5 years was greater (2.0% and NNT=50) than for coronary heart disease mortality and morbidity (1.0% with NNT=100).<B> </B>The evidence of benefit pertains mostly to a primary prevention population and first-line treatment with a thiazide. This comprehensive systematic review provides additional evidence in people aged 80 and older where antihypertensive treatment reduced total cardiovascular morbidity and mortality, but not total mortality.<B> </B>In the very elderly the absolute risk reduction in cerebrovascular mortality and morbidity over 2.2 years was 1.8% with NNT=56, but there was no significant reduction in coronary heart disease mortality and morbidity. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-08-11 15:43:45 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Individual patient based meta-analyses of data from existing trials should be used to derive evidence for the treatment of specific subgroups of elderly hypertensive patients, such as persons with diabetes, functional impairment, recent stroke or persons of African descent. Further<B> </B>long term RCTs are needed to investigate which first-line drug is best in elderly patients and to study different approaches to treatment e.g. an RCT comparing the use of two drugs at low dose (as in the <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK> trial) with traditional antihypertensive therapy with 3 to 4 drugs in maximal doses. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-11 15:45:47 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>We would like to acknowledge the authors of the previous (1998) version of this systematic review: Cynthia Mulrow, Joseph Lau, John Cornell, and M Brand. <BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-08-11 15:46:10 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>None. <BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-08-11 15:46:01 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Vijaya Musini and Aaron Tejani did an updated literature search, data abstraction, data entry, verification and data analysis. James Wright and Ken Bassett verified data and resolved differences. All authors contributed in writing the results and discussion section. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-08-11 15:46:08 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>None. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-07-14 06:28:21 -0700" MODIFIED_BY="Vijaya M Musini">
<P>This systematic review has been substantially updated by a new team of authors. The updated review includes two additional trials identified (<LINK REF="STD-HYVET-P-2003" TYPE="STUDY">HYVET P 2003</LINK> and <LINK REF="STD-HYVET-2008" TYPE="STUDY">HYVET 2008</LINK>) and excludes <LINK REF="STD-HDFP-1982" TYPE="STUDY">HDFP 1982</LINK> and <LINK REF="STD-CASTEL-1994" TYPE="STUDY">CASTEL 1994</LINK> trials that were included in the previous review. Also meta-analysis of data in the very elderly (80 years or older) has been added to the updated review.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-11 15:59:56 -0700" MODIFIED_BY="Ciprian D Jauca">
<STUDIES MODIFIED="2009-07-14 07:36:19 -0700" MODIFIED_BY="Vijaya M Musini">
<INCLUDED_STUDIES MODIFIED="2009-07-14 06:37:05 -0700" MODIFIED_BY="Vijaya M Musini">
<STUDY DATA_SOURCE="PUB" ID="STD-ANBP-1981" NAME="ANBP 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Australian National Blood Pressure Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet. 1980;1:1261-1267.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Australian National Blood Pressure Management Committee</AU>
<TI>The Australian Therapeutic Trial in Mild Hypertension</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>1261-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Management Committee</AU>
<TI>Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia</TI>
<SO>Med J Aust</SO>
<YR>1981</YR>
<VL>2</VL>
<PG>398-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1970" NAME="Carter 1970" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;Carter AB. Hypotensive therapy in stroke survivors. Lancet 1970;1:485-489.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter AB</AU>
<TI>Hypotensive therapy in stroke survivors</TI>
<SO>Lancet</SO>
<YR>1970</YR>
<VL>1</VL>
<PG>485-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EWPHE-1989" NAME="EWPHE 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amery A, Bixko P, Clement D, de Schaepdryver A, Fagard R, Forte J</AU>
<TI>Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>8442</NO>
<PG>1349-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Working Party on High Blood Pressure in the Elderly (EWPHE)</AU>
<TI>An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization</TI>
<SO>Arch Int Pharmacodyn</SO>
<YR>1985</YR>
<VL>275</VL>
<PG>300-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley KO, McCormack P, O'Brien ET</AU>
<TI>Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly</TI>
<SO>J Hypertens</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>suppl 1</NO>
<PG>S105-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, Fletcher A</AU>
<TI>Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>298</VL>
<PG>1552-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HEP-1986" NAME="HEP 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coope J, Warrender TS</AU>
<TI>Randomized trial of treatment of hypertension in elderly patients in primary care</TI>
<SO>BMJ</SO>
<YR>1986</YR>
<VL>293</VL>
<PG>1145-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HTN-Coop-1974" MODIFIED="2009-07-14 06:31:34 -0700" MODIFIED_BY="Vijaya M Musini" NAME="HTN Coop 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hypertension-Stroke Cooperative Study Group on Agents</AU>
<TI>Effect of antihypertensive treatment on stroke recurrence</TI>
<SO>JAMA</SO>
<YR>1974</YR>
<VL>229</VL>
<PG>409-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HYVET-2008" MODIFIED="2009-07-14 06:37:05 -0700" MODIFIED_BY="Vijaya M Musini" NAME="HYVET 2008" YEAR="">
<REFERENCE MODIFIED="2009-07-14 06:37:05 -0700" MODIFIED_BY="Vijaya M Musini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt C</AU>
<TI>Treatment of Hypertension in Patients 80 Yearsof Age or Older</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>18</NO>
<PG>1887-1898</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HYVET-P-2003" MODIFIED="2009-04-06 09:26:33 -0700" MODIFIED_BY="[Empty name]" NAME="HYVET P 2003" YEAR="1999">
<REFERENCE MODIFIED="2009-04-06 09:26:33 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bulpitt CJ, Beckett NS, Cooke J, Dumiktrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thijs L</AU>
<TI>Results of the pilot study for the Hypertension in the VeryElderly Trial</TI>
<SO>Journal of Hypertension</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>2409-2417</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuramoto-1981" NAME="Kuramoto 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuramoto K, Matsushita S, Kuwajima T, Murakami M</AU>
<TI>Prospective study on the treatment of mild hypertension in the aged</TI>
<SO>Jpn Heart J</SO>
<YR>1981</YR>
<VL>22</VL>
<NO>1</NO>
<PG>75-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRCOA-1992" NAME="MRCOA 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;MRC Working Party. Medical Research Council Trial of Treatment of Hypertension in Older Adults: principal results. BMJ 1992;304:405-12.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MRC Working Party</AU>
<TI>Medical Research Council Trial of Treatment of Hypertension in Older Adults: principal results</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<NO>6824</NO>
<PG>405-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SHEP-1991" NAME="SHEP 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et. al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994;154:2154-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al</AU>
<TI>al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the Systolic Hypertension in the Elderly Program</TI>
<SO>Arch Intern Med</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>2154-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulley SB, Furberg CD, Gurland B, McDonald R, Perry HM, Schnaper HW, et al</AU>
<TI>Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone</TI>
<SO>Am J Cardiol</SO>
<YR>1985</YR>
<VL>56</VL>
<NO>15</NO>
<PG>913-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SHEP Cooperative Research Group</AU>
<TI>Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP)</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>265</VL>
<NO>24</NO>
<PG>3255-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SHEP Cooperative Research Group</AU>
<TI>Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension</TI>
<SO>J Clin Epidemiol</SO>
<YR>1988</YR>
<VL>41</VL>
<NO>12</NO>
<PG>1197-1208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SHEP_x002d_PS-1986" NAME="SHEP-PS 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black DM, Brand RJ, Greenlick M, Hughes G, Smith J</AU>
<TI>Compliance to treatment for hypertension in elderly patients: the SHEP pilot study</TI>
<SO>J Gerentol</SO>
<YR>1987</YR>
<VL>42</VL>
<NO>5</NO>
<PG>552-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulley SB, Furberg CD, Gurland B, McDonald R, Perry HM, Schnaper HW, et al</AU>
<TI>for the SHEP Research Group. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone</TI>
<SO>Am J Cardiol</SO>
<YR>1985</YR>
<VL>56</VL>
<PG>913-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry HM, McDonald RH, Hulley SB, Smith WM, Furberg CD, Greenlick MR</AU>
<TI>Systolic Hypertension in the Elderly Program, Pilot Study (SHEP-PS): morbidity and mortality experience</TI>
<SO>J Hypertens</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>6</NO>
<PG>S21-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry HM, Smith WM, McDonald RH, Black D, Cutler JA, Furberg CD, et al</AU>
<TI>Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>1</NO>
<PG>4-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sprackling-1981" NAME="Sprackling 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sprackling ME, Mitchell JRA, Short AH, Watt G</AU>
<TI>Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa</TI>
<SO>BMJ</SO>
<YR>1981</YR>
<VL>283</VL>
<PG>1151-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STOP-1991" NAME="STOP 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester P-O</AU>
<TI>Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension)</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>1281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Syst_x002d_Eur-1991" NAME="Syst-Eur 1991" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amery A, Birkenhager W, Bulpitt CJ, et al</AU>
<TI>Syst-Eur: a multicenter trial on the treatment of isolated systolic hypertension in the elderly; objectives, protocol and organisation</TI>
<SO>Aging</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>287-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Celis H, Yodfat Y, Thijs L, Clement D, Cozic J, De Cort P, Forette F, Gregoire M, Heyrman J, Stibbe G, Van den Haute M, Staessen J, Fagard R</AU>
<TI>Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. The Syst-Eur Investigators</TI>
<SO>Fam Pract</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>2</NO>
<PG>138-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Girerd X, Amery A, Birkenhager W, Bulpitt C, Cox J, De Leeuw P. [SYST-EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report].[French] Archives des Maladies du Coeur et des Vaisseaux 1992;85(8):1243-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girerd X, Amery A, Birkenhager W, Bulpitt C, Cox J, De Leeuw P</AU>
<TI>[SYST-EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report]</TI>
<SO>[French] Archives des Maladies du Coeur et des Vaisseaux</SO>
<YR>1992</YR>
<VL>85</VL>
<NO>8</NO>
<PG>1243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slovick D, Staessen J, Bert P, Bulpitt C, de Cort P, Fagard R, et al</AU>
<TI>Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst-Eur trial</TI>
<SO>J Hum Hypertens</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>4</NO>
<PG>411-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slovick DI, Amery A, Birkenhager W, Bulpitt CJ, Cox J, de Leeuw P, et al</AU>
<TI>Syst-Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report</TI>
<SO>J Hum Hypertens</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>2</NO>
<PG>201-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slovick DI, Amery A, Birkenhager W, Bulpitt CJ, Cox J, de Leeuw P, et al</AU>
<TI>Syst-Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report</TI>
<SO>J Hum Hypertens</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>2</NO>
<PG>201-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staessen J, Bert P, Bulpitt C</AU>
<TI>de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst-Eur trial</TI>
<SO>J Hum Hypertens</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>3</NO>
<PG>265-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staessen JA, Fagard R, Thijs Lutgarde, Celis H, Arabidze GG, et al for the Systolic Hypertension in Euorpose (Syst-Eur) Trial Investigators</AU>
<TI>Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>757-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Staessen JA, Thijs L, Clement D, Davidson C, Fagard R, Lehtonen A, Mancia G, Palatini P, O'Brien ET, Parati G, et al. Ambulatory pressure decreases on long-term placebo treatment in older patients with isolated systolic hypertension. Syst-Eur Investigators. J Hypertens 1994:12(9):1035-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staessen JA, Thijs L, Clement D, Davidson C, Fagard R, Lehtonen A, Mancia G, Palatini P, O'Brien ET, Parati G, et al</AU>
<TI>Ambulatory pressure decreases on long-term placebo treatment in older patients with isolated systolic hypertension. Syst-Eur Investigators</TI>
<SO>J Hypertens</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>9</NO>
<PG>1035-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staessen JA, Thijs L, Mancia G, Parati G, O'Brien ET</AU>
<TI>Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst-Eur Investigators</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<NO>8936</NO>
<PG>1552-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staessen JA, Thijs L, Mancia G, Parati G, O'Brien ET</AU>
<TI>Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst-Eur Investigators</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<NO>8936</NO>
<PG>1552-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staessen JA, Tijs L, Bieniaszewski L, O'Brien ET, Palatini P, Davidson C, Dobovisek J, Jaaskivi M, Laks T, Lehtonen A, Vanhanen H, Webster J, Fagard R</AU>
<TI>Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators</TI>
<SO>Hypertension</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>3 Pt 1</NO>
<PG>414-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thijs L, Dabrowska E, Clement D, Fagard R, Laks T, Mancia G, O'Brien E, Omboni S, Parati G, Staessen J, et al</AU>
<TI>Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST-EUR Investigators</TI>
<SO>J Hum Hypertens</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>11</NO>
<PG>917-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VA-Coop-1970" NAME="VA Coop 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration Cooperative Study Group on Antihypertensive Agents</AU>
<TI>Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg</TI>
<SO>JAMA</SO>
<YR>1970</YR>
<VL>213</VL>
<NO>7</NO>
<PG>1143-1152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-07-14 07:36:19 -0700" MODIFIED_BY="Vijaya M Musini">
<STUDY DATA_SOURCE="PUB" ID="STD-ADVANCE-2007" MODIFIED="2009-04-06 08:47:55 -0700" MODIFIED_BY="[Empty name]" NAME="ADVANCE 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-04-06 08:47:55 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The ADVACNCE Collaborative Group</AU>
<TI>Eff ects of a fi xed combination of perindopril and indapamideon macrovascular and microvascular outcomes in patientswith type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial.</TI>
<SO>The Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<PG>829-840</PG>
<IDENTIFIERS MODIFIED="2009-04-06 08:47:55 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 08:47:55 -0700" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0140-6736(07)61303-8"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-04-06 08:44:52 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 08:44:52 -0700" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ALLHAT-1996" NAME="ALLHAT 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis BR, Cutler JA, Gordon DJ, et al, for the ALLHAT Research Group</AU>
<TI>Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</TI>
<SO>Am J Hypertens</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>342-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barraclough-1973" NAME="Barraclough 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barraclough M, Bainton D, Cochrane AL, et al</AU>
<TI>Control of moderately raised blood pressure: report of a cooperative randomized controlled trial</TI>
<SO>BMJ</SO>
<YR>1973</YR>
<VL>3</VL>
<PG>434-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BMJ-1973" NAME="BMJ 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Control of moderately raised blood pressure. Report of a co-operative randomized controlled trial</TI>
<SO>Br Med J</SO>
<YR>1973</YR>
<VL>3</VL>
<PG>434-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CASTEL-1994" MODIFIED="2009-04-06 09:04:20 -0700" MODIFIED_BY="[Empty name]" NAME="CASTEL 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-04-06 09:04:20 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casiglia E, Spolaore P, Mazza A, Ginocchio G, Colangeli G, Onesto C, et al</AU>
<TI>Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL)</TI>
<SO>Jpn Heart J</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>5</NO>
<PG>589-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-06 09:04:20 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casiglia E, Spolaore P, Mormino P, Maschio O, Colangeli G, Celegon L</AU>
<TI>The CASTEL project (CArdiovascular STudy in the ELderly): protocol, study design, and preliminary results of the initial survey</TI>
<SO>Cardiologia</SO>
<YR>1991</YR>
<VL>36</VL>
<NO>7</NO>
<PG>569-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GLANT-1995" NAME="GLANT 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Study Group on Long-term Antihypertensive Therapy. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - the GLANT Study. Hypertens Res 1995;18:235-244.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Study Group on Long-term Antihypertensive Therapy</AU>
<TI>A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - the GLANT Study</TI>
<SO>Hypertens Res</SO>
<YR>1995</YR>
<VL>18</VL>
<PG>235-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HAPPHY-1987" NAME="HAPPHY 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, Hornkvist PE, Pennert K, Tuomilehto J, Wedel H</AU>
<TI>Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial</TI>
<SO>J Hypertens</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>5</NO>
<PG>561-572</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HDFP-1982" MODIFIED="2009-07-14 07:36:19 -0700" MODIFIED_BY="Vijaya M Musini" NAME="HDFP 1982" YEAR="1982">
<REFERENCE MODIFIED="2009-03-28 11:35:16 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curb JD, Borhani NO, Schnaper H, Kass E, Entwisle G, Williams W, Berman R.</AU>
<TI>Detection and treatment of hypertension in older individuals.</TI>
<SO>Am J Epidemiol</SO>
<YR>1985</YR>
<VL>121</VL>
<NO>3</NO>
<PG>371-376</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-28 11:38:30 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hypertension Detection and Follow-up Program Cooperative Group</AU>
<TI>Five-year findings of the Hypertension Detection and Follow-up Program: III. Reduction in stroke incidence among persons with high blood pressure</TI>
<SO>JAMA</SO>
<YR>1982</YR>
<VL>247</VL>
<NO>5</NO>
<PG>633-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-14 07:35:47 -0700" MODIFIED_BY="Vijaya M Musini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hypertension Detection and Follow-up Program Cooperative Group</AU>
<TI>Five-year findings of the Hypertension Detection and Follow-up Program: reduction in mortality in persons with high blood pressure, including mild hypertension</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>242</VL>
<PG>2562-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-14 07:36:19 -0700" MODIFIED_BY="Vijaya M Musini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hypertension Detection and Follow-up Program Cooperative Group</AU>
<TI>The effect of treatment on mortality in "mild" hypertension: results of the Hypertension Detection and Follow-up Program</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<NO>16</NO>
<PG>976-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-28 11:39:31 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hypertension Detection and Follow-up Program Cooperative Group.</AU>
<TI>Five-year findings of the Hypertension Detection and Follow-up Program: II. Mortality by race-sex and age.</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>242</VL>
<PG>2572-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-28 11:43:08 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maxwell MH, Ford CE.</AU>
<TI>Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry</TI>
<SO>J Cardiovasc Pharmacol</SO>
<YR>1985</YR>
<VL>7</VL>
<NO>2</NO>
<PG>S5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HOT-1995" NAME="HOT 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansson L, Zanchetti A</AU>
<TI>The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. With special reference to age and gender</TI>
<SO>Blood Pressure</SO>
<YR>1995</YR>
<VL>4</VL>
<PG>313-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HYVET_x002d_Cog-2008" MODIFIED="2009-07-14 06:40:10 -0700" MODIFIED_BY="Vijaya M Musini" NAME="HYVET-Cog 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-14 06:40:10 -0700" MODIFIED_BY="Vijaya M Musini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C</AU>
<TI>Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>8</NO>
<PG>683-689</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IPPPSH-1985" NAME="IPPPSH 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>IPPPSH Collaborative Group</AU>
<TI>Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH)</TI>
<SO>J Hypertens</SO>
<YR>1985</YR>
<VL>3</VL>
<NO>4</NO>
<PG>379-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jikei-2007" MODIFIED="2009-07-14 06:41:22 -0700" MODIFIED_BY="Vijaya M Musini" NAME="Jikei 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-14 06:41:22 -0700" MODIFIED_BY="Vijaya M Musini" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N</AU>
<TI>Valsartan in a Japanese population with hypertensionand other cardiovascular disease (Jikei Heart Study):a randomised, open-label, blinded endpointmorbidity-mortality study</TI>
<SO>The Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<PG>1431-1439</PG>
<IDENTIFIERS MODIFIED="2009-07-14 06:41:22 -0700" MODIFIED_BY="Vijaya M Musini"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-04-06 09:05:50 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 09:05:50 -0700" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuramoto-1994" NAME="Kuramoto 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuramoto K</AU>
<TI>Treatment of elderly hypertensives in Japan: National Intervention Cooperative Study in Elderly Hypertensives. The National Intervention Cooperative Study Group</TI>
<SO>J Hypertens Suppl</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>6</NO>
<PG>S35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MAPHY-1988" NAME="MAPHY 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G</AU>
<TI>Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>259</VL>
<NO>13</NO>
<PG>1976-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Materson-1993" NAME="Materson 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al</AU>
<TI>Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo</TI>
<SO>N Engl J Med</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>13</NO>
<PG>914-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Materson BJ, Reda DJ, Cushman WC</AU>
<TI>Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents</TI>
<SO>Am J Hypertens</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>2</NO>
<PG>189-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MIDAS-1996" NAME="MIDAS 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, et al</AU>
<TI>Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>10</NO>
<PG>785-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-1980" NAME="Morgan 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan TO, Adams WR, Hodgson M, Gibberd RW</AU>
<TI>Failure of therapy to improve prognosis in elderly males with hypertension</TI>
<SO>Med J Aust</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1985" NAME="MRC 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council</AU>
<TI>MRC trial of treatment of mild hypertension: principal results</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1985</YR>
<VL>291</VL>
<NO>6488</NO>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oslo--1986" NAME="Oslo  1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Leren P, Helgeland A. Oslo Hypertension Study. Drugs. 1986;31(Suppl 1):41-45.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leren P, Helgeland A</AU>
<TI>Oslo Hypertension Study</TI>
<SO>Drugs</SO>
<YR>1986</YR>
<VL>31</VL>
<NO>1</NO>
<PG>41-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PATS-1995" NAME="PATS 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>PATS Collaborating Group</AU>
<TI>Post-stroke antihypertensive treatment study. A preliminary result</TI>
<SO>Chinese Medical Journal</SO>
<YR>1995</YR>
<VL>108</VL>
<NO>9</NO>
<PG>710-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SCOPE-2003" MODIFIED="2009-04-06 08:51:53 -0700" MODIFIED_BY="[Empty name]" NAME="SCOPE 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-06 08:51:53 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A</AU>
<TI>The Study on Cognition and Prognosis in the Elderly(SCOPE): principal results of a randomized double-blindintervention trial</TI>
<SO>Journal of Hypertension</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>875-886</PG>
<IDENTIFIERS MODIFIED="2009-04-06 08:51:53 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 08:51:53 -0700" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/01.hjh.0000059028.82022.89"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-04-06 08:48:59 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-06 08:48:59 -0700" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/01.hjh.0000059028.82022.89"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SHELL-1994" NAME="SHELL 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Malacco E, Gnemmi AE, Romagnoli A, Coppini A. Systolic hypertension in the elderly: long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group. J Cardiovasc Pharmacology 1994;23 Suppl 5:S6206.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malacco E, Gnemmi AE, Romagnoli A, Coppini A</AU>
<TI>Systolic hypertension in the elderly: long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group</TI>
<SO>J Cardiovasc Pharmacology</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>5</NO>
<PG>S6206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STONE-1996" NAME="STONE 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gong L, Zwang W, Zhu Y, et al</AU>
<TI>Shanghai Trial of Nifedipine in the Elderly (STONE) Study</TI>
<SO>J Hypertens</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>1237-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STOP_x002d_2-1993" NAME="STOP-2 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Dahlof B, Hansson L, Lindholm LH, et al: STOP-Hypertension-2: A prospective intervention trial of &amp;quot;newer&amp;quot; versus &amp;quot;older&amp;quot; treatment alternatives in old patients with hypertension. Blood Pressure 1993;2:136-41.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahlof B, Hansson L, Lindholm LH, et al</AU>
<TI>STOP-Hypertension-2: A prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension</TI>
<SO>Blood Pressure</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>136-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Syst_x002d_China-1993" NAME="Syst-China 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Anonymous. [Systolic hypertension in the elderly: Chinese trial (Syst-China)--second interim report].[Chinese] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 1993;21(3):135-7,185.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>[Systolic hypertension in the elderly: Chinese trial (Syst-China)--second interim report]</TI>
<SO>[Chinese] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>3</NO>
<PG>135-7,185</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Anonymous. [Systolic hypertension in the elderly: Chinese trial (Syst-China). Interim report].[Chinese] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 1992;20(5):270-5,323.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>[Systolic hypertension in the elderly: Chinese trial (Syst-China). Interim report]</TI>
<SO>[Chinese] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>5</NO>
<PG>270-5,323</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TOMHS-1995" NAME="TOMHS 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elmer PJ, Grimm R, Laing B, Grandits G, Svedsen K, Van Heel N, et al</AU>
<TI>Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS)</TI>
<SO>Prev Med</SO>
<YR>1995</YR>
<VL>24</VL>
<PG>378-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Treatment of Mild Hypertension Research Group</AU>
<TI>The Treatment of Mild Hypertension Study: a randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies</TI>
<SO>Arch Intern Med</SO>
<YR>1991</YR>
<VL>151</VL>
<PG>1413-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USPHS-Coop-1977" NAME="USPHS Coop 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;US Public Health Service Hospitals Cooperative Study Group. Treatment of mild hypertension: results of a ten year intervention trial. Circ Res. 1977;40(suppl 1):98-105.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>US Public Health Service Hospitals Cooperative Study Group</AU>
<TI>Treatment of mild hypertension: results of a ten year intervention trial</TI>
<SO>Circ Res</SO>
<YR>1977</YR>
<VL>40</VL>
<NO>1</NO>
<PG>98-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VA-Coop-1962" NAME="VA Coop 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration Cooperative Study Group on Antihypertensive Agents</AU>
<TI>A double-blind control study of antihypertensive agents. I. Comparative effect of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, clorisondamine, mecamylamine, and pentolinium tartrate</TI>
<SO>Arch Intern Med</SO>
<YR>1960</YR>
<VL>106</VL>
<PG>133-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration Cooperative Study Group on Antihypertensive Agents</AU>
<TI>A double-blind control study of antihypertensive agents. II. Further report on the comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, clorisondamine, mecamylamine, and pentolinium tartrate</TI>
<SO>Arch Intern Med</SO>
<YR>1962</YR>
<VL>110</VL>
<PG>222-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration Cooperative Study Group on Antihypertensive Agents</AU>
<TI>A double-blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results</TI>
<SO>Arch Intern Med</SO>
<YR>1962</YR>
<VL>110</VL>
<PG>230-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VA_x002f_NHLBI-1978" NAME="VA/NHLBI 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Veterans Administration/National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Ann NY Acad Sci. 1978;304:267-288.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration/National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension</AU>
<TI>Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial</TI>
<SO>Ann NY Acad Sci</SO>
<YR>1978</YR>
<VL>304</VL>
<PG>267-288</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1995" NAME="White 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White WB, Stimpel M</AU>
<TI>Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension</TI>
<SO>J Human Hypertens</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>11</NO>
<PG>879-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-1966" NAME="Wolf 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf FW, Lindeman RD</AU>
<TI>Effects of treatment in hypertension. Results of a controlled study</TI>
<SO>J Chronic Dis</SO>
<YR>1966</YR>
<VL>19</VL>
<PG>227-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-07-13 19:04:08 -0700" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-11 15:59:56 -0700" MODIFIED_BY="Ciprian D Jauca">
<ADDITIONAL_REFERENCES MODIFIED="2009-08-11 15:58:15 -0700" MODIFIED_BY="Ciprian D Jauca">
<REFERENCE ID="REF-Alderman-1981" NAME="Alderman 1981" TYPE="JOURNAL_ARTICLE">
<AU>Alderman MH, Madhavan S</AU>
<TI>Management of the hypertensive patient: a continuing dilemma</TI>
<SO>Hypertension</SO>
<YR>1981</YR>
<VL>3</VL>
<PG>192-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderman-1993" NAME="Alderman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Alderman MH</AU>
<TI>Blood pressure management: Individualized treatment based on absolute risk and the potential for benefit</TI>
<SO>Ann Intern Med</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>329-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Applegate-1992" MODIFIED="2009-08-11 15:17:45 -0700" MODIFIED_BY="Ciprian D Jauca" NAME="Applegate 1992" TYPE="JOURNAL_ARTICLE">
<AU>Applegate WB, Miller ST, Elam JT, Cushman WC, el Derwi D, Brewer A, Graney M J</AU>
<TI>Nonpharmacologic intervention to reduce blood pressure in older patients with mild hypertension</TI>
<SO>Arch-Intern-Med</SO>
<YR>1992</YR>
<VL>152</VL>
<NO>6</NO>
<PG>1162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Browner-1989" MODIFIED="2009-07-13 19:06:57 -0700" MODIFIED_BY="[Empty name]" NAME="Browner 1989" TYPE="JOURNAL_ARTICLE">
<AU>Browner WS, Hulley SB</AU>
<TI>Implications of hypertension trials: effect of risk status on treatment criteria</TI>
<SO>Hypertension</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1</NO>
<PG>51-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Celis-1993" NAME="Celis 1993" TYPE="JOURNAL_ARTICLE">
<AU>Celis H, Fagard R, Staessen J, Thijs L, Amery A</AU>
<TI>The older hypertensive: Assessment and treatment</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>1993</YR>
<VL>43</VL>
<PG>S66-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1990" NAME="Collins 1990" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH</AU>
<TI>Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<NO>8693</NO>
<PG>827-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1987" NAME="Davidson 1987" TYPE="JOURNAL_ARTICLE">
<AU>Davidson RA, Caranasos GJ</AU>
<TI>Should the elderly hypertensive be treated? Evidence from clinical trials</TI>
<SO>Arch Intern Med</SO>
<YR>1987</YR>
<VL>147</VL>
<PG>1933-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebrahim-2006" MODIFIED="2009-08-11 13:11:43 -0700" MODIFIED_BY="Ciprian D Jauca" NAME="Ebrahim 2006" TYPE="COCHRANE_REVIEW">
<AU>Ebrahim S, Beswick A, Burke M, Davey Smith G</AU>
<TI>Multiple risk factor interventions for primary prevention of coronary heart disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-08-11 13:11:43 -0700" MODIFIED_BY="Ciprian D Jauca">
<IDENTIFIER MODIFIED="2009-08-11 13:11:43 -0700" MODIFIED_BY="Ciprian D Jauca" TYPE="DOI" VALUE="10.1002/14651858.CD001561.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gueyffier-1997" NAME="Gueyffier 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al</AU>
<TI>Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators</TI>
<SO>Ann Intern Med</SO>
<YR>1997</YR>
<VL>126</VL>
<NO>10</NO>
<PG>761-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gueyffier-F-1999" MODIFIED="2009-04-14 14:58:34 -0700" MODIFIED_BY="Vijaya M Musini" NAME="Gueyffier F 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gueyffier F, Bulpitt C, Boissel, et al for INDANA group</AU>
<TI>Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9155</NO>
<PG>793-796</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Insua-1994" MODIFIED="2009-08-11 15:58:15 -0700" MODIFIED_BY="Ciprian D Jauca" NAME="Insua 1994" TYPE="JOURNAL_ARTICLE">
<AU>Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers T</AU>
<TI>Drug treatment of hypertension in the elderly: A meta-analysis</TI>
<SO>Ann Intern Med</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>355-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-1997" NAME="Ioannidis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JPA, Lau J</AU>
<TI>The impact of high-risk patients on the results of clinical trials</TI>
<SO>J Clin Epidemiol</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>10</NO>
<PG>1089-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leonetti-1992" MODIFIED="2009-07-13 19:07:08 -0700" MODIFIED_BY="[Empty name]" NAME="Leonetti 1992" TYPE="JOURNAL_ARTICLE">
<AU>Leonetti G, Cuspidi C, Fastidio M, Lonati L, Chianca R</AU>
<TI>Arterial hypertension as a risk factor in the elderly and its treatment</TI>
<SO>Journal of Hypertension</SO>
<YR>1992</YR>
<VL>10</VL>
<NO>2</NO>
<PG>S3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacMahon-1993" NAME="MacMahon 1993" TYPE="JOURNAL_ARTICLE">
<AU>MacMahon S, Rogers A</AU>
<TI>The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives</TI>
<SO>Clin Exper Hypertension</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>6</NO>
<PG>967-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mann-1992" NAME="Mann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Mann SJ</AU>
<TI>Systolic hypertension in the elderly</TI>
<SO>Arch Intern Med</SO>
<YR>1992</YR>
<VL>152</VL>
<PG>1977-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Musini-VM-2008" MODIFIED="2009-07-14 07:43:39 -0700" MODIFIED_BY="Vijaya M Musini" NAME="Musini VM 2008" TYPE="JOURNAL_ARTICLE">
<AU>Musini VM, Tejani A, Bassett K and Wright JM</AU>
<TI>Treatment of elevated blood pressure in the elderly. Less is better</TI>
<SO>Therapeutics Initiative (www.ti.ubc.ca)</SO>
<YR>September - October 2008</YR>
<VL>Therapeutics Letter 71</VL>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pearce-1995" NAME="Pearce 1995" TYPE="JOURNAL_ARTICLE">
<AU>Pearce KA, Furberg CD, Rushing J</AU>
<TI>Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life?</TI>
<SO>Arch Fam Med</SO>
<YR>1995</YR>
<VL>4</VL>
<PG>943-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Psaty-1997" MODIFIED="2009-07-10 13:43:22 -0700" MODIFIED_BY="James M Wright" NAME="Psaty 1997" TYPE="JOURNAL_ARTICLE">
<AU>Psaty BM. Smith NL. Siscovick DS. Koepsell TD, et al.</AU>
<TI>Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>277</VL>
<PG>739-745</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Psaty-2003" MODIFIED="2009-07-10 13:47:20 -0700" MODIFIED_BY="James M Wright" NAME="Psaty 2003" TYPE="JOURNAL_ARTICLE">
<AU>Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS</AU>
<TI>Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<PG>2534-2544</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmid-1998" NAME="Schmid 1998" TYPE="JOURNAL_ARTICLE">
<AU>Schmid CH, Lau J, McIntosh MW, Cappelleri JC</AU>
<TI>An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>17</NO>
<PG>1923-1942</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staessen-1988" NAME="Staessen 1988" TYPE="JOURNAL_ARTICLE">
<AU>Staessen J, Fagard R, Van Hoof R, Amery A</AU>
<TI>Mortality in various intervention trials in elderly hypertensive patients: A review</TI>
<SO>European Heart Journal</SO>
<YR>1988</YR>
<VL>9</VL>
<PG>215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staessen-1990a" MODIFIED="2009-07-13 19:07:53 -0700" MODIFIED_BY="[Empty name]" NAME="Staessen 1990a" TYPE="JOURNAL_ARTICLE">
<AU>Staessen J, Fagard R, Van Hoof R, Amery A</AU>
<TI>Intervention trials in elderly hypertensive patients: a review</TI>
<SO>Journal of Hypertension</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>4</NO>
<PG>S63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staessen-1990b" NAME="Staessen 1990b" TYPE="JOURNAL_ARTICLE">
<AU>Staessen J, Amery A, Fagard R</AU>
<TI>Isolated systolic hypertension in the elderly</TI>
<SO>Journal of Hypertension</SO>
<YR>1990</YR>
<VL>8</VL>
<PG>393-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thijs-1992" NAME="Thijs 1992" TYPE="JOURNAL_ARTICLE">
<AU>Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoof R, Amery A</AU>
<TI>A meta-analysis of outcome trials in elderly hypertensives</TI>
<SO>Journal of Hypertension</SO>
<YR>1992</YR>
<VL>10</VL>
<PG>1103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thijs-1994" MODIFIED="2009-07-14 07:45:56 -0700" MODIFIED_BY="Vijaya M Musini" NAME="Thijs 1994" TYPE="JOURNAL_ARTICLE">
<AU>Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoof R, Amery A</AU>
<TI>Why is antihypertensive drug therapy needed in elderly patients with systodiastolic hypertension?</TI>
<SO>Journal of Hypertension</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>6</NO>
<PG>S25-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-JM-1999" MODIFIED="2009-07-13 19:08:22 -0700" MODIFIED_BY="[Empty name]" NAME="Wright JM 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wright JM, Lee Cheng-Han, Chambers KG</AU>
<TI>Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug?</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>161</VL>
<PG>25-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-JM-2009" MODIFIED="2009-07-14 07:46:30 -0700" MODIFIED_BY="Vijaya M Musini" NAME="Wright JM 2009" TYPE="COCHRANE_REVIEW">
<AU>Wright JM, Musini VM . Cochrane Database of Systematic Reviews</AU>
<TI>First-line drugs for hypertension</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<PG>CD001841. DOI: 10.1002/14651858.CD001841.pub2</PG>
<IDENTIFIERS MODIFIED="2009-07-10 13:50:31 -0700" MODIFIED_BY="James M Wright">
<IDENTIFIER MODIFIED="2009-07-10 13:50:31 -0700" MODIFIED_BY="James M Wright" TYPE="DOI" VALUE="CD001841. DOI: 10.1002/14651858.CD001841.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-08-11 15:59:56 -0700" MODIFIED_BY="Ciprian D Jauca">
<REFERENCE ID="REF-Mulrow-1994" NAME="Mulrow 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C</AU>
<TI>Hypertension in the elderly: Implications and generalizability of randomized trials</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<PG>1932-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1998" MODIFIED="2009-08-11 15:59:56 -0700" MODIFIED_BY="Ciprian D Jauca" NAME="Mulrow 1998" TYPE="COCHRANE_REVIEW">
<AU>Mulrow CD, Lau J, Cornell J, Brand M</AU>
<TI>Pharmacotherapy for hypertension in the elderly</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-08-11 15:59:56 -0700" MODIFIED_BY="Ciprian D Jauca">
<IDENTIFIER MODIFIED="2009-08-11 15:59:56 -0700" MODIFIED_BY="Ciprian D Jauca" TYPE="DOI" VALUE="10.1002/14651858.CD000028"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES>
<REFERENCE ID="REF-Dahlof-1991" NAME="Dahlof 1991" NOTES="&lt;p&gt;Dahlof B, Lindholm LH, Hansson L, et. al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;23(338):1281-5.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dahlof B, Lindholm LH, Hansson L, et al</AU>
<TI>al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>23</VL>
<NO>338</NO>
<PG>1281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-13 19:04:08 -0700" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-06-09 17:05:57 -0700" MODIFIED_BY="Vijaya M Musini" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-04-17 13:41:44 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ANBP-1981">
<CHAR_METHODS MODIFIED="2009-04-17 13:41:44 -0700" MODIFIED_BY="[Empty name]">
<P> Multisite study.<BR/>Randomization: stratified by age and sex; method of randomization not stated.<BR/>Patients blinded; providers blinded.<BR/>Lost to follow-up: 2.1%<BR/>% not on assigned therapy at study end:<BR/>placebo group: 35%<BR/>treatment group: 33%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: Australia<BR/>Study setting: community.<BR/>n = 582 (45% female)<BR/>Age range: 60-69 mean: 63.6<BR/>Race: White.<BR/>Mean blood pressure at entry: 165/101 mmHg<BR/>Pre-existing risk factors:<BR/> myocardial infarction: excluded if in last three months; 0.5% before 3 months<BR/> diabetes: excluded<BR/> smoking: 17.5%<BR/> hyperlipidemia: 62.2% (cholesterol &gt;220 mg/dL)<BR/>Blood pressure (BP) entry criteria: systolic BP &lt; 200 mm Hg and diastolic BP 95 - 110 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: matching placebo.<BR/>Treatment: Step 1 - chlorothiazide 500mg daily; Step 2 - chlorothiazide 500mg twice daily or methyldopa or propranolol or pindolol; Step 3 - hydralazine or clonidine.<BR/>Average follow-up: 3.9 years.<BR/>Difference in blood pressure at end of study (Treatment - Control) diastolic: -6.7 (systolic not stated)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality - death from any cause.<BR/>CHD (Coronary Heart Disease mortality) mortality - fatal ischemic heart disease<BR/>CHD M&amp;M (morbidity and mortality) - CHD mortality; non-fatal myocardial infarction.<BR/>Cerebrovascular mortality<BR/>Cerebrovascular M&amp;M - non-fatal cerebrovascular hemorrhage or thrombosis<BR/>Cardiovascular mortality -CHD mortality; cerebrovascular mortality<BR/>Cardiovascular M&amp;M - CHD M&amp;M; cerebrovascular M&amp;M; transitory cerebral ischemic attacks; aortic aneurysms.<BR/>Dropouts due to side effects: not stated.<BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: on treatment for hypertension in past 3 months; history of myocardial infarction in past 3 months; history of stroke; pregnancy; taking estrogen and progesterone in combination; asthma; diabetes; gout; secondary hypertension; evidence of cerebrovascular disease, transient cerebral vascular attacks, acute coronary insufficiency, angina pectoris, plasma creatinine &gt;2mg/dL; other serious complications of hypertension; ECG evidence of myocardial ischemia; any potentially fatal disease; taking tricyclic antidepressants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Carter-1970">
<CHAR_METHODS>
<P>Single site study.<BR/>Random allocation: method not described.<BR/>Patients and providers not blinded.<BR/>Lost to follow-up: 2.8%.<BR/>% not on assigned therapy at study end: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic area: England<BR/>Study setting: recruited in hospital, treatment group followed up in clinic.<BR/>n = 71 (47.9% female)<BR/>Age range: 60 - 79 mean: not reported.<BR/>Race: not reported.<BR/>Mean blood pressure (BP) at entry: not reported (entry criteria were systolic BP &gt;160 mmHg and/or diastolic BP &gt; 110 mmHg.<BR/>Pre-existing factors:<BR/> stroke: 100%<BR/>Blood pressure (BP) entry criteria: (systolic BP &gt; 160 mm Hg and diastolic BP &lt; 110 mm Hg) or (diastolic BP &gt;= 110 mm Hg irrespective of systolic BP).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: observation without placebo.<BR/>Treatment: first choice - thiazide diuretic; second choice - methyldopa; third choice - bethanidine, debrisoquine or guanethidine.<BR/>Average follow-up: 4.0 years<BR/>Difference in blood pressure at study end: not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality: death from all causes.<BR/>Dropouts due to side effects: not reported.<BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: cerebral hemorrhage, embolism, tumor, accelerated hypertension, "those with an obvious need for hypotensive therapy," left ventricular failure, congestive cardiac failure, gross radiological cardiac enlargement, various cardiac arrhythmias, evidence of renal failure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-EWPHE-1989">
<CHAR_METHODS>
<P>Multisite study.<BR/>Random allocation; method not stated; stratified by age, sex, presence or absence of cardiovascular complications and site.<BR/>Patients blinded; providers blinded; outcomes assessors blinded.<BR/>Lost to follow-up: 15.2%<BR/>% not on assigned therapy at study end:<BR/> placebo group: &gt;35%<BR/> treatment group: &gt;35%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: Europe (Belgium (25%), United Kingdom (19%), Finland (17%), France (14%), Italy (7%), The Netherlands (7%), Ireland (6%), Portugal (3%), Norway (2%), West-Germany (1%)) <BR/>Study setting: Hospitals (geriatric); physician offices; nursing home.<BR/>n = 840 (69.8% female)<BR/>Age range: 60-97 mean: 72.0<BR/>Race: not stated.<BR/>Mean blood pressure at entry: 182/101 mmHg<BR/>Pre-existing factors:<BR/> smoking: 16.4%<BR/>Blood pressure (BP) entry criteria: systolic BP 160 - 239 mm Hg and diastolic BP 90 - 119 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: matching placebo.<BR/>Treatment: Step 1 - hydrochlorothiazide 25-50mg + triamterene 50-100mg daily; Step 2 - methyldopa 250-2000mg daily.<BR/>Average follow-up: placebo 4.63 years; treatment 4.69 years<BR/>Difference in blood pressure at study end (Treatment - Control) systolic/diastolic: -22/-10 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality - death from any cause.<BR/>CHD (Coronary Heart Disease mortality) mortality - fatal myocardial infarction and ischemic heart disease, sudden death and fatal arrhythmia, fatal heart failure.<BR/>Cerebrovascular mortality - fatal stroke<BR/>Cardiovascular mortality - CHD mortality plus cerebrovascular mortality.<BR/>Dropouts due to side effects: not stated.<BR/>Quality of life or functional outcomes: not stated.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: curable causes of high blood pressure; certain complications of hypertension (ie, retinopathy grade III or IV, congestive heart failure, history of cerebral or subarachnoid hemorrhage); concurrent diseases such as hepatitis or cirrhosis, gout, malignancy and diabetes mellitus requiring insulin treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HEP-1986">
<CHAR_METHODS>
<P>Multisite study.<BR/>Randomization: random number table used and allocation assignment distributed in opaque envelopes; not stratified by site. <BR/>Patients and providers not blinded; assessors of morbidity and mortality outcomes were blinded.<BR/>% lost to follow-up: not stated.<BR/>% not on assigned therapy at study end:<BR/> control group: 9% <BR/> treatment group: 5%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: England and Wales<BR/>Study setting: primary care (physician's offices)<BR/>n = 884 (69.5% female)<BR/>Age range: 60-79 mean: 68.8<BR/>Race: not stated.<BR/>Mean blood pressure at entry: 196/99 mmHg<BR/>Pre-existing factors:<BR/> smoking: 24%<BR/>Blood pressure (BP) entry criteria: systolic BP 170 - 280 mm Hg and /or diastolic BP 105 - 120 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: observation without placebo<BR/>Treatment: Step 1 - atenolol 100mg daily; Step 2 - bendrofluazide 5mg daily; Step 3 - methyldopa 500mg daily; Step 4 - any recognized therapy.<BR/>Average follow-up: 4.4 years<BR/>Difference in blood pressure at end of study (Treatment - Control) systolic/diastolic: -18/-11</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality - death from all causes.<BR/>CHD (Coronary Heart Disease) mortality - fatal myocardial infarctions; sudden death.<BR/>CHD M&amp;M (morbidity and mortality) - fatal and non-fatal myocardial infarctions.<BR/>Cerebrovascular mortality - fatal strokes.<BR/>Cerebrovascular M&amp;M - fatal strokes; major strokes and minor strokes.<BR/>Cardiovascular mortality - fatal coronary artery attacks; fatal strokes and fatal ruptured aneurysms.<BR/>Cardiovascular M&amp;M - CHD M&amp;M; cerebrovascular M&amp;M; transient ischemic attacks, ventricular failure.<BR/>Dropouts due to side effects: not stated.<BR/>Quality of life or functional status outcomes: symptom questionnaires showed no significant differences between groups.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: atrial fibrillation, A-V heart block, ventricular failure, bronchial asthma, diabetes mellitus (needing pharmacological treatment), any serious concomitant disease limiting the prospect of fruitful living, untreated hypertension with levels persistently above 280 mm Hg systolic or 120 mm Hg diastolic, patients already being treated for hypertension (within three months), dementia.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-06 11:27:42 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HTN-Coop-1974">
<CHAR_METHODS>
<P>Multisite study.<BR/>Randomization: patients randomly allocated by biostatisticians at central register; stratified by sex, race and diastolic blood pressure.<BR/>Patients blinded. Providers blinded.<BR/>% lost to follow-up: not reported.<BR/>% not on assigned therapy at study end: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: United States of America<BR/>Study setting: outpatient clinics.<BR/>n = 200 (39.5% female)<BR/>Age range:60-75 mean: not reported<BR/>Race: Black (77.5%); non-Black (22.5%)<BR/>Mean blood pressure at entry: 167/100 mmHg for entire study group (ie, this data not reported for &gt;60 age sub-group).<BR/>Pre-existing risk factors: all patients had history of stroke and/or TIA.<BR/> stroke only: 80%<BR/> transient ischemic attack (TIA) only: 4%<BR/> both stroke and TIA: 16%<BR/> diabetes: 36%<BR/> smoking: 60%<BR/> obesity: 29%<BR/> hyperlipidemia: 22%<BR/>Blood pressure (BP) entry criteria: systolic BP 140 - 220 mm Hg and diastolic BP 90 - 115 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: placebo.<BR/>Treatment: deserpidine 0.5mg and methyclothiazide 5mg in one tablet twice daily.<BR/>Average follow-up: 2.3 years.<BR/>Difference in blood pressure at study end (Treatment - Control) systolic/diastolic: -27 / -12 mmHg; estimated from graphical presentation of data and for entire study group (ie, this data not reported for &gt;60 age sub-group).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-06 11:27:42 -0700" MODIFIED_BY="[Empty name]">
<P>Cerebrovascular morbidity and mortality (M&amp;M) - fatal and non-fatal stroke<BR/>Dropouts due to side effects: for entire study group (ie, this data not reported for &gt;60 age sub-group).<BR/>during 6-week pre-trial run-in phase with treatment drugs: 1.4%<BR/>during post-randomization period on treatment drugs: 3%<BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: non-ambulatory subjects, &gt;= 75 years old, concomitant disease that might be influenced adversely by prolonged treatment with drug or placebo, development of intolerable side effects during 6-week pre-trial run in on deserpidine and methyclothiazide.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-06-09 17:05:57 -0700" MODIFIED_BY="Vijaya M Musini" STUDY_ID="STD-HYVET-2008">
<CHAR_METHODS MODIFIED="2009-04-06 12:05:22 -0700" MODIFIED_BY="[Empty name]">
<P>Multisite study.<BR/>Randomization: Sequence generation not reported. Randomization was stratified according to age (80 to 89 years and 90 years or older) and sex; permuted blocks of 4 and 6 of any 10 patients were used to ensure roughly equal assignment to each of the two groups within large centers.<BR/>Patients and providers were blinded<BR/>% lost to follow-up: active treatment 0.3%, placebo 0.6%<BR/>% not on assigned therapy at study end: active treatment 0.8%, placebo 0.6%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-09 17:05:57 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Geographic region: Western Europe (86 patients), Eastern Europe (2144), China (1526), Australasia (19),<BR/>and Tunisia (70).<BR/>Study setting: Outpatient<BR/>n =3845 (61% women)<BR/>Age range: 80-105 mean age = 84 years<BR/>Race: not stated.<BR/>Mean blood pressure at entry: sitting active treatment 173±8.4/90.8±8.5 and sitting placebo 173.0±8.6/90.8±8.5; standing active treatment 168.0±11.0/88.7±9.3, sitting placebo 167.9±11.1/88.6±9.3</P>
<P>Pre-existing factors:<BR/>Cardiovascular disease =12.0%<BR/>Hypertension = 89.9%<BR/>Antihypertensive treatment = 64%<BR/>Stroke = 6.8%<BR/>Myocardial infarction = 3.1%</P>
<P>Diabetes = 6.8%<BR/>Heart failure = 2.9%<BR/>smoking: 6.5%<BR/>Blood pressure (BP) entry criteria: mean of the four systolic blood-pressure measurements taken at the second and third visits (two at each visit) was between 160 and 199mm Hg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-06 12:30:09 -0700" MODIFIED_BY="[Empty name]">
<P>Control: placebo.<BR/>Treatment: indapamide alone, indapamide plus perindopril 2mg, or indapamide plus perindopril 4mg<BR/>Average follow-up: 2.1 years (median 1.8 years)<BR/>Difference in blood pressure at study end (Treatment - Control) systolic/diastolic: sitting -15.0/-6.1 mmHg, standing -14.7/-5.4 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-06 12:35:57 -0700" MODIFIED_BY="[Empty name]">
<P>Fatal/non-fatal stroke</P>
<P>All-cause mortality</P>
<P>Non-cardiovascular /unknown cause mortality</P>
<P>Cardiovascular mortality</P>
<P>Cardiac mortality</P>
<P>Heart failure mortality</P>
<P>Any cardiovascular event</P>
<P>Myocardial infarction</P>
<P>Heart failure</P>
<P>Quality of life<BR/>Dropouts due to side effects: not reported<BR/>Quality of life or functional status outcomes: not reported (yet)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-17 13:44:36 -0700" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-06-09 15:44:56 -0700" MODIFIED_BY="Vijaya M Musini" STUDY_ID="STD-HYVET-P-2003">
<CHAR_METHODS MODIFIED="2009-04-06 10:56:34 -0700" MODIFIED_BY="[Empty name]">
<P>Multisite study.<BR/>Randomization: SAS Random Allocation of Treatments Balanced in Blocks Program was used to generate the schedule. Restricted random allocation to groups was used to ensure equal allocation per group within each centre and allocation to groups was performed centrally. Stratified into four groups on the basis of<BR/>sex and age (80&#8211;89 years and . 90 years).<BR/>Patients and providers were not blinded<BR/>% lost to follow-up: diuretic 2%, ACEI 2%, no treatment 2%<BR/>% not on assigned therapy at study end: diuretic 97%, ACEI 96%, no treatment 99.2%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-09 15:44:56 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Geographic region: 1130 (88%) in Bulgaria, 39 (3%) in Spain, 39 (3%) in Romania, 32 (2.5%) in the UK, 20<BR/>(1.5%) in Poland and smaller numbers in Finland, Lithuania, Ireland, Greece and Serbia.<BR/>Study setting: both primary and secondary care<BR/>n =1283 (63% women)<BR/>Age range: 79.5-96.1 mean: mean age = 84 years<BR/>Race: not stated.<BR/>Mean blood pressure at entry: systolic blood pressure averaged 181.5 <U>+</U> 11.3 mmHg (range 160&#8211;217 mmHg) and entry diastolic pressure averaged 99.6 <U>+</U> 3.4 mmHg (range 90&#8211;114 mmHg)</P>
<P>Pre-existing factors: patients were not obese, with an average body mass index of 25 kg/m2; 48% had been previously treated, 3.0% had had a previous myocardial infarction, 4.5% a previous stroke, and 20.7% drank more than 1 unit of alcohol per day.<BR/>smoking: 4.2%<BR/>Blood pressure (BP) entry criteria: systolic blood pressure (average of four readings)<BR/>160&#8211;219 mmHg, diastolic blood pressure 95&#8211;109 mmHg (later changed to 90&#8211;109 mmHg), standing<BR/>systolic blood pressure &gt;140 mmHg (average of two readings)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-06 11:27:19 -0700" MODIFIED_BY="[Empty name]">
<P>Control: no treatment<BR/>Treatment: Diuretic usually bendroflumethiazide (bendrofluazide) 2.5 mg and ACEI usually lisinopril 2.5 mg. <BR/>To attain target blood pressure in the actively treatedg groups, the procedure allowed for the dose of diureticor ACE inhibitor to be doubled (step 2), diltiazem slow-release 120 mg to be added (step 3) and diltiazem slow-release 240 mg to be added (step 4). The target blood pressures were a sitting systolic pressure less than 150 mmHg plus a sitting diastolic pressure less than 80 mmHg<BR/>Average follow-up: 13 months<BR/>Difference in blood pressure at study end (Treatment - Control):sitting BP difference between diuretic/ACEI and no treatment -23/-11 mmHg;standing BP difference between duiretic and no treatment -23/-11 mmHg and difference between ACEI and no treatment -24/-12 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-06 11:48:17 -0700" MODIFIED_BY="[Empty name]">
<P>Stroke events<BR/>total mortality</P>
<P>cardiovascular mortality</P>
<P>cardiac mortality</P>
<P>stroke mortality.<BR/>Dropouts due to side effects: not reported<BR/>Quality of life or functional status outcomes: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kuramoto-1981">
<CHAR_METHODS>
<P>Single site study.<BR/>Allocation of individuals within matched pairs to treatment and control groups made by a blinded statistical coordinator; thought to be randomized, but not entirely clear (unpublished information as per personal conversation with author).<BR/>Patients blinded. Providers blinded.<BR/>Lost to follow-up: 13.2%<BR/>% not on assigned therapy at study end:<BR/> placebo group: 17% (withdrawn due to "elevated blood pressure") <BR/> treatment group: not clear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic area: Tokyo, Japan.<BR/>Study setting: home for the aged.<BR/>n = 91 (45% female)<BR/>Age range: &gt; 60 mean: 76.1<BR/>Race: not stated.<BR/>Mean blood pressure at entry: 169/86 mmHg (isolated systolic hypertension in 44% of subjects).<BR/>Pre-existing factors: not reported.<BR/>Blood pressure (BP) entry criteria: not clearly stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: placebo<BR/>Treatment: Step 1 - trichlormethiazide 1-4mg/day; Step 2 - reserpine 0.3 mg/day or methyldopa 125-500mg/day or hydralazine 50-100mg/day.<BR/>Average follow-up: 4.0 years.<BR/>Difference in blood pressure at study end (based on only 29 patients) (Treatment - Control) systolic/diastolic: 0.8 / 1.3 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality - death from all causes.<BR/>Coronary heart disease (CHD) mortality - fatal myocardial infarction and sudden death.<BR/>CHD morbidity and mortality (M&amp;M) - CHD mortality plus non-fatal myocardial infarctions.<BR/>Cerebrovascular morbidity - fatal cerebral infarction or cerebral hemorrhage.<BR/>Cerebrovascular M&amp;M - fatal and non-fatal cerebral infarction or cerebral hemorrhage.<BR/>Cardiovascular mortality - CHD mortality plus cerebrovascular mortality.<BR/>Cardiovascular M&amp;M - CHD M&amp;M plus cerebrovascular M&amp;M plus congestive heart failure with arrhythmia.<BR/>Dropout due to side effects: not reported.<BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-06-09 15:24:26 -0700" MODIFIED_BY="Vijaya M Musini" STUDY_ID="STD-MRCOA-1992">
<CHAR_METHODS>
<P>Multisite study.<BR/>Randomization: stratified by gender and site; at each site subjects were assigned to therapy based on computer generated lists.<BR/>Patients blinded; providers not blinded; mortality outcome assessors blinded.<BR/>Lost to follow-up: 25%<BR/>% not on assigned therapy at study end (including withdrawals and lost to follow-up):<BR/> placebo group: 53%<BR/> diuretic arm: 48%<BR/> beta-blocker arm: 63%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-09 15:24:26 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Geographic region: UK<BR/>Study setting: general practice<BR/>n = 4396 (58% female)<BR/>Age range: 60-74 mean: 70.3 years<BR/>Race: not reported<BR/>Mean blood pressure at entry: 184/91 mmHg<BR/>Pre-existing risk factors:<BR/>myocardial infarction: excluded if within last 3 months<BR/>stroke: excluded if within last 3 months<BR/>diabetes: excluded<BR/>smoking: 17.5%<BR/>Blood pressure (BP) entry criteria: systolic BP 160 - 209 mm Hg and diastolic BP &lt; 115 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: matching placebo<BR/>Diuretic Arm: Step 1 - hydrochlorothiazide 25mg or 50mg + amiloride 2.5mg or 5 mg daily; Step 2 - atenolol 50mg daily; Step 3 - nifedipine up to 20mg daily; Step 4 - other drugs<BR/>Beta-blocker Arm: Step 1 - atenolol 50mg daily; Step 2 - hydrochlorothiazide 25mg or 50mg + amiloride 2.5mg or 5 mg daily; Step 3 - nifedipine up to 20mg daily; Step 4 - other drugs<BR/>Average follow-up: 5.8 years<BR/>Difference in blood pressure at study end (Treatment - Control) systolic/diastolic: -6.3/-5.9 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality - death from any cause.<BR/>CHD (Coronary Heart Disease mortality) mortality - sudden death thought to be due to a coronary cause; death known to be due to a myocardial infarction.<BR/>CHD M&amp;M (morbidity and mortality) - CHD mortality; non-fatal myocardial infarction.<BR/>Cerebrovascular mortality - fatal stroke.<BR/>Cerebrovascular M&amp;M - fatal or non-fatal stroke.<BR/>Cardiovascular mortality -CHD mortality and fatal stroke.<BR/>Cardiovascular M&amp;M - CHD M&amp;M plus cerebrovascular M&amp;M plus deaths due to hypertension and to rupture or dissection of an aortic aneurysm.<BR/>Dropouts due to side effects:<BR/> Control group: 82 (3.7%)<BR/> Diuretic Arm: 160 (14.8%)<BR/> Beta-blocker Arm: 333 (30.2%)<BR/>Quality of life or functional outcomes: no perceptible negative effect of treatment compared to control on measures of cognitive function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: known or suspected secondary hypertension; taking antihypertensive drugs; cardiac failure or any other accepted indication for antihypertensive treatment; receiving treatment for angina pectoris; history of myocardial infarction or stroke within preceding three months; impaired renal function; diabetic; asthma; serious intercurrent disease, including malignancy known to be present at time of examination; serum potassium concentration &lt;= 3.4 mmol/L or &gt; 5.0 mmol/L.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-06-09 15:24:34 -0700" MODIFIED_BY="Vijaya M Musini" STUDY_ID="STD-SHEP-1991">
<CHAR_METHODS>
<P>Multisite study.<BR/>Randomization: stratified by site and by antihypertensive medication status at initial contact; patients randomly allocated by coordinating center.<BR/>Patients blinded; providers blinded; morbidity and mortality outcomes assessors were blinded.<BR/>% lost to follow-up: &lt;1%.<BR/>% not on assigned therapy at study end:<BR/> placebo group: 44%<BR/> treatment group: 10%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-09 15:24:34 -0700" MODIFIED_BY="Vijaya M Musini">
<P>Geographic region: United States of America<BR/>Study setting: community<BR/>n = 4736 (55.8% female)<BR/>Age range 60 to &gt;80 mean: 71.6 years<BR/>Race: White non-Hispanic (79.2%), Black (13.8%), Hispanic (1.8%), Asian (4.3%), other (0.9%)<BR/>Mean blood pressure at entry: 170/77 mmHg<BR/>Pre-existing risk factors:<BR/>myocardial infarction: 4.9%<BR/>stroke: 1.4%<BR/>diabetes: 10.1%<BR/>smoking: 12.7%<BR/>Blood pressure (BP) entry criteria: systolic BP 160 - 219 mm Hg and diastolic BP &lt; 90 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: matching placebo.<BR/>Treatment: Step 1 - chlorthalidone 12.5 or 25 mg daily; Step 2 - atenolol 25 or 50mg or reserpine 0.05 or 0.10mg daily. <BR/>Average length of follow-up: 4.5 years<BR/>Difference in blood pressure at study end (Treatment - Control) systolic/diastolic: -11.1/-3.4 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality - death from any cause.<BR/>CHD (Coronary Heart Disease mortality) mortality - fatal myocardial infarction; sudden (&lt;1h) or rapid (1-24h) cardiac death.<BR/>CHD M&amp;M (morbidity and mortality) - CHD mortality; non-fatal myocardial infarction.<BR/>Cerebrovascular mortality - fatal stroke.<BR/>Cerebrovascular M&amp;M - fatal or non-fatal stroke.<BR/>Cardiovascular mortality - CHD mortality plus fatal stroke plus fatal left ventricular failure, fatal presumed myocardial infarction..<BR/>Cardiovascular M&amp;M - CHD M&amp;M plus cerebrovascular M&amp;M plus left ventricular failure, transient ischemic attacks, presumed myocardial infarction.<BR/>Dropouts due to side effects:<BR/> Control group: 7%<BR/> Treatment group: 13%<BR/>Quality of life or functional outcomes: no perceptible negative effect of treatment compared to control on measures of cognitive, physical, and emotional function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: history and/or signs of major cardiovascular diseases likely to require pharmacologic and other treatment (eg, previous myocardial infarction, coronary artery surgery, major arrhythmias, conduction defect, recent stroke, carotid artery disease, history of transient ischemic attack (TIA) with bruit matched with TIA localization, two or more TIAs and signs or symptoms in a single neurological distribution); other major diseases (eg, cancer, alcoholic liver disease, established renal dysfunction) with competing risk factors for the primary endpoint - stroke; presence of medical management problems (eg, insulin dependent diabetes, history of dementia, evidence of alcohol abuse); bradycardia; people maintained on beta-blockers, diuretics, other antihypertensive drugs, anticoagulants, or experimental drugs on recommendation of their physicians.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SHEP_x002d_PS-1986">
<CHAR_METHODS>
<P>Multisite study.<BR/>Randomization: patients randomly allocated by coordinating center. Randomization adapted for race, sex, age and systolic blood pressure.<BR/>Patients blinded. Providers blinded. Outcomes assessors blinded.<BR/>No loss to follow-up.<BR/>% not on assigned therapy at study end:<BR/> placebo group: 40%<BR/> treatment group: 30%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: United States of America<BR/>Study setting: community<BR/>n = 551 (63% female)<BR/>Age range: &gt; 60 (15% &gt;80) mean: 72<BR/>Race: White (82%); non-White (18%)<BR/>Mean blood pressure at entry: 172/75 mmHg<BR/>Pre-existing risk factors:<BR/> myocardial infarction: 4%<BR/> stroke: 1%<BR/> smoking: 11%<BR/>Blood pressure (BP) entry criteria: systolic BP 160 - 219 mm Hg and diastolic BP &lt; 90 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: matching placebo.<BR/>Treatment: Step 1 - chlorthalidone 25; Step 1 dose 2 - 50mg daily; Step 2 - randomized to either reserpine 0.05mg twice daily or metoprolol 50mg twice daily or hydralazine 25mg twice daily or matching placebo twice daily; Step 2 dose 2 - double dose of Step 2.<BR/>Average length of follow-up: 2.8 years.<BR/>Difference in blood pressure at study end (Treatment - Control) systolic/diastolic: -17/-5 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality - death from all causes.<BR/>CHD (coronary heart disease) mortality - fatal myocardial infarction and sudden death.<BR/>CHD morbidity and mortality (M&amp;M) - CHD mortality plus non-fatal myocardial infarctions.<BR/>Cerebrovascular mortality - fatal strokes.<BR/>Cerebrovascular M&amp;M - fatal and non-fatal strokes.<BR/>Cardiovascular mortality - CHD mortality plus cerebrovascular mortality plus left ventricular failure.<BR/>Cardiovascular M&amp;M - CHD M&amp;M plus cerebrovascular M&amp;M plus left ventricular failure and transient ischemic attacks.<BR/>Dropouts due to side effects (at 12 months; data not reported for end of study):<BR/> Control group: 2 (1.8%)<BR/> Treatment group: 7 (1.6%) <BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: coronary bypass surgery within 2 years; heart attack within 6 months; stroke with residua; current treatment with antihypertensive drugs, insulin or anticoagulants; allergy to study medications; specified arrhythmias or a pacemaker; uncontrolled congestive heart failure; serum creatinine level of 2.0 mg/dL or more; alcohol abuse; cancer or other life-threatening disease; chronic obstructive pulmonary disease; peripheral vascular disease with tissue injury; senile dementia; residence in a nursing home; carotid bruit with history of transient ischemic attacks; history of malignant hypertension.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sprackling-1981">
<CHAR_METHODS>
<P>Multisite study.<BR/>Randomization: random numbers generated by computer and allocation assignment distributed in sealed envelopes; stratified by site.<BR/>Patients not blinded; providers not blinded.<BR/>Lost to follow-up: 2%<BR/>% not on assigned therapy at study end: not clear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: Nottinghamshire, England<BR/>Study setting: welfare homes for the elderly.<BR/>n = 123 (74% female)<BR/>Age range: not reported; mean age: 80.7<BR/>Race: not stated.<BR/>Mean blood pressure at entry: 199/106 mmHg<BR/>Pre-existing factors:<BR/> stroke: 11.3%<BR/>Blood pressure (BP) entry criteria: diastolic BP &gt; 100 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: observation without placebo.<BR/>Treatment: methyldopa 250mg twice daily<BR/>Average follow up: not clearly stated, approximately 4 - 5 years<BR/>Difference in blood pressure at study end (Treatment - Control) systolic/diastolic: -18.4/-7.8</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality: death from all causes.<BR/>Cardiovascular morbidity and mortality: myocardial infarction, stroke, heart failure, or the deterioration of pre-existing heart failure.<BR/>Dropouts due to side effects:<BR/> control group: not stated (implied 0%)<BR/> treatment group: 9 (15%)<BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: not reported (implied "none")</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-STOP-1991">
<CHAR_METHODS>
<P>Multisite study<BR/>Randomization: method of randomization and allocation not described.<BR/>Patients blinded; providers blinded; outcomes assessors blinded.<BR/>No loss to follow-up.<BR/>% not on assigned therapy at study end:<BR/> placebo group: 23%<BR/> treatment group: 16%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: Sweden <BR/>Study setting: primary care.<BR/>n = 1627 (63% female)<BR/>Age range: 70-84 mean: 75.6<BR/>Race: White<BR/>Mean blood pressure at entry: 195/102 mmHg<BR/>Pre-existing risk factors: not reported.<BR/>Blood pressure (BP) entry criteria: (systolic BP 180 - 230 mm Hg and diastolic BP &gt;= 90 mm Hg) or (diastolic BP 105 - 120 mm Hg irrespective of systolic BP).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: matching placebo<BR/>Treatment: Step 1 - atenolol 50mg daily, or hydrochlorothiazide 25mg + amiloride 2.5mg daily, or metoprolol 100mg daily, or pindolol 5mg daily; Step 2 - patients on a beta-blocker received the diuretics and patients on the diuretics received a beta-blocker.<BR/>Average follow up: 2.1 years<BR/>Difference in blood pressure at study end (Treatment - Control) systolic/diastolic: -27.0/-10.0 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality: death from all causes.<BR/>CHD (Coronary Heart Disease mortality) mortality - fatal myocardial infarction.<BR/>CHD M&amp;M (morbidity and mortality) - fatal or non-fatal myocardial infarction.<BR/>Cerebrovascular mortality - fatal stroke.<BR/>Cerebrovascular M&amp;M - fatal or non-fatal stroke.<BR/>Cardiovascular mortality - fatal myocardial infarction; fatal stroke; sudden death; fatal congestive heart failure and fatal cardiovascular events not covered by above definitions (eg, ruptured aortic aneurysm).<BR/>Dropouts due to side effects:<BR/> Control group: 47 (5.7%)<BR/> Treatment group: 58 (7.1%)<BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: isolated systolic hypertension (180 mmHg or higher with diastolic below 90 mmHg); orthosatic hypotension (more than 30 mmHg fall in systolic blood pressure on standing); contraindications to any of the drugs; myocardial infarction or stroke in previous 12 months; angina pectoris requiring treatment with drugs other than glyceryl trinitrate; other severe or incapacitating illnesses; or unwillingness to take part.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Syst_x002d_Eur-1991">
<CHAR_METHODS>
<P>Multisite study.<BR/>Randomization: stratified by center, sex and previous cardiovascular complications. Group allocation determined by computerized random function.<BR/>Patients blinded; providers blinded; outcome assessors blinded.<BR/>Lost to follow-up: 2% at 2 years<BR/>% not on assigned therapy at study end (2 years) including open follow-up and lost to follow-up:<BR/> placebo group: 27%<BR/> treatment group: 18%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: 23 countries across western and eastern Europe, mainly from Finland, Bulgaria, the Russian Federation, Belgium, Italy, Israel, UK, France, Estonia, Lithuania, Spain, Poland and Romania. <BR/>Study setting: community based and referral clinic.<BR/>n = 4695 (66.8% female)<BR/>Age range: 60+ mean: 70.3<BR/>Race: not reported<BR/>Mean blood pressure at entry:174/86 mm Hg<BR/>Pre-existing risk factors:<BR/> myocardial infarction: 1.2%<BR/> stroke: 3.5%<BR/> smoking: 7.3%<BR/>Blood pressure (BP) entry criteria: systolic BP 160 - 219 mm Hg and diastolic BP &lt; 95 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: matching placebos with stepped therapy schedule similar to treatment groups.<BR/>Treatment: Step 1 - nitrendipine 10 - 40 mg/day; Step 2 - enalapril 5 - 20 mg/day and/or hydrochlorothiazide 12.5 - 25 mg/day.<BR/>Average follow-up: 2 years (median)<BR/>Difference in blood pressure at end of study (Treatment - Control) systolic/diastolic: -10.1 / -4.5 mm Hg at 2 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality - death from any cause.<BR/>CHD (Coronary Heart Disease) mortality - fatal myocardial infarctions and sudden death.<BR/>CHD M&amp;M (morbidity and mortality) - CHD mortality plus non-fatal myocardial infarctions.<BR/>Cerebrovascular mortality - fatal strokes.<BR/>Cerebrovascular M&amp;M - fatal and non-fatal strokes.<BR/>Cardiovascular mortality - CHD mortality plus cerebrovascular mortality plus deaths from dissecting aortic aneurysms or heart failure.<BR/>Cardiovascular M&amp;M - CHD M&amp;M plus cerebrovascular M&amp;M plus dissecting aortic aneurysms, heart failure, pulmonary embolism, or peripheral arterial disease.<BR/>Dropouts due to side effects (no significant difference between groups):<BR/> placebo: &lt;7.3%<BR/> treatment: &lt;7.8%<BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: hypertension secondary to a disorder that needed specific medical or surgical treatment; retinal hemorrhage or papilledema; congestive heart failure; dissecting aortic aneurysm; serum creatinine concentration at presentation of 180 micromols/L or more; history of severe nose bleeds, stroke, or myocardial infarction in the year before the study; dementia; substance abuse; any disorder prohibiting a sitting or standing position; any severe concomitant cardiovascular or non-cardiovascular disease.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-VA-Coop-1970">
<CHAR_METHODS>
<P>Multisite study.<BR/>Randomization: stratified by diastolic blood pressure (ie, 90-114 mm Hg and 115-129 mmHg); group allocation determined by sealed envelope containing randomized assignment. Assignment was determined by a statistician utilizing a random number table.<BR/>Patients blinded. Providers blinded.<BR/>% lost to follow-up: 14.7% for entire study group (ie, this data not reported for &gt;60 age sub-group).<BR/>% not on assigned therapy at study end: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Geographic region: United States of America<BR/>Study setting: recruited from Veterans Affairs hospitals and seen in outpatient clinics<BR/>n = 81 (0% female)<BR/>Age range: 60-75 mean: not reported.<BR/>Race: White (57.6%), Black (41.3%), Asian (1.1%); for entire study group (ie, this data not reported for &gt;60 age sub-group).<BR/>Mean blood pressure at entry: 176/103 mmHg<BR/>Pre-existing factors: not reported.<BR/>Blood pressure (BP) entry criteria: diastolic BP 90 - 114 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: placebo<BR/>Treatment: hydrochlorothiazide 50mg and reserpine 0.1mg twice daily plus hydralazine 25mg three time daily.<BR/>Average follow-up: 3.3 years.<BR/>Difference in blood pressure at study end (Treatment - Control) diastolic: -18.6 mmHg (systolic not reported).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Coronary heart disease (CHD) morbidity and mortality (M&amp;M) - myocardial infarction or sudden death.<BR/>Cerebrovascular M&amp;M - cerebrovascular accidents.<BR/>Cardiovascular M&amp;M - CHD M&amp;M plus cerebrovascular M&amp;M plus congestive heart failure and aneurysms.<BR/>Dropouts due to side effects: for entire study group (ie, this data not reported for &gt;60 age sub-group)<BR/> Control group: 3.1%<BR/> Treatment group: 5.9%<BR/>Quality of life or functional status outcomes: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusions: severe hypertension; surgically curable hypertension; uremia; concomitant fatal diseases such as carcinoma; hemorrhages, exudates, or papilledema in the optic fundi; history of cerebral or subarachnoid hemorrhage; dissecting aneurysm; congestive heart failure resistant to digitalis and mercurial diuretics; patients who wished to return to the care of their private physicians; patients unable to attend clinic regularly; patients of dubious reliability such as alcoholics, vagrants and poorly motivated patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-13 19:02:39 -0700" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-04-06 09:14:11 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ADVANCE-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 09:14:11 -0700" MODIFIED_BY="[Empty name]">
<P>Control group included non-specific antihypertensive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-ALLHAT-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head-to-head comparison of different drug therapies without a non-drug control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barraclough-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a trial in elderly persons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-BMJ-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not report results separately for elderly subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 09:13:09 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CASTEL-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 09:13:09 -0700" MODIFIED_BY="[Empty name]">
<P>Control group included non-specific antihypertensive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-GLANT-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Employed alternate allocation (ie, not random allocation). Head-to-head comparison of different drug therapies without a non-drug control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-HAPPHY-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not report results separately for elderly subjects (age range 40 - 64).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-31 22:30:05 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HDFP-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-31 22:30:05 -0700" MODIFIED_BY="[Empty name]">
<P>Based on the comments received regarding improper inclusion of this trial in the previous systematic review we excluded this trial since the intervention was multifactorial. It has also been included as multifactorial intervention trial in another Cochrane systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-HOT-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Evaluates the effects of achieving pre-specified levels of diastolic blood pressure control with all patients receiving antihypertensive treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-13 19:02:39 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HYVET_x002d_Cog-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-13 19:02:39 -0700" MODIFIED_BY="[Empty name]">
<P>this publication is a substudy of the HYVET 2008 trial and did not provide any additional data for analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-IPPPSH-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not report results separately for elderly subjects (age range 40 - 64).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 09:15:13 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jikei-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 09:15:13 -0700" MODIFIED_BY="[Empty name]">
<P>Did not truly randomize subjets to treatment arms and control group included non-specific antihypertensive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuramoto-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head-to-head comparison of different drug therapies (nicardipine vs trichlormethiazide) without a non-drug control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MAPHY-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not report results separately for elderly subjects (age range 40 - 64).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Materson-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Morbidity and mortality were not assessed. Blood pressure control and incidence of termination of treatment were the main outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MIDAS-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Evaluated two antihypertensives (isradipine vs hydrochlorothiazide) directly without a control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morgan-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation to the four study groups (no treatment, reduced salt intake, thiazide diuretic, beta-blocker) was non-random (ie, "based on their week of presentation at the clinic").</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not report results separately for elderly subjects (age range 35 - 64).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oslo--1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a trial in elderly persons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-PATS-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients were hypertensive.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 09:12:30 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SCOPE-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 09:12:30 -0700" MODIFIED_BY="[Empty name]">
<P>Control group included non-specific antihypertensive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-SHELL-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head-to-head comparison of different drug therapies without a non-drug control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-STONE-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Employed alternate allocation (ie, not random allocation). Four weeks after group assignment, attending physicians were allowed to reallocate participants from the placebo group to the treatment group if their diastolic blood pressure was at least 110 mm Hg.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-STOP_x002d_2-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head-to-head comparison of different drug therapies without a non-drug control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Syst_x002d_China-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation to treatment and control groups not random (ie, alternate allocation was employed).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TOMHS-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Morbidity and mortality data not reported separately for elderly subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-USPHS-Coop-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a trial in elderly persons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-VA-Coop-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not report results separately for elderly subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-VA_x002f_NHLBI-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a trial in elderly persons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-White-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head-to-head comparison of different drug therapies without a non-drug control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolf-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not report results separately for elderly subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-07-13 19:04:08 -0700" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-06-02 15:59:10 -0700" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-04-17 13:17:40 -0700" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:14:43 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ANBP-1981">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:14:57 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1970">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:15:16 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EWPHE-1989">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-10 23:02:26 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HEP-1986">
<DESCRIPTION>
<P>Random number table used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-10 23:03:25 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HTN-Coop-1974">
<DESCRIPTION>
<P>patients randomly allocated by biostatisticians at central register</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:15:40 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HYVET-2008">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-06 12:48:00 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HYVET-P-2003">
<DESCRIPTION>
<P>"The unit of randomization was the individual and the SAS Random Allocation of Treatments Balanced in Blocks Program was used to generate the schedule."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:15:54 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuramoto-1981">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:16:02 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MRCOA-1992">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:16:08 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SHEP-1991">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:16:15 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SHEP_x002d_PS-1986">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:17:31 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-STOP-1991">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-10 22:38:42 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sprackling-1981">
<DESCRIPTION>
<P>Stated that a computer program was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-10 22:35:57 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Syst_x002d_Eur-1991">
<DESCRIPTION>
<P>"randomized<SUP> </SUP>to double-blind treatment with active medication or placebo<SUP> </SUP>by means of a computerized random function"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:17:40 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VA-Coop-1970">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-04-17 13:24:07 -0700" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:14:49 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ANBP-1981">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:15:06 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1970">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:15:20 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EWPHE-1989">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-10 23:02:06 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HEP-1986">
<DESCRIPTION>
<P>"allocation assignment distributed in opaque envelopes; not stratified by site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:15:31 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HTN-Coop-1974">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:10:14 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HYVET-2008">
<DESCRIPTION>
<P>An interactive voice response system<BR/>(IVRS) is employed to tell the investigator which<BR/>6-month drug pack to prescribe.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:15:48 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HYVET-P-2003">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kuramoto-1981">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-MRCOA-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-10 22:48:42 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHEP-1991">
<DESCRIPTION>
<P>"Each randomization was carried out by telephone"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:24:07 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SHEP_x002d_PS-1986">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-STOP-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-10 22:39:43 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sprackling-1981">
<DESCRIPTION>
<P>"a block of 24 sealed envelopes was prepared for each of the seven homes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Syst_x002d_Eur-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-17 13:17:43 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VA-Coop-1970">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-04-17 13:15:57 -0700" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.06" NO="6" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 23:06:55 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ANBP-1981">
<DESCRIPTION>
<P>Clinicians blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-17 13:15:09 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carter-1970">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 23:07:56 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EWPHE-1989">
<DESCRIPTION>
<P>Triple blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 23:00:34 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HEP-1986">
<DESCRIPTION>
<P>Patients and providers not blinded; assessors of morbidity and mortality outcomes were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 22:59:20 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HTN-Coop-1974">
<DESCRIPTION>
<P>Stated that neither patient nor the clinician was aware of assigned treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-17 13:12:38 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HYVET-2008">
<DESCRIPTION>
<P>The main trial is a randomised, double-blind,<BR/>placebo-controlled trial.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-06 12:49:20 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HYVET-P-2003">
<DESCRIPTION>
<P>"The trial recruited individuals from both primary and secondary care and was of an open design."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-17 13:15:57 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuramoto-1981">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 22:50:55 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRCOA-1992">
<DESCRIPTION>
<P>Patients were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 22:46:49 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHEP-1991">
<DESCRIPTION>
<P>Described as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 23:08:30 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHEP_x002d_PS-1986">
<DESCRIPTION>
<P>Triple blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 22:37:38 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STOP-1991">
<DESCRIPTION>
<P>Described as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 22:40:45 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sprackling-1981">
<DESCRIPTION>
<P>Open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 22:36:07 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Syst_x002d_Eur-1991">
<DESCRIPTION>
<P>"randomized<SUP> </SUP>to double-blind treatment with active medication or placebo<SUP> </SUP>by means of a computerized random function"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2009-04-10 22:30:43 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VA-Coop-1970">
<DESCRIPTION>
<P>Described as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-06-02 15:59:01 -0700" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 22:53:19 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ANBP-1981">
<DESCRIPTION>
<P>"in 504 (of the randomized population), pressures fell before tablets were due to be dispensed and never reached again the threshold to qualify them to start tablets..."</P>
<P>"Thus, in subjects who prematurely stopped their regimen, the match between active and placebo groups in respect to entry charatceristics, time of stopping, endpoint rates, end point rates, and reasons for stopping makes it unlikely that factors associated with premature stopping biased the results of the trial in favour of the active group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 22:20:09 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1970">
<DESCRIPTION>
<P>"Of the 99 patients in the trial, 2 have been lost to follow up..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 22:49:01 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EWPHE-1989">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-05-15 08:52:43 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HEP-1986">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 22:36:17 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HTN-Coop-1974">
<DESCRIPTION>
<P>"The high degree of cooperation over the long period of the observation is worthy of comment. Only 30 patients (7%) of those randomized were unreliable."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 22:53:51 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HYVET-2008">
<DESCRIPTION>
<P>Reported on the number of patients lost to follow-up (16 patients)</P>
<P>"...vital status was unknown in 17 patients..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 22:48:19 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HYVET-P-2003">
<DESCRIPTION>
<P>"Of the 1283 patients who were assigned to groups, only 27 (2.1%) were lost<BR/>to follow-up (had no end-of-trial information)."</P>
<P>"Of the 426 patients allocated randomly to a diuretic-based treatment, 385 (88.5%) were alive and provided information at the end of the trial. The corresponding numbers were 397 (89.8%) for ACE based treatment and 394 (90.1%) for no treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 22:56:07 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuramoto-1981">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 23:01:30 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MRCOA-1992">
<DESCRIPTION>
<P>"Overall the beta-blocker group had significantly more drop outs than the diuretic group both for major side effects and inadequate blood pressure control..."</P>
<P>Over the five and a half years 25% of people were lost to follow up...48% in the duiretic group and 68% in the beta blocker group..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-02 15:53:18 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHEP-1991">
<DESCRIPTION>
<P>"We specified an &#8220;intention to treat&#8221; rule (with<BR/>study groups divided by the randomized assignment regardless<BR/>of subsequent crossovers) and a plan for replacing any<BR/>missing annual visit BP with the last available value."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-05-15 10:28:42 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SHEP_x002d_PS-1986">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-05-15 10:35:57 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-STOP-1991">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-01 23:07:49 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sprackling-1981">
<DESCRIPTION>
<P>60 patients were randomized to each group but " the blood pressures at the first routine visit after 6 months from the entry to the trial were available in 36 surviving treated patients and 39 surviving observed patients."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-02 15:59:01 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Syst_x002d_Eur-1991">
<DESCRIPTION>
<P>"For patients who withdrew from<BR/>treatment for whom regular follow-up was not possible, we<BR/>annually collected information on vital status, occurrence of major<BR/>endpoints and other events, and the use of antihypertensive<BR/>medications (non-supervised open follow-up). Patients without<BR/>any report within the year before the trial stopped were counted as<BR/>lost to follow-up."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-05-15 10:38:46 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VA-Coop-1970">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-06-02 15:59:10 -0700" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-01 22:02:35 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ANBP-1981">
<DESCRIPTION>
<P>"The occurence of any trial endpoint terminated the subject's participation in the study."</P>
<P>"For subjects who prematurely stopped their trial regimen, the withdrawal date was taken as their exact date of cessation where known, or, if not, 4 months from the date of last contact."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 08:43:32 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1970">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-02 15:49:57 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-EWPHE-1989">
<DESCRIPTION>
<P>Patients were censored if they had "one of the specific study terminating events,<BR/>including death, non-fatal cerebral or subarachnoid haemorrhage,<BR/>development of hypertensive retinopathy grade III or IV, dissecting<BR/>aneurysm, congestive heart failure not controllable without<BR/>diuretics or antihypertensive drugs, hypertensive encephalopathy,<BR/>severe increase in left ventricular hypertrophy, and a rise in blood<BR/>pressure exceeding the defined limits."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 08:54:08 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HEP-1986">
<DESCRIPTION>
<P>"Once the patients reached the age of 80 and had been in the study for 5 years they were excluded from further analyses." "Patients who left the practices were excluded at that time." "For this paper, however, no events that occurred to the patient after leaving the practices were included in the analysis." "A fatal event cancelled out non-fatal events of the same kind." "In the case of stroke, the most serious, major, minor, or transient ischemic attack, was counted."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 08:58:54 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HTN-Coop-1974">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-01 22:41:15 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HYVET-2008">
<DESCRIPTION>
<P>Cannot extract the number of patients in each group that had a non-fatal myocardial infarctions.</P>
<P>Correspondence with the author:</P>
<P>"The serious adverse events noted in the publication...are the numbers the total serious adverse events OR was the first event counted and analyzed? <B>Answer:It is the total number of SAEs. Patients could contribute more than one SAE."</B>
</P>
<P>Correspondence with the author:</P>
<P>"If a patient had an event after being censored were those events counted? If not, is it possible to see that data?<B> Answer: It would depend on the event. If it was a recurrent endpoint then it was not counted (e.g. a further non-fatal stoke). If the event was a new endpoint (e.g. a fatal MI in someone who had previously had a non-fatal stroke) then it was.</B>"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-01 22:46:23 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HYVET-P-2003">
<DESCRIPTION>
<P>"As this was an open study, the randomized treatment could be continued after a non-fatal event."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 10:12:21 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuramoto-1981">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 10:24:22 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MRCOA-1992">
<DESCRIPTION>
<P>"A patient's participation in a trial ended with a stroke, whether non-fatal or fatal; coronary events...;other cardiovascular events, and death from any cause."</P>
<P>"If a patient had a non-fatal event followed by a fatal event in the same category, only the fatal event was included in the analyses. If a patient had two events in different categories, for example, a non-fatal stroke then a coronary event (fatal or non-fatal), then both were included."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-02 15:54:59 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SHEP-1991">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 10:33:15 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SHEP_x002d_PS-1986">
<DESCRIPTION>
<P>"For any participant who had two or more events, one was designated the study event based on a hierarchical classification headed by death followed by four categories of nonfatal events in rank order of stroke, other hypertensive events, atherosclerotic events, and noncardiovascular events. When there were two events in one category, the event that occurred first was used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 10:36:00 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-STOP-1991">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 10:34:45 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sprackling-1981">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-02 15:59:10 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Syst_x002d_Eur-1991">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 10:38:49 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VA-Coop-1970">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2009-05-15 08:34:56 -0700" MODIFIED_BY="[Empty name]" NO="7">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-10-27 00:02:52 -0700" MODIFIED_BY="Vijaya M Musini">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-07-13 18:03:11 -0700" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2009-07-13 18:03:06 -0700" MODIFIED_BY="Grade Profiler">Antihypertensive drug therapy compared to control in elderly (60 years or older) for hypertension in the elderly</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Antihypertensive drug therapy compared to control in elderly (60 years or older) for hypertension in the elderly</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with hypertension in the elderly<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Antihypertensive drug therapy<BR/>
<B>Comparison: </B>control in elderly (60 years or older)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>control in elderly (60 years or older)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Antihypertensive drug therapy</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Total mortality - Elderly 60 years or older</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.9 </B>
<BR/>(0.84 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>23119<BR/>(12 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>116 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>104 per 1000</B>
<BR/>(97 to 113)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
<BR/>(84 to 97)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>270 per 1000</B>
<BR/>(252 to 291)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Cardiovascular mortality and morbidity - Elderly 60 years or older</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.72 </B>
<BR/>(0.68 to 0.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>23094<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>153 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
<BR/>(104 to 118)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>108 per 1000</B>
<BR/>(102 to 115)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>288 per 1000</B>
<BR/>(272 to 308)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The upper confidence interval is approaching no effect.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2009-10-27 00:02:52 -0700" MODIFIED_BY="Vijaya M Musini" NO="2" READONLY="YES">
<TITLE MODIFIED="2009-10-27 00:02:50 -0700" MODIFIED_BY="Grade Profiler">Antihypertensive drug therapy compared to control in very elderly 80 years or older for hypertension</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Antihypertensive drug therapy compared to control in very elderly 80 years or older for hypertension </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with Elderly patients with primary hypertension <BR/>
<B>Settings:</B> Ambulatory<BR/>
<B>Intervention:</B> Antihypertensive drug therapy<BR/>
<B>Comparison: </B>Control </P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Antihypertensive drug therapy</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Total mortality - Very elderly 80 years or older</B>
<BR/>Follow-up: mean 2 years</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.87 to 1.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>6701<BR/>(8 studies<SUP>3</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>142 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>139 per 1000</B>
<BR/>(124 to 156)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>60 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 1000</B>
<BR/>(52 to 66)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>160 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>157 per 1000</B>
<BR/>(139 to 176)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Cardiovascular mortality and morbidity - Very elderly 80 years or older</B>
<BR/>Follow-up: mean 2 years</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.75 </B>
<BR/>(0.65 to 0.87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>6546<BR/>(7 studies<SUP>3</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>86 per 1000</B>
<BR/>(75 to 100)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
<BR/>(65 to 87)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>188 per 1000</B>
<BR/>(162 to 218)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Significant heterogeneity I square = 83%<BR/>
<SUP>2</SUP> Confidence intervals are wide and include 10% benefit or harm.<BR/>
<SUP>3</SUP> Please note that the duration of the trials is only 2 years and not 4.5 years as in the 60 years or older patients<BR/>
<SUP>4</SUP> confidence interval is wide</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-07-13 18:04:22 -0700" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-11-08 21:41:02 -0800" MODIFIED_BY="James M Wright">
<COMPARISON ID="CMP-001" MODIFIED="2010-11-08 21:38:57 -0800" MODIFIED_BY="James M Wright" NO="1">
<NAME>Antihypertensive drug therapy vs control in elderly 60 years or older</NAME>
<DICH_OUTCOME CHI2="13.606985676496054" CI_END="0.9718272239692666" CI_START="0.8410459161388041" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9040748408798148" ESTIMABLE="YES" EVENTS_1="1215" EVENTS_2="1299" I2="19.159171167492406" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.012410939133865147" LOG_CI_START="-0.07518029364160128" LOG_EFFECT_SIZE="-0.04379561638773323" METHOD="MH" MODIFIED="2010-11-08 21:38:16 -0800" MODIFIED_BY="James M Wright" NO="1" P_CHI2="0.25550825603918936" P_Q="0.0" P_Z="0.006237581687466002" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11953" TOTAL_2="11166" WEIGHT="100.0" Z="2.735023530952833">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.606985676496054" CI_END="0.9718272239692666" CI_START="0.8410459161388041" DF="11" EFFECT_SIZE="0.9040748408798148" ESTIMABLE="YES" EVENTS_1="1215" EVENTS_2="1299" I2="19.159171167492406" ID="CMP-001.01.01" LOG_CI_END="-0.012410939133865147" LOG_CI_START="-0.07518029364160128" LOG_EFFECT_SIZE="-0.04379561638773323" MODIFIED="2009-08-08 14:46:43 -0700" MODIFIED_BY="Vijaya M Musini" NO="1" P_CHI2="0.25550825603918936" P_Z="0.006237581687466002" STUDIES="12" TAU2="0.0" TOTAL_1="11953" TOTAL_2="11166" WEIGHT="100.0" Z="2.735023530952833">
<NAME>Elderly 60 years or older</NAME>
<DICH_DATA CI_END="0.853733593532604" CI_START="0.38530504086087414" EFFECT_SIZE="0.573539760731879" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="63" LOG_CI_END="-0.06867762920408145" LOG_CI_START="-0.4141953091709049" LOG_EFFECT_SIZE="-0.24143646918749315" MODIFIED="2009-08-08 14:46:37 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="1785" O_E="0.0" SE="0.2029587955526119" STUDY_ID="STD-STOP-1991" TOTAL_1="812" TOTAL_2="815" VAR="0.041192272692166916" WEIGHT="4.815155131531039"/>
<DICH_DATA CI_END="0.9864426675654235" CI_START="0.689948440015097" EFFECT_SIZE="0.8249815632188969" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="235" LOG_CI_END="-0.00592815104385396" LOG_CI_START="-0.16118336296360983" LOG_EFFECT_SIZE="-0.08355575700373193" MODIFIED="2009-08-08 14:46:38 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="137" O_E="0.0" SE="0.09119768000735824" STUDY_ID="STD-HYVET-2008" TOTAL_1="1933" TOTAL_2="1912" VAR="0.008317016838724508" WEIGHT="18.09275198392718"/>
<DICH_DATA CI_END="1.0895981143882563" CI_START="0.6787758440125136" EFFECT_SIZE="0.8599958602972063" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="137" LOG_CI_END="0.0372663429979648" LOG_CI_START="-0.16827362156759007" LOG_EFFECT_SIZE="-0.06550363928481263" ORDER="1786" O_E="0.0" SE="0.12073519262504062" STUDY_ID="STD-Syst_x002d_Eur-1991" TOTAL_1="2398" TOTAL_2="2297" VAR="0.014576986738205662" WEIGHT="10.716066673812229"/>
<DICH_DATA CI_END="1.051271697627692" CI_START="0.7406522052221349" EFFECT_SIZE="0.8823982667342267" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="242" LOG_CI_END="0.021714972480386743" LOG_CI_START="-0.13038567975505835" LOG_EFFECT_SIZE="-0.05433535363733579" ORDER="1783" O_E="0.0" SE="0.08934467603347182" STUDY_ID="STD-SHEP-1991" TOTAL_1="2365" TOTAL_2="2371" VAR="0.007982471135526033" WEIGHT="18.507002135831744"/>
<DICH_DATA CI_END="2.062620987271167" CI_START="0.4096311389837737" EFFECT_SIZE="0.9191919191919192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.31441943240410913" LOG_CI_START="-0.3876070369570217" LOG_EFFECT_SIZE="-0.0365938022764563" MODIFIED="2009-08-08 14:46:39 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="185" O_E="0.0" SE="0.4123738231897971" STUDY_ID="STD-Carter-1970" TOTAL_1="22" TOTAL_2="26" VAR="0.17005217005217002" WEIGHT="0.6317208493799189"/>
<DICH_DATA CI_END="1.1162354602693634" CI_START="0.763983953978711" EFFECT_SIZE="0.9234641197728446" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="149" LOG_CI_END="0.04775581495065958" LOG_CI_START="-0.11691576285321569" LOG_EFFECT_SIZE="-0.03457997395127804" MODIFIED="2009-08-08 14:46:40 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="1780" O_E="0.0" SE="0.09672889993945281" STUDY_ID="STD-EWPHE-1989" TOTAL_1="416" TOTAL_2="424" VAR="0.009356480083496673" WEIGHT="11.300601768532434"/>
<DICH_DATA CI_END="1.3286968459964452" CI_START="0.7009003470823472" EFFECT_SIZE="0.9650306111860537" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="69" LOG_CI_END="0.12342590409604041" LOG_CI_START="-0.15434372495594656" LOG_EFFECT_SIZE="-0.01545891042995309" MODIFIED="2009-08-08 14:46:40 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="187" O_E="0.0" SE="0.1631632550869764" STUDY_ID="STD-HEP-1986" TOTAL_1="419" TOTAL_2="465" VAR="0.02662224781057773" WEIGHT="5.008551069908909"/>
<DICH_DATA CI_END="1.121520389610981" CI_START="0.8366813075407218" EFFECT_SIZE="0.9686873313991958" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="315" LOG_CI_END="0.04980717360783405" LOG_CI_START="-0.07743993356311082" LOG_EFFECT_SIZE="-0.013816379977638385" MODIFIED="2009-08-08 14:46:41 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="1782" O_E="0.0" SE="0.07474558063555217" STUDY_ID="STD-MRCOA-1992" TOTAL_1="2183" TOTAL_2="2213" VAR="0.005586901824545832" WEIGHT="23.955644716786846"/>
<DICH_DATA CI_END="2.7998216336819652" CI_START="0.40753038799607466" EFFECT_SIZE="1.0681818181818181" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4471303649225461" LOG_CI_START="-0.389840002023486" LOG_EFFECT_SIZE="0.02864518144953001" MODIFIED="2009-08-08 14:46:42 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="1781" O_E="0.0" SE="0.4916405366142342" STUDY_ID="STD-Kuramoto-1981" TOTAL_1="44" TOTAL_2="47" VAR="0.24171041724233214" WEIGHT="0.5183350559014719"/>
<DICH_DATA CI_END="1.3623220522763722" CI_START="0.9024456253866794" EFFECT_SIZE="1.1087928464977646" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" LOG_CI_END="0.1342797867200398" LOG_CI_START="-0.044578955966266536" LOG_EFFECT_SIZE="0.04485041537688663" MODIFIED="2009-08-08 14:46:42 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="188" O_E="0.0" SE="0.10506251081899161" STUDY_ID="STD-Sprackling-1981" TOTAL_1="61" TOTAL_2="62" VAR="0.011038131179590727" WEIGHT="3.3417861734135546"/>
<DICH_DATA CI_END="2.456393076350673" CI_START="0.5056454114635981" EFFECT_SIZE="1.1144792002579813" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="7" LOG_CI_END="0.3902978645988559" LOG_CI_START="-0.2961539294597973" LOG_EFFECT_SIZE="0.04707196756952929" ORDER="1784" O_E="0.0" SE="0.4032251818212355" STUDY_ID="STD-SHEP_x002d_PS-1986" TOTAL_1="443" TOTAL_2="108" VAR="0.16259054725476846" WEIGHT="0.861889172931696"/>
<DICH_DATA CI_END="2.077225412415711" CI_START="0.7985061714172768" EFFECT_SIZE="1.2878964675930837" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="22" LOG_CI_END="0.31748362703894667" LOG_CI_START="-0.09772172297933482" LOG_EFFECT_SIZE="0.10988095202980593" MODIFIED="2009-08-08 14:46:43 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="189" O_E="0.0" SE="0.24389367790036862" STUDY_ID="STD-HYVET-P-2003" TOTAL_1="857" TOTAL_2="426" VAR="0.059484126119768756" WEIGHT="2.2504952680429846"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="39.67225729308061" CI_END="0.7714373603362653" CI_START="0.6753203288268694" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7217806674133208" ESTIMABLE="YES" EVENTS_1="1276" EVENTS_2="1709" I2="69.752162294801" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.11269933229006777" LOG_CI_START="-0.17049017673554287" LOG_EFFECT_SIZE="-0.14159475451280534" METHOD="MH" MODIFIED="2010-11-08 21:38:57 -0800" MODIFIED_BY="James M Wright" NO="2" P_CHI2="8.14924038354814E-5" P_Q="0.0" P_Z="7.666903019292308E-22" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11947" TOTAL_2="11147" WEIGHT="100.0" Z="9.604310921835589">
<NAME>Cardiovascular mortality and morbidity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="39.67225729308061" CI_END="0.7714373603362653" CI_START="0.6753203288268694" DF="12" EFFECT_SIZE="0.7217806674133208" ESTIMABLE="YES" EVENTS_1="1276" EVENTS_2="1709" I2="69.752162294801" ID="CMP-001.02.01" LOG_CI_END="-0.11269933229006777" LOG_CI_START="-0.17049017673554287" LOG_EFFECT_SIZE="-0.14159475451280534" MODIFIED="2009-08-08 14:40:03 -0700" MODIFIED_BY="Vijaya M Musini" NO="1" P_CHI2="8.14924038354814E-5" P_Z="7.666903019292308E-22" STUDIES="13" TAU2="0.0" TOTAL_1="11947" TOTAL_2="11147" WEIGHT="100.0" Z="9.604310921835589">
<NAME>Elderly 60 years or older</NAME>
<DICH_DATA CI_END="1.1868546770892463" CI_START="0.492341341030975" EFFECT_SIZE="0.764419795221843" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="40" LOG_CI_END="0.07439754557466834" LOG_CI_START="-0.307733695757171" LOG_EFFECT_SIZE="-0.11666807509125131" MODIFIED="2009-03-28 15:56:55 -0700" MODIFIED_BY="[Empty name]" ORDER="1841" O_E="0.0" SE="0.22446578273847406" STUDY_ID="STD-ANBP-1981" TOTAL_1="293" TOTAL_2="289" VAR="0.050384887620395835" WEIGHT="2.3401931401786205"/>
<DICH_DATA CI_END="0.971653963965549" CI_START="0.5918769753230948" EFFECT_SIZE="0.7583532219570406" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="120" LOG_CI_END="-0.012488373239443872" LOG_CI_START="-0.2277685542410551" LOG_EFFECT_SIZE="-0.1201284637402495" MODIFIED="2009-06-09 11:39:25 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="227" O_E="0.0" SE="0.12645664397442907" STUDY_ID="STD-HEP-1986" TOTAL_1="419" TOTAL_2="465" VAR="0.01599128280527551" WEIGHT="6.609826789233835"/>
<DICH_DATA CI_END="1.2240770653631239" CI_START="0.5323253021521881" EFFECT_SIZE="0.8072218986604542" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" LOG_CI_END="0.08780876095362487" LOG_CI_START="-0.27382289072388205" LOG_EFFECT_SIZE="-0.09300706488512858" MODIFIED="2009-03-28 15:56:57 -0700" MODIFIED_BY="[Empty name]" ORDER="1842" O_E="0.0" SE="0.21242422230091382" STUDY_ID="STD-HTN-Coop-1974" TOTAL_1="101" TOTAL_2="99" VAR="0.04512405022014805" WEIGHT="1.995342119301753"/>
<DICH_DATA CI_END="0.8717881285294566" CI_START="0.5737790298356907" EFFECT_SIZE="0.7072579067143075" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="193" LOG_CI_END="-0.05958904923121917" LOG_CI_START="-0.24125532815879885" LOG_EFFECT_SIZE="-0.15042218869500898" MODIFIED="2009-03-28 15:56:57 -0700" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.10671167150464413" STUDY_ID="STD-HYVET-2008" TOTAL_1="1933" TOTAL_2="1912" VAR="0.011387380835315078" WEIGHT="11.275606046257924"/>
<DICH_DATA CI_END="1.513401483835164" CI_START="0.6038050092201352" EFFECT_SIZE="0.9559285521945965" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="26" LOG_CI_END="0.17995415544171608" LOG_CI_START="-0.21910328835227288" LOG_EFFECT_SIZE="-0.019574566455278424" MODIFIED="2009-03-28 15:56:58 -0700" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.2344083178507942" STUDY_ID="STD-HYVET-P-2003" TOTAL_1="857" TOTAL_2="426" VAR="0.05494725947763896" WEIGHT="2.0182482679636924"/>
<DICH_DATA CI_END="1.4315074927226294" CI_START="0.1574460252041273" EFFECT_SIZE="0.47474747474747475" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.15579362552532705" LOG_CI_START="-0.8028682988489919" LOG_EFFECT_SIZE="-0.32353733666183243" MODIFIED="2009-06-08 15:39:53 -0700" MODIFIED_BY="[Empty name]" ORDER="1843" O_E="0.0" SE="0.5631227598305343" STUDY_ID="STD-Kuramoto-1981" TOTAL_1="44" TOTAL_2="47" VAR="0.31710724263915757" WEIGHT="0.5057092163327898"/>
<DICH_DATA CI_END="0.9876993451978561" CI_START="0.72535906625851" EFFECT_SIZE="0.8464258235526954" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="309" LOG_CI_END="-0.005375234149844372" LOG_CI_START="-0.13944695633712706" LOG_EFFECT_SIZE="-0.07241109524348573" MODIFIED="2009-08-08 14:40:03 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="1844" O_E="0.0" SE="0.07875439327853813" STUDY_ID="STD-MRCOA-1992" TOTAL_1="2183" TOTAL_2="2213" VAR="0.006202254460670651" WEIGHT="17.832063677158718"/>
<DICH_DATA CI_END="0.7562363333285496" CI_START="0.5906915531469225" EFFECT_SIZE="0.6683579985905568" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="519" LOG_CI_END="-0.12134246082030561" LOG_CI_START="-0.22863923948234124" LOG_EFFECT_SIZE="-0.17499085015132343" MODIFIED="2009-03-17 11:57:03 -0700" MODIFIED_BY="[Empty name]" ORDER="1845" O_E="0.0" SE="0.06302665891370006" STUDY_ID="STD-SHEP-1991" TOTAL_1="2365" TOTAL_2="2371" VAR="0.003972359733823888" WEIGHT="30.118537820881347"/>
<DICH_DATA CI_END="1.035311974335561" CI_START="0.31896323682018957" EFFECT_SIZE="0.5746533376330216" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="14" LOG_CI_END="0.01507123705546962" LOG_CI_START="-0.49625937012841037" LOG_EFFECT_SIZE="-0.24059406653647036" MODIFIED="2009-03-17 11:57:04 -0700" MODIFIED_BY="[Empty name]" ORDER="1846" O_E="0.0" SE="0.3003581297871382" STUDY_ID="STD-SHEP_x002d_PS-1986" TOTAL_1="443" TOTAL_2="108" VAR="0.09021500612922735" WEIGHT="1.308058712956849"/>
<DICH_DATA CI_END="1.1992150668438986" CI_START="0.894894181980171" EFFECT_SIZE="1.0359394703656999" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="52" LOG_CI_END="0.07889707631625623" LOG_CI_START="-0.04822831540930281" LOG_EFFECT_SIZE="0.015334380453476733" MODIFIED="2009-06-09 11:39:24 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="228" O_E="0.0" SE="0.07467408438043133" STUDY_ID="STD-Sprackling-1981" TOTAL_1="61" TOTAL_2="62" VAR="0.005576218878055778" WEIGHT="2.9969199456535365"/>
<DICH_DATA CI_END="0.7108720182509226" CI_START="0.43279589770023946" EFFECT_SIZE="0.5546733212341198" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="152" LOG_CI_END="-0.14820858038195867" LOG_CI_START="-0.3637168643862205" LOG_EFFECT_SIZE="-0.25596272238408957" MODIFIED="2009-03-28 15:57:00 -0700" MODIFIED_BY="[Empty name]" ORDER="1847" O_E="0.0" SE="0.12659063280731409" STUDY_ID="STD-STOP-1991" TOTAL_1="812" TOTAL_2="815" VAR="0.016025188314556224" WEIGHT="8.815747429451088"/>
<DICH_DATA CI_END="0.8634042126432446" CI_START="0.5830985112289443" EFFECT_SIZE="0.7095419022024526" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="216" LOG_CI_END="-0.06378583670447653" LOG_CI_START="-0.2342580674211434" LOG_EFFECT_SIZE="-0.14902195206280994" MODIFIED="2009-03-17 11:57:05 -0700" MODIFIED_BY="[Empty name]" ORDER="1848" O_E="0.0" SE="0.10013623217412158" STUDY_ID="STD-Syst_x002d_Eur-1991" TOTAL_1="2398" TOTAL_2="2297" VAR="0.010027264994029582" WEIGHT="12.82077882889442"/>
<DICH_DATA CI_END="0.7607202590127227" CI_START="0.21814724730255763" EFFECT_SIZE="0.4073684210526316" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.11877501773962142" LOG_CI_START="-0.6612502628002513" LOG_EFFECT_SIZE="-0.3900126402699363" MODIFIED="2009-06-08 15:40:44 -0700" MODIFIED_BY="[Empty name]" ORDER="1849" O_E="0.0" SE="0.3186526442443849" STUDY_ID="STD-VA-Coop-1970" TOTAL_1="38" TOTAL_2="43" VAR="0.10153950768393853" WEIGHT="1.362968005735431"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.424301685852887" CI_END="2.002564079204525" CI_START="1.452425026203059" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7054542460036672" ESTIMABLE="YES" EVENTS_1="372" EVENTS_2="215" I2="54.79512605582064" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.30158642178482814" LOG_CI_START="0.16209372347429815" LOG_EFFECT_SIZE="0.23184007262956316" METHOD="MH" MODIFIED="2009-08-11 10:44:53 -0700" MODIFIED_BY="James M Wright" NO="3" P_CHI2="0.10946505202150303" P_Q="0.0" P_Z="7.268460539392284E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3620" TOTAL_2="3294" WEIGHT="100.0" Z="6.515010434675816">
<NAME>Withdrawal due to adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2198081604507824" CI_START="1.5486238700421247" EFFECT_SIZE="1.8540895081382613" ESTIMABLE="YES" EVENTS_1="307" EVENTS_2="166" LOG_CI_END="0.34631544361386507" LOG_CI_START="0.1899459490691133" LOG_EFFECT_SIZE="0.26813069634148917" ORDER="1853" O_E="0.0" SE="0.09185221513706875" STUDY_ID="STD-SHEP-1991" TOTAL_1="2365" TOTAL_2="2371" VAR="0.008436829425586361" WEIGHT="76.78328105194963"/>
<DICH_DATA CI_END="4.049736641955023" CI_START="0.17978330738185613" EFFECT_SIZE="0.8532731376975169" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.6074267815690955" LOG_CI_START="-0.7452506343407839" LOG_EFFECT_SIZE="-0.06891192638584424" ORDER="1854" O_E="0.0" SE="0.7945694099666614" STUDY_ID="STD-SHEP_x002d_PS-1986" TOTAL_1="443" TOTAL_2="108" VAR="0.6313405472547684" WEIGHT="1.4894339531331604"/>
<DICH_DATA CI_END="1.7970872370566968" CI_START="0.8536783557630344" EFFECT_SIZE="1.2386018237082066" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="47" LOG_CI_END="0.2545691598317067" LOG_CI_START="-0.06870572957966449" LOG_EFFECT_SIZE="0.0929317151260211" MODIFIED="2009-03-17 11:44:14 -0700" MODIFIED_BY="[Empty name]" ORDER="1855" O_E="0.0" SE="0.18989327027675032" STUDY_ID="STD-STOP-1991" TOTAL_1="812" TOTAL_2="815" VAR="0.03605945409639894" WEIGHT="21.727284994917206"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-11-08 21:40:03 -0800" MODIFIED_BY="James M Wright" NO="2">
<NAME>Antihypertensive drug therapy vs control in very elderly 80 years or older</NAME>
<DICH_OUTCOME CHI2="12.918196070808177" CI_END="1.1003416765874003" CI_START="0.8713911583108687" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.979197634851728" ESTIMABLE="YES" EVENTS_1="461" EVENTS_2="437" I2="53.5538865712182" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.04152756262682467" LOG_CI_START="-0.05978685100605029" LOG_EFFECT_SIZE="-0.009129644189612825" METHOD="MH" MODIFIED="2010-11-08 21:39:30 -0800" MODIFIED_BY="James M Wright" NO="1" P_CHI2="0.0443536435180395" P_Q="0.0" P_Z="0.7239141159548436" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3617" TOTAL_2="3084" WEIGHT="100.0" Z="0.353232539412344">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.918196070808177" CI_END="1.1003416765874003" CI_START="0.8713911583108687" DF="6" EFFECT_SIZE="0.979197634851728" ESTIMABLE="YES" EVENTS_1="461" EVENTS_2="437" I2="53.5538865712182" ID="CMP-002.01.01" LOG_CI_END="0.04152756262682467" LOG_CI_START="-0.05978685100605029" LOG_EFFECT_SIZE="-0.009129644189612825" MODIFIED="2009-10-26 18:22:12 -0700" MODIFIED_BY="Vijaya M Musini" NO="1" P_CHI2="0.0443536435180395" P_Z="0.7239141159548436" STUDIES="8" TAU2="0.0" TOTAL_1="3617" TOTAL_2="3084" WEIGHT="100.0" Z="0.353232539412344">
<NAME>Very elderly 80 years or older</NAME>
<DICH_DATA CI_END="1.396532028060082" CI_START="0.9866073749127535" EFFECT_SIZE="1.1738095238095239" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="60" LOG_CI_END="0.14505090025919137" LOG_CI_START="-0.005855642500532221" LOG_EFFECT_SIZE="0.06959762887932958" ORDER="191" O_E="0.0" SE="0.08864325021649574" STUDY_ID="STD-EWPHE-1989" TOTAL_1="70" TOTAL_2="85" VAR="0.007857625808944273" WEIGHT="12.18919880176037"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-08 15:03:12 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="187" O_E="0.0" SE="0.0" STUDY_ID="STD-HEP-1986" TOTAL_1="3" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9864426675654235" CI_START="0.689948440015097" EFFECT_SIZE="0.8249815632188969" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="235" LOG_CI_END="-0.00592815104385396" LOG_CI_START="-0.16118336296360983" LOG_EFFECT_SIZE="-0.08355575700373193" ORDER="190" O_E="0.0" SE="0.09119768000735824" STUDY_ID="STD-HYVET-2008" TOTAL_1="1933" TOTAL_2="1912" VAR="0.008317016838724508" WEIGHT="53.14481997414804"/>
<DICH_DATA CI_END="2.077225412415711" CI_START="0.7985061714172768" EFFECT_SIZE="1.2878964675930837" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="22" LOG_CI_END="0.31748362703894667" LOG_CI_START="-0.09772172297933482" LOG_EFFECT_SIZE="0.10988095202980593" ORDER="186" O_E="0.0" SE="0.24389367790036862" STUDY_ID="STD-HYVET-P-2003" TOTAL_1="857" TOTAL_2="426" VAR="0.059484126119768756" WEIGHT="6.6105015963887555"/>
<DICH_DATA CI_END="1.2950112627702972" CI_START="0.6694182083590893" EFFECT_SIZE="0.9310768600542783" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="59" LOG_CI_END="0.11227354551203572" LOG_CI_START="-0.17430247888841646" LOG_EFFECT_SIZE="-0.0310144666881904" ORDER="192" O_E="0.0" SE="0.16833617530702483" STUDY_ID="STD-SHEP-1991" TOTAL_1="331" TOTAL_2="319" VAR="0.02833706791699739" WEIGHT="13.515254149060302"/>
<DICH_DATA CI_END="76.64121380936336" CI_START="0.2922129664193644" EFFECT_SIZE="4.732394366197183" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="1.8844623742872701" LOG_CI_START="-0.5343005169457329" LOG_EFFECT_SIZE="0.6750809286707687" ORDER="188" O_E="0.0" SE="1.420793295379677" STUDY_ID="STD-SHEP_x002d_PS-1986" TOTAL_1="70" TOTAL_2="15" VAR="2.018653588195842" WEIGHT="0.18355518994714404"/>
<DICH_DATA CI_END="3.052153985790518" CI_START="0.531417902977548" EFFECT_SIZE="1.2735655737704918" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.4846064406498508" LOG_CI_START="-0.2745638186999449" LOG_EFFECT_SIZE="0.10502131097495296" MODIFIED="2009-10-26 18:22:12 -0700" MODIFIED_BY="Vijaya M Musini" ORDER="193" O_E="0.0" SE="0.44594036829546124" STUDY_ID="STD-STOP-1991" TOTAL_1="122" TOTAL_2="113" VAR="0.1988628120754916" WEIGHT="1.8682694982069994"/>
<DICH_DATA CI_END="1.66959240197372" CI_START="0.913518661642851" EFFECT_SIZE="1.234991423670669" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="53" LOG_CI_END="0.22261045966281498" LOG_CI_START="-0.039282576318306305" LOG_EFFECT_SIZE="0.09166394167225436" ORDER="189" O_E="0.0" SE="0.15383726572674675" STUDY_ID="STD-Syst_x002d_Eur-1991" TOTAL_1="231" TOTAL_2="210" VAR="0.023665904326281687" WEIGHT="12.488400790488388"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5395710176548776" CI_END="0.8702284253603344" CI_START="0.6466510164096679" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7501560476113254" ESTIMABLE="YES" EVENTS_1="296" EVENTS_2="344" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.060366734907336066" LOG_CI_START="-0.1893300354634095" LOG_EFFECT_SIZE="-0.12484838518537279" METHOD="MH" MODIFIED="2010-11-08 21:40:03 -0800" MODIFIED_BY="James M Wright" NO="2" P_CHI2="0.7386977709859542" P_Q="0.0" P_Z="1.4773137858556425E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3547" TOTAL_2="2999" WEIGHT="100.00000000000001" Z="3.794852294198525">
<NAME>Cardiovascular mortality and morbidity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5395710176548776" CI_END="0.8702284253603344" CI_START="0.6466510164096679" DF="6" EFFECT_SIZE="0.7501560476113254" ESTIMABLE="YES" EVENTS_1="296" EVENTS_2="344" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.060366734907336066" LOG_CI_START="-0.1893300354634095" LOG_EFFECT_SIZE="-0.12484838518537279" MODIFIED="2009-05-17 08:48:11 -0700" MODIFIED_BY="Vijaya M Musini" NO="1" P_CHI2="0.7386977709859542" P_Z="1.4773137858556425E-4" STUDIES="7" TAU2="0.0" TOTAL_1="3547" TOTAL_2="2999" WEIGHT="100.00000000000001" Z="3.794852294198525">
<NAME>Very elderly 80 years or older</NAME>
<DICH_DATA CI_END="7.710774232907604" CI_START="0.02251539286031531" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8870979874151412" LOG_CI_START="-1.6475204708383533" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="208" O_E="0.0" SE="1.4888474289418194" STUDY_ID="STD-HEP-1986" TOTAL_1="3" TOTAL_2="4" VAR="2.2166666666666663" WEIGHT="0.37059648510644855"/>
<DICH_DATA CI_END="0.8717881285294566" CI_START="0.5737790298356907" EFFECT_SIZE="0.7072579067143075" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="193" LOG_CI_END="-0.05958904923121917" LOG_CI_START="-0.24125532815879885" LOG_EFFECT_SIZE="-0.15042218869500898" ORDER="212" O_E="0.0" SE="0.10671167150464413" STUDY_ID="STD-HYVET-2008" TOTAL_1="1933" TOTAL_2="1912" VAR="0.011387380835315078" WEIGHT="53.93682448719545"/>
<DICH_DATA CI_END="1.513401483835164" CI_START="0.6038050092201352" EFFECT_SIZE="0.9559285521945965" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="26" LOG_CI_END="0.17995415544171608" LOG_CI_START="-0.21910328835227288" LOG_EFFECT_SIZE="-0.019574566455278424" ORDER="211" O_E="0.0" SE="0.2344083178507942" STUDY_ID="STD-HYVET-P-2003" TOTAL_1="857" TOTAL_2="426" VAR="0.05494725947763896" WEIGHT="9.654283960805012"/>
<DICH_DATA CI_END="0.9445334232834222" CI_START="0.47130968296115167" EFFECT_SIZE="0.6672089240065071" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="65" LOG_CI_END="-0.024782669514799238" LOG_CI_START="-0.32669363765729975" LOG_EFFECT_SIZE="-0.1757381535860495" ORDER="207" O_E="0.0" SE="0.17734399717029983" STUDY_ID="STD-SHEP-1991" TOTAL_1="331" TOTAL_2="319" VAR="0.031450893332339316" WEIGHT="18.40011548553517"/>
<DICH_DATA CI_END="2.095590703920157" CI_START="0.19720707166211718" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.32130646324167794" LOG_CI_START="-0.7050775157195043" LOG_EFFECT_SIZE="-0.1918855262389131" ORDER="213" O_E="0.0" SE="0.6029030299244345" STUDY_ID="STD-SHEP_x002d_PS-1986" TOTAL_1="70" TOTAL_2="15" VAR="0.3634920634920635" WEIGHT="1.3733869742180154"/>
<DICH_DATA CI_END="1.4036209310808507" CI_START="0.34380320149647986" EFFECT_SIZE="0.694672131147541" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.1472498358793158" LOG_CI_START="-0.4636900834785727" LOG_EFFECT_SIZE="-0.15822012379962844" ORDER="209" O_E="0.0" SE="0.3588691328321983" STUDY_ID="STD-STOP-1991" TOTAL_1="122" TOTAL_2="113" VAR="0.128787054499734" WEIGHT="4.617474503794389"/>
<DICH_DATA CI_END="1.4107078298206295" CI_START="0.6458864164022124" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" LOG_CI_END="0.14943707680496576" LOG_CI_START="-0.18984384898153964" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="210" O_E="0.0" SE="0.19929529527466203" STUDY_ID="STD-Syst_x002d_Eur-1991" TOTAL_1="231" TOTAL_2="210" VAR="0.03971861471861472" WEIGHT="11.647318103345526"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-11-08 21:41:02 -0800" MODIFIED_BY="James M Wright" NO="3">
<NAME>Antihypertensive drug therapy vs control in elderly with ISH</NAME>
<DICH_OUTCOME CHI2="0.38016388364857645" CI_END="1.0120312020234712" CI_START="0.7670512981225546" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8810674476183039" ESTIMABLE="YES" EVENTS_1="368" EVENTS_2="386" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.005193902481766103" LOG_CI_START="-0.11517559074908812" LOG_EFFECT_SIZE="-0.054990844133661045" METHOD="MH" MODIFIED="2010-11-08 21:40:26 -0800" MODIFIED_BY="James M Wright" NO="1" P_CHI2="0.8268914298564916" P_Q="0.0" P_Z="0.07332211525826211" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5206" TOTAL_2="4776" WEIGHT="100.00000000000001" Z="1.7908204327939163">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.38016388364857645" CI_END="1.0120312020234712" CI_START="0.7670512981225546" DF="2" EFFECT_SIZE="0.8810674476183039" ESTIMABLE="YES" EVENTS_1="368" EVENTS_2="386" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.005193902481766103" LOG_CI_START="-0.11517559074908812" LOG_EFFECT_SIZE="-0.054990844133661045" MODIFIED="2009-04-28 10:49:48 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8268914298564916" P_Z="0.07332211525826211" STUDIES="3" TAU2="0.0" TOTAL_1="5206" TOTAL_2="4776" WEIGHT="100.00000000000001" Z="1.7908204327939163">
<NAME>Elderly 60 years or older</NAME>
<DICH_DATA CI_END="1.051271697627692" CI_START="0.7406522052221349" EFFECT_SIZE="0.8823982667342267" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="242" LOG_CI_END="0.021714972480386743" LOG_CI_START="-0.13038567975505835" LOG_EFFECT_SIZE="-0.05433535363733579" ORDER="430" O_E="0.0" SE="0.08934467603347182" STUDY_ID="STD-SHEP-1991" TOTAL_1="2365" TOTAL_2="2371" VAR="0.007982471135526033" WEIGHT="61.51579851482745"/>
<DICH_DATA CI_END="2.456393076350673" CI_START="0.5056454114635981" EFFECT_SIZE="1.1144792002579813" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="7" LOG_CI_END="0.3902978645988559" LOG_CI_START="-0.2961539294597973" LOG_EFFECT_SIZE="0.04707196756952929" ORDER="432" O_E="0.0" SE="0.4032251818212355" STUDY_ID="STD-SHEP_x002d_PS-1986" TOTAL_1="443" TOTAL_2="108" VAR="0.16259054725476846" WEIGHT="2.8648508448337444"/>
<DICH_DATA CI_END="1.0895981143882563" CI_START="0.6787758440125136" EFFECT_SIZE="0.8599958602972063" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="137" LOG_CI_END="0.0372663429979648" LOG_CI_START="-0.16827362156759007" LOG_EFFECT_SIZE="-0.06550363928481263" ORDER="431" O_E="0.0" SE="0.12073519262504062" STUDY_ID="STD-Syst_x002d_Eur-1991" TOTAL_1="2398" TOTAL_2="2297" VAR="0.014576986738205662" WEIGHT="35.619350640338816"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5599318491836406" CI_END="0.7510602605251886" CI_START="0.6111822475125044" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6775209945419491" ESTIMABLE="YES" EVENTS_1="539" EVENTS_2="749" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.12432521643971423" LOG_CI_START="-0.21382926882917344" LOG_EFFECT_SIZE="-0.1690772426344438" METHOD="MH" MODIFIED="2010-11-08 21:41:02 -0800" MODIFIED_BY="James M Wright" NO="2" P_CHI2="0.7558095164812128" P_Q="0.0" P_Z="1.312266308356377E-13" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5206" TOTAL_2="4776" WEIGHT="100.0" Z="7.404922957608499">
<NAME>Cardiovascular morbidity and mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5599318491836406" CI_END="0.7510602605251886" CI_START="0.6111822475125044" DF="2" EFFECT_SIZE="0.6775209945419491" ESTIMABLE="YES" EVENTS_1="539" EVENTS_2="749" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-0.12432521643971423" LOG_CI_START="-0.21382926882917344" LOG_EFFECT_SIZE="-0.1690772426344438" MODIFIED="2009-04-28 10:49:48 -0700" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7558095164812128" P_Z="1.312266308356377E-13" STUDIES="3" TAU2="0.0" TOTAL_1="5206" TOTAL_2="4776" WEIGHT="100.0" Z="7.404922957608499">
<NAME>Elderly 60 years or older</NAME>
<DICH_DATA CI_END="0.7562363333285496" CI_START="0.5906915531469225" EFFECT_SIZE="0.6683579985905568" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="519" LOG_CI_END="-0.12134246082030561" LOG_CI_START="-0.22863923948234124" LOG_EFFECT_SIZE="-0.17499085015132343" ORDER="467" O_E="0.0" SE="0.06302665891370006" STUDY_ID="STD-SHEP-1991" TOTAL_1="2365" TOTAL_2="2371" VAR="0.003972359733823888" WEIGHT="68.06852965622161"/>
<DICH_DATA CI_END="1.035311974335561" CI_START="0.31896323682018957" EFFECT_SIZE="0.5746533376330216" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="14" LOG_CI_END="0.01507123705546962" LOG_CI_START="-0.49625937012841037" LOG_EFFECT_SIZE="-0.24059406653647036" ORDER="468" O_E="0.0" SE="0.3003581297871382" STUDY_ID="STD-SHEP_x002d_PS-1986" TOTAL_1="443" TOTAL_2="108" VAR="0.09021500612922735" WEIGHT="2.956240233988121"/>
<DICH_DATA CI_END="0.8634042126432446" CI_START="0.5830985112289443" EFFECT_SIZE="0.7095419022024526" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="216" LOG_CI_END="-0.06378583670447653" LOG_CI_START="-0.2342580674211434" LOG_EFFECT_SIZE="-0.14902195206280994" ORDER="466" O_E="0.0" SE="0.10013623217412158" STUDY_ID="STD-Syst_x002d_Eur-1991" TOTAL_1="2398" TOTAL_2="2297" VAR="0.010027264994029582" WEIGHT="28.975230109790267"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.424301685852887" CI_END="2.002564079204525" CI_START="1.452425026203059" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7054542460036672" ESTIMABLE="YES" EVENTS_1="372" EVENTS_2="215" I2="54.79512605582064" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.30158642178482814" LOG_CI_START="0.16209372347429815" LOG_EFFECT_SIZE="0.23184007262956316" METHOD="MH" MODIFIED="2009-08-11 10:45:36 -0700" MODIFIED_BY="James M Wright" NO="3" P_CHI2="0.10946505202150303" P_Q="0.0" P_Z="7.268460539392284E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3620" TOTAL_2="3294" WEIGHT="100.0" Z="6.515010434675816">
<NAME>Withdrawal due to adverse effects 60 years or older</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2198081604507824" CI_START="1.5486238700421247" EFFECT_SIZE="1.8540895081382613" ESTIMABLE="YES" EVENTS_1="307" EVENTS_2="166" LOG_CI_END="0.34631544361386507" LOG_CI_START="0.1899459490691133" LOG_EFFECT_SIZE="0.26813069634148917" ORDER="472" O_E="0.0" SE="0.09185221513706875" STUDY_ID="STD-SHEP-1991" TOTAL_1="2365" TOTAL_2="2371" VAR="0.008436829425586361" WEIGHT="76.78328105194963"/>
<DICH_DATA CI_END="4.049736641955023" CI_START="0.17978330738185613" EFFECT_SIZE="0.8532731376975169" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.6074267815690955" LOG_CI_START="-0.7452506343407839" LOG_EFFECT_SIZE="-0.06891192638584424" ORDER="474" O_E="0.0" SE="0.7945694099666614" STUDY_ID="STD-SHEP_x002d_PS-1986" TOTAL_1="443" TOTAL_2="108" VAR="0.6313405472547684" WEIGHT="1.4894339531331604"/>
<DICH_DATA CI_END="1.7970872370566968" CI_START="0.8536783557630344" EFFECT_SIZE="1.2386018237082066" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="47" LOG_CI_END="0.2545691598317067" LOG_CI_START="-0.06870572957966449" LOG_EFFECT_SIZE="0.0929317151260211" ORDER="473" O_E="0.0" SE="0.18989327027675032" STUDY_ID="STD-STOP-1991" TOTAL_1="812" TOTAL_2="815" VAR="0.03605945409639894" WEIGHT="21.727284994917206"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-08 21:41:03 -0800" MODIFIED_BY="James M Wright">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-11-08 21:38:17 -0800" MODIFIED_BY="James M Wright" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antihypertensive drug therapy vs control in elderly 60 years or older, outcome: 1.1 Total mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuMAAAGQCAMAAAAz/Z5kAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAABdXElEQVR42u29C3QUx53vX7KNRpMgSycxyVpgUIQEZjR49eIQ45sT
726I77kLiP0bBt+IhwzXcOwlF63/FyIJByQSJMwmG2Xlta/ECgsBOTDgLHL433sdn2TtXSTCMgI2
GgkL4VhgC2+CzZ0x7LYaEvHv6q6qrq5+j+YhpPoem+pHVf2qqks93T2f+XaaB3BxTWjdx4eAi8/x
SaPc3FxH+UIPh1PYyFmO20FlndSNHcdzPF1UFExOuNCWgYEBR8FGhvqTPxpd0khk7ATg4KWgUTvw
blpU1knd2HE8x6fl5W2b95W8PJ/BvtbZYXjeBbOmAPl/w/2udHb+3oY5+TPh4qxZuZrjBQc/F0wJ
4z1pqRmP3Ue+VhsEj80O4A1pBrvpRitZtb2ZjI0dx3N8eHjYd+3nw8OzW6u7xWB0mzhPGop9i8Wl
QdC1rr8sKFz7t62Xbu1ouXRLOiUou4XW6tDiDLTfVTBhP+isv/LhbwMgmn7p0oBUY9fSnK3iDhCp
AzuqwamBR29twHtSJP86GLtPCILoPlFcoWzctyys2d3952LeTtRoOWuK2jyeGnsvXI9vri99+u60
N76yZG1Y6O/rGakDnkxQ5QMbom8fAdtfOwL6QFTZLWWd3xPF+12pzYcK/P3NhpEqeJI5/sHfL9ke
TCsCywuls9C/znyR7EmRoofnAXD3GgBH1jb0Kq3tWrvar9kdLs1/uhY1GmZNWZvHUWPvhTm+Iavz
5IybJdfKo/3eH6V/fcVvwmXNPjhcvkOBqqILgcx+EFZ2w6zDVWS/C4k3PUqByP9ZWJ+1GnRKiw3/
VzqnZC0HJWuklR/89il1T0pUnvHWHvzRfzdjF0zW1TUEtLs37ro/X2003ZvJ29h74rlKHhybQ+IC
6ZKiZeBWpXwhA/+B01K6ztsA8G6UFe93IU/mb9Dn6MnbeFshfRFZQO9JzfX4SxfRUumS7QXV8qw4
Wcjs7hIHKulCqWrzeGrsvfPssMLj8QTOVTZ42s13j+XDInpMWcg0zZKZ2gHwbwc1yt9h2du9mfXw
I/2RJWuDmt2RsoWe0Hho83hq7L0wx9vgOXXJ4Z09HdIY3e2uzOkHIOebYXk7PuWi3W0ou7zfjbwb
QG11z4zWndnN53eE/mReObXvnPy0BRjsSa6yD/Svlhf+6Ojjr8gLr9RJNx/M7hmHpPsT3OjUtXkc
NXacz/Hp8ikW9r9xW61/FSjM3L6h42IdmH/xg0blGgUqHe+WN22QCsn7XalMOtv431+XD9Ye2D7/
vj3qR4K/qj5dWWL3JF2rMs/IZ8L65bfW7Zbb8UT7+Qp6988OnHn/p0sOhkmjU9fm8dPYtHuHV8kd
Qv/KC8qabrfZqqMAAAyZBx6HY2G1Zxw1OtWNTeNMFtcEF+dVuPgc5+Lic5yLi89xLq7xMseNAeru
HNs7Z7pc98Hx2dWktMs2yJQpsbRoCqSrhVlWlZkcL8NDirf15ORMn5n4QTFmwzVEuWUzHZP99nP8
lDgwYEAyCU/esP4+RVtOeLJxbCMiPA+p8YpYiloh59p2JSUIaJkdBhEYpQWPj3Brlt1ISU2DnF6X
SI1p2m+lQ9BDEGvUeroy4+MVfX5gYF5YIbal+iLp4g5pY/oTaKf/gw9+MxgWnp8dy48+ukRYLLKY
GgiZko2IReo6JMXDxmw4TZS3DgzkBVG/MsJCq1gkVd3yAPpjQGR/V4w/JaDm+NkFFQW9NQbs9Qbr
KnA5h9nt1QaO5n3lRZOdlmS4Djmnc29IfpC0/n7QB84D4cJKtMU7+6h+pJhwbeCktH5OdwjS2NZr
KjM6AEL16yd635e/VHkkO7sGHPT1bg+CI77Dys6m3R6PZ44ftA3HdqD6OwHoO6nfTmEnu/PyDvgp
jBwi4nhwqHPBuuCcp8ulGdz2rezsLHDuv+c/3gi6tpxQ5pdK9o/5PC617GrZGsRmb6uGMLb0R7lF
nN4EwL6lUgO6FAw42irmSWcDQca61XKkCEjvFjOOykWrp60IK/lwIZRJ3phx1LhNG3wlw9dKcUgj
MjxUJYpGnDFGzv0onJJbYc5TEaRYmuFh8Juw2FSIQ+zsJCMjjZQh7b4BRDtBZKPVYVNaDyvr/kI1
iFbtRNXj44UkNj29qqz5vLTd9ztBWAPSCwszQdfeQ2hnMeQBr4zhrHSM+VPUyz88vAqy4dGqp8Ng
3wrpk+TSJemDRTpTz1P5QuGCr/jKdvlb/VWC8Fs/mPGhLz9S1iGToCrZH6seUBcLweGi+gDwZN6s
8oGmfAA254PotJu7Z6yThmjtgyCyctFxOMWn3fxK9bqFF8Dmm/VPU+VwEQDOrP7u95Z3PgWLfnSy
Ts53FxfCmTbfDMJMxg3vPz+js9S31gOEFz3RaY8oZPjN+odlMlxqnZD1yAnR6tc4uI1K7tq+np11
KQlSsKRTeBFE+6M+Hw7xl2hQ4ciAM/NJOPo8/q2fHQPMB0n0a18ADfQfWl8uGIKVFa+qbzjyP0Mv
KtU/go4XUZ+S3O1f8S+/kKbMGzn3bRnq9KNdxWP7zV7RkubwDO93v0dvC+do2VgRNvPuNZB1asH7
ofmdx2vuOzGj7BjoqKxY+gzdHQAuywV3fql5FfD0zdi4uwaTuITsj8N5PLt3yYXyCqCw1xuUz7zw
zfW71mRC5ulX4b7fyB+40qZrG6veC8tYd0Ath4tIfxBv7u0Cfbgowr9xIZRpg5LJpFWB91cBf+Z5
6fxXbkyGD4O1ayx6hdso50bMeSqCZC+72fd6rjQWmX4SQh1UAExod3/ze7MO766Sljq8kuSPu/+U
pvl7iy4fGJBH09sIais7cPVq1bI8VWd2HKiUFjJy510tCIJNvzx46tPdI9Pi8zOEtOVSwGKIUIVg
M+Ub6O0ffPCMZpAHBpRgpdvOzF8YiFyG1yh9wrd9devOkkzeimjdw/OlCwLvF298uHwFKOtNOzH9
nX3fkWskZH9c7jnL3j4C9gf17LU0ktkr+s8f+qqfXNQUSUeLsNq4HBlZP/BIf5bk0lDOhwsZZNIp
a9BzGWQ19/cdLQ4YkeHef4wuF62fSeBwwxRznoIgnv5v5KVnHq2EEwGFoC+azWj3kujN11+XD/A3
Pvc5Lxy1rMZPP62lcsw7MWeOcjiyDwBfQFO9eunh3XNg+8UD8BB9vDcEpA+ORf/W45ve+Gx5kD7J
x6xvZe6sl2/bRe/nPvc5ubZOj6eXztIwZ47SR+9qAKQOnIwuLwWX5XlL/c3+pyPR7CPSlR34+LdC
pnQzUva7vC3VH/xtB7xUVMn++Dw7lP62OvFNDRClGXgXHkkIq5aAwOsYeoQfHfP05VAR5bNRziRd
8pEsqJBBJr2mK3/5YHklHEEDMvyJ0SPgOcueU200Yc6TEqQE/Db9yg//FRSyIaiRMbqKXfLxo5fg
wnM/+/TTG/UGj9PSCq9cQWf0Y6A/iKsnxwvly9ro2SNmoUtR+RnY3r5bgfolyoYzYzyfX2m+8M/y
pHjixqeffroHbc2nHwWSZsIL9waQlukb9HgupGVKDRWpfOvevjhbmQ3ZP4RnjchjHfmFwjJ5phCy
Pw5zvGtHT+gwKFfY6w0j3i9Jd8x+cPrL1TfhqGeCJQE0Vi8f7arMCBB8G5dDRUDb+Z2h+nkFhWD/
Q144k9roQjgTUDIZP1fp/7OHHz4ICqtAVrkhGS780dxCNEeNRcIpHLnCnLclPwjIXwJWSp9X0hUl
FUIzMka0+2XvCmk82zSPWtBj2gHlcSd6EgI3dwz3gpowqh4fL5xv+swprRufDoBQz5RjIF26qFjQ
eCe9U3kWkt0Oynf0dD8VZhvtXH6QZ3gdERr4nO5JY+VXtp0JSp+bdTO6q9M3XKhufUKayihfqCe3
e4GvHESP5nZvlAZLqFkfAB/NkD/2Cdkfl/P4dv/8JulCH7LX3oqLkWrpui47dPHqg5nS4fC+AgL4
sn10ednKIPWRqJTDRcCGosj8k/WB7N7MB2dlepRLe1yIZAJZIZjJ+KEBuDo01CjlBUv8xmT4XwzO
z6rzm38IkDbC3Jg535D8INIFufR3XAyKNSE0I2NAu0ubn5ldr6lqw3Tt8za0LmXp2lhXdra/DlWP
jxfOt2Pw1rrdhwEY8d9aW3EIROZLx/fx/vkKz73piHToSq+qtbvWE7NvGX6DkK/bFClbf22N9Le4
9sDh90v/j3fDkvofHaDuTP0DpQulW+G7ywdKixr9oOPdw6Dkb99/R34iTcj+mO8bPJoPwiElHaI3
yivCi++a34Tnsty1XOaRf7sTmm9y6w6rcwwNG5Hhrgpj5jzFQchu/cg4jSS8+EitTfVyQvKRQ6qw
8WycXDAEEqGW1y44Gm+ST22ncTPH0k7N9fgQqkhTn7LS0VRnXskQ2wB5veqWOH9enen3PM5bPWSw
6qrwkIP8SQhCdutHxmmkc9dr7aof0uQjh3TIsEdDiZnikZ/WOhpvNZ/aTuNmjqWdTn8jMSXnituq
c99YlvZRHOubOLIcGa54i/8OiIuLi4ufx7m43ElM6qyL6TcSmHtmwXIdD4253zHhvw4Cc3GZ634K
yhLmznr3p8esFm90/eEPf1j3L4/2X5dXHx258CpVl4C2E+37+08/few6EGa2ffrYP7469sYKJoG5
7jH94YFUncfFxrvWixi6xt9OsEwms96ytmFuQRSAjsoTPedXx6O1ZoG5uJzN8eyLAetFhC3LixhU
JuR1t/gm0IDmkcqF9UNXh2G6alG7wkZoeW0EXSuEOYVrs4Q63mAWmB9GLgu5/NCQoWt51iFQmSKv
ZZicAs0vg9mLv/+tVYHLoPwCQGQK2t2mlJqNoGuZMF9EcG0doU42mAQ+yY8jV/zuOSF0DYVBZYq8
PrkMaEBzEfzEe+QnNeERiNCiG2m0O6xxE0eFCa6tI9TJBpPA/DByxW+Oy9C19vJYS15ToHk6qNi1
rr2/PwPSlghVJru1buJSYQ2uzRLqLH1u5DjOxeV8jucaLsoigBoBlVnyWgXN5cuTNMgTdyr56d16
N3Ea19YR6uoG08BcXA7m+Kx+0DdLYY91i8pzFQW6blPBcpq8lv9RQfPsV84dDW32+bLbzxztrlyo
bFR2M27isByFa+sIdXqDYWAuLnPRz8cjL/4D+MXvL4itK9/VL8Ln0S9d/1U0Erm86fqV63vONES/
eW7Gf50ZzNz16vH/OlfaJO2W/tn92onvo99tHLv27dfyG/8EHPvDC60LDykPtJXde5RSj//t//6X
vfsGNsmFr/6v17L+ZjHMs+fC33e0rvyfr8r1sRuMAnPdY0ru8/ExfJdvbB6tAc21VLBmt9ZN3KAi
t4G57h0l97v8+2P/i4owqaKZ1S3qz+8iEW1K7Y7gfyO6CmMLzMXP43E/jxvLBgyf1Nw4V0rO45w7
5Jroc5x7M3NNdPE5zsXnOBcXn+NcXHyOc3GNkznO/iTN4idqeFe8fsXmTCSafVhdX1xHcdC1sfWe
Lp0ba5DpDwe1eUzHSBOO3hd6+OCkmeP7BgbEo+hNIBUAHBDl92zA91fk4R8vTFssGy9Gnh+QDfVw
ircnWC1SA3fgllr6UQpSVvhyBtywFnFAdGqYhyonwRwH6ZJf9GFTe3OFtrTssg9ask2DbBkYwC3H
AVrgEULvnqjOvqvJg5uND41RPbjhuL7VjZNljkfWdnpGCnPmTm1dOHduF2jZ1OkZrSoLg7bg1IO1
u+Usdx9QXiVR85ln5NhuNcXbE6zNHk9oLzzGewY9U7dZ5Tz31x5P1TG1Yd8b9IRqnbm04spxMOdB
gK9gzpdtvLJPbWRKtz33cR04i17tYKCOdz0CaTkK8Ew4XNCOXbnrV2ny4GbjQ2NUD244qq9s++2E
HK7f//73422OD0r/Z/mHhu6kFw4NDUUqOwLAu/ZZ6U/cc6ckU4FMsj9WXl/RVg6ymg+TFG9PtO4o
DsPCtxv94M6QZda7YfmtNLhhH/lB4RJHMUjld7CdseMgwHP1is23uGe/8ZK2tJDmSwOzHms0G79I
ZS3IPovfIIECZJWW/rqyzjgPHiN8aAzrQQ130GA3EhkZbBJTPMfnVJXTH+dZ8PPXW3QeLvfdLB8X
f5EzDng7/EC8uXmxWG2ZseSby/78YL1mU/ifHV1OqZUrwVwEuXt+qc2FbeSxjuXa0t4/bgguC/zA
nIOHhyHtti7AwfUB4zxmzabz4IbbN9iVPIwMNnlSPMez/uZArfqCMepTekf6/ArNQfA218zsqkwn
abIk7Dyn/KDoi+/09li+d1Bsm/JT7St1uhZ0OPysQZWTYI6DzM9bESiyLNFGzUxUetPmuryTP376
qOXnhS5AV1ONSR7UbMNDc5dpuH2DJ9w9p3djr/rDMWpCBKYVHNeWWvudwZ8duK2mSZL3uR8r15T1
d8p2nrfKeXDlQO802u7iVFmn098MocpJMMdBsobX9Vq+mqFr87kv1O1foS29qP/lv1pcs92sTE6/
6jpOAkT/RPMCIToPbjZ7aOg8OLRtg8emBx54YNzNcQDK6kT19aXwpiT67ZXw/XNX2ckGX8FRrKbJ
kydTOlS2V9bC/1sOynZQRzi0wOkUpyv3ZLoKApT3hJjLn/eZd+XCN7SlI95jYnlhnsndbdps+Jma
zgTofWSlRR652cyhofPQDc8HE1/UHA8dBUKYvEMru732KIju0AwmALl3b8PXV0v/d/2oXE3x9gRr
JgDnbkqnn2UN4ehhyz+tDdLdVb/aYKHN9z96ehzFIJWjYM6DwGfc4Syri/6s4eHhwkLpimHfSrV0
TUMJ6BPfN7mQylpRB0LS/aJcBAcQDn/Vb5YHNxsfmn0r9XlwaNsGTxCptwMhaa1oUFpob5DXjyjr
o1WdJIsAS6z3wB8aZ8GtOMXbE6xWKQps28g2ABZa5uyVTmXw7UqoYaPwPYCg01EQXDkO5jiI5ywA
82xjhOAwtReT0u1SLCETBM3yj25TmgGL4AAC1ZXWTm0e3GxyiIr19eCGk/oKPckVSGo0w3elmK3r
9yTqXRs2YR3EHUPLUFEHNTBZXMaUs+e6CWIQoHn4J1cN86C0a/N5g8KaLkZPvNyf3BMr/40Elwsd
eLHJ6kW5YF+W7Y1I99K/3MXnOBfXvTvHOXfINYmeq3Bx8TnOxTWZ5nguTnON08TIeRQGAnfSLPc9
cA+pm1We66wI6Q7ZouPHTbtsmmcS8ePC83C0unygBTIMEXGrjDJ0+SBALmb0qmA5UHlsTCWTFJHJ
8RWLrZvz42xOTFPbw+CkSzirOQ3OBrGH1HEOenjQNjf8OC5OB2L5cTw2Vvw4i/8nhR//vaxUn8ex
PeaqM9JgHFy4XDb8PrQStAXnzv2j+QQsh8I8NqaScUrI5LiKxdbN+XE2J6ap7WFw0iWS1ZQGZ4PY
Q+o4Bz08aJsbfhwX1wRi+HE8Nlb8OIP/J4ofH8/XKtntL4e7th4qGZWGM/LWSgA88F3OGCyXsyAe
G1PJKp2MyeS4isXWzflxJieBwB3A4BgxJ1lN4Wo2iD2kTghzaniUbe74cVScCUTnwWNjxY/r8P9E
iyLHU0GRa+Z4ePr06fAMtuprNXXf9XubpTl+9EFp9MM9M/TnQJnHxlQyTg247QQMmT0/ToRpalsY
nHQJZ40JrraB1PXD44ofp4prAlF5TMdGw5gnWRQ5ngqKXDPHjwmCACna7Lrjw9ulqX4+KFyohdcr
fzpPd/2h8tiYSoapntuOo1Qm2o4fJzkxBG4Pg5Mu4ay2cLUBom0HqRsMjxt+XC2uD0RevqeMjRU/
nir8f1xcq9TfuHGjTj5hZMIku6pT/Dk8XeyJvs2emxGPjalknOq47biKMNG2/DjOiWlqexicdAln
tYerdfS8LaRuNDwu+HFSnAlE58FjY8WPpwj/H5fPDle/UVFsfF5CPDamknFqhFTH80SuMNH2/DhN
T2MI3BoG1yDmOGu+4yBsDSbPSIyGxzk/Toozgeg8ZGws+PHU4P8PyBp3c7zwaz+Vx7Ivd9Ys7cFC
PDamkgmdTJDq+EqLrVvx4wzgjmlqexicIOY4a645XM0EcQCpoxJ4eGSoG21zwY+j4mwgOg8ZGyt+
XIf/T3BRpLIMiocgbzyaqQDKMnyswtftDSQr2oSpZJxiMjm+YrF1c36czYlpansYnHQJZzWnwdkg
9pA6LoGHB44r2uaGH0fFNYFYfhyPTbsFP97O4v+TiB+P6RTLkOQJJcqd8+NjaJbzIjH0VVfEFT9u
EFHHjzP4uyE/ru0i58e5xrU4P87nONc4FOfHubj4HOfi4nOci8twjo+J/U4KQG4fg83hvllOfMfZ
dMyV5zorou+Nc37c9GBNNv9xsy+vFYhc/2VcUhzJWUDbnAZnc+DmOODaSRCMnFMm3yZBUEpgddMS
hB+njcKV3LHw4/SRMuPH2R7TBwTnTyo/Pi7muOw/rp2YLSryL0Pk+i/jkuJIzgLa5jQ4mwM3xwHX
joPgohqTb8MgOMVBzEvgummIW8m9JBZ+XMPPm/DjbI/pA4LzJ5sfT9GPJHT+463StBZeCHYvFotA
VyVlZCtD5EJVUP5/X84W5a8hKY7kLKBtToMzOVRC2p5rx0Fw5YzJt0EQlJIg5iVQ3RoYXMl9MQZ+
nOXnjfhxXY+pA4LzJ4sf15iPKwtJhch1/uM+6Yxy7q2lTy6a2gb82xYGycgoEPmrQP5/9IOs1FzD
aRBv5znccO1qUY3Jt0EQPS9uXkKZ11qIW8odCz+uY8SN+HGrHieZJdeYj6vf5adijiv+4/7+IPjV
aumsfqdUGovyUjALCrAQ+fpdpXQ1yUKStYi3bQ7SHBdcu1q53uRbGwSlVJ/NS1AXDWotMHdM/LgB
P8/w47Y9vgsmJT8u+49ntzZG/m6l953X5dupyyBySdJvwwxEfpul1ZKDJDOIt30O3BwXXDupnDH5
1gfBKemzeQkkDeiNcsfCjzP8vBE/btVjnD/Z/HiK4Fq9/3hJdOeDfrAI/yo2W/ZypQ/d7a8bzYxk
IMkGiLdNDtQcl1y7Unkv40utC4JT0mfTEkhao3CU2z0/zvLzRvy4VY9J/uTbx6f6PI78x0s+2lsr
XZTKN163qSsCBSLf0Der+qTmSWsyHMkZQNuUBtflwM1xwrWjFuOijMm3PggJhoOYlsB1ayBunNs9
P87y84b8uAZVp7oH8+D8k48fx/7j7T6Fpt4JN2UNavFqKdMjSzplajl5juQsoG1Kg+ty4OY44Npx
i3FRwcyvHAchwdQ+d9rUTUPcKHcM/LiGnzfjx2lUXXOgiqn8k5AfV3Di5k9i+WF9Uh3JnaPdLhzL
nVc+hhJx4sfVbab8OEpVftygzsnBj99P3wREItI/Z//Lf4/FBEguS6UJlX0QXXOct8t9D1yU0GWN
uCqiH+VnGv/6H6zyPP6NY+Z1Ksmyysp3kzvH/5DUW089Py48egVwcU2c8zj/jQTXRJ/jnK3lmkTP
Drm4Jv4cd49BJ9ZtnH4OABw2lG2YGzdxm3XzIC46kusstkkRJ/y462ZMOn6cuJAjYhwmeQixTQos
biAMarOIt3lOkgPR1OZm4rqikporgJWbOBsEc+Pmw2DkP46aFAs/TlfD8uMUxN5cYdAEuk48Ksni
x1NkQa7nx7ELOSbG24JTD9YqRtZJgcUNhEFtFvE2z4lzENLa1ExcVxSAUxu163ZBMDduPgxG/uOo
SbHw45pqGH5chdiVbrBN0NSpNGES+Y8r/Di1z6O4jXvulGQq3xEkBRY3EAa2WcTbPCfmxwlNbWom
risKzn7jJc26XRDCjZsPg5H/uNKkmPzHGTbcAEtXu6FrAp3fflTi9iRFY0EOkmpBruPHVRdy1Xa8
72bKoQYtqO2UHyc0tTMzcblo5LGO5YZBzYJA2XDjWDTUrTQpJv9xlg3XY+mabpjWGZPFemzSWpCD
pFqQ6/hx1YUcE+M70udXaI5BCvyrtX7bjvlxQlPbmomrRdvIdDV3E2cxdifcuHwKo6Bu1KRY+HEj
NpzB0qlumNfpaFQm1j2nzI9TLuSIGA9MKziuLZR0/2rGb9s5P45panszcVy0a/O5L9TtXwGs3MTZ
ILbcODnDUlA3blIM/DjLhhtg6Wo3LOp0MioT7dkh5Mcv67L4h68yW5LtX21g7O2MH6dJ63xnQfx5
n3lXLnzDyk1ch7HbcePk84eBuuUmuefH2WqMsHTSDZs685M52VJkQa7jx6lO62zHkwOL66cG8dtm
EG/znCgHoalzzc3EmaJZw8PDhYV3LdzEdZA64cbNh8HAfxw3yT0/ztLwRlg67oYlP24/KhPtPC4u
F+9rCoINeH1D7cClS9S6dMoZWNB3S7q6fUUU/2xPQE3x9oSpf9DvD6pxtopiWUPAKifOsfbrBRmn
D0u3FqK41u6dV6io6bppELGpXDM8Bk9HlD3eDf2iuFcqOdpHmtRyuh6safTWmbVq7WJxPgwiFcHF
STUGeUhjsEb7tMcOruP8TkZlAsiAH3egpMLiFvEd5NC6cSe7GVZFlMX48+PM7THnx/X8uBMlFRa3
iO8gh4aUTnozrIooi/Hnx7Xi/Dhna7lSIM7WcnHxOc7Fxec4F5fJHHfJIbPZk4WTu2kik46hdw6C
5LqpU7Psroi6yTk/nmtQ56TzHwdd4sCAaP+dAIuRY2RZY4OdSJkbfetzaq3CXQj3znkQSwN3WQZG
4W74cXXA1d7o/McRN87C7HQZkh81ePL4j4OWNSc8npHPtMfPYGawGDlGlmmMOaEyN/pmxVqFuxDu
nfMgGltwQxkYhbvhx3GTNL1h+HHMjbMwO10G50dNSCY/nhIHctrM6QfEMKti0OPp+Mq24hA0WxrZ
RtaxpRZ5GTOyYYKmT7Lx09mFyfE+Mvek0uVc0qlJHYrunbMg+OXUNo1GI4Ryj/7VoFA8x7wzuiJ4
wJeo71nWDvyvs15arx4kw5FA+UmD4+eTZTvd7r//fleTMh6iz+NZ6FvgtBMjb3YqHuPf2rYwOLv6
k6mLV1t7jsvIcjJtrR0C28DcKjyugpXrbMH10huFu+LHDXqly2PBjZMyKL+DBsd+xjT/I3DgBZew
axVyfbtoVVYz/HJ3/a7SK77yUrGpfHrhbWDqOQ5ofvpucqa4U2CbsQp3IVdwPKrcwBbc4EoPLyi5
XfDj9IDreoOrNefGtWXuAqcNnkjX4xk5aOGA+GglwB7jkLUtH1iQbuE5jvlpDcacUDkGtlmrcBdy
AcfjyhlbcL2MjMJd8OOkSUxvqDzm3DhVhuS3bXDclWK2Nv+icnsd2dT5XiudZ550MX7B6FSn9d3W
YswJlVNgW2cV7uZE7hiOR5WnLbHLaGQU7oIfJ01iekPnMeXGqTI4v32DJ9x5PLt9/05pLKr7QH7o
Tbzxdh/wPLU6nKsByRmMHCPLGEtOuCyMvpmMrFW4Czk25ybkOWMLbnBtbWQU7oIfR01ie6OpFnPj
FC9ON5Lmx+0bPPGeHW46UiuK8z3+ZwvXBPajx0wlZzLe3/N4wcDn6SfHDEaOkWWMJSdcLCNtIQyB
m8PgZsK9cx4Ew+oW1z8U6I1yu+DH1SYxvaHzsAeJbENlaH7cvsETQgx3SJhmLdZsAjnrzbRTxJMn
RGOjwx3kkJdd8eMG9Y+JH1fSScWPU0yzlkc2oZP1ZtqRCfTnPzY63EEOedkVP25Q/5j4cSXl/DgX
1719HufcIddkuufk4uJznItrMs5x1hI7kQz5GOqOo1e4Qc4xtyjXWT43/LhjpnwS8eOK4fgs6D9+
CtLgzx9VrMdZR3I5M8uQY0ts59S1C7G+4w7cxFmK2hbtpoHrZtpc3T4I61xuXjcNdaPOxJsfJ2w9
02M6NBlPVM8k4sdlw/ErvgYA+vr7gfi6D1mPs47kUCxDji2xnVPXLqTzHbd3E2coanu0mwKulaJO
esI6lWstv/V101A36ky8+XHM1rM9pkPjZVRPkvnx36dyjgPZcLzkJhC+DQZB36P5lPU4lUEWY0WO
LbHV9XhK5ztu75uN3LdxM4kPuX0QVNRJT1incsbyW1837VCudMaN/zhpEmONbuQ/rusxHRovm1us
x1+iSCzIZf9xMXkW5Jo5LhuOF/YHxdntx8A5+fty2Xpc70iuE2uJnRghw29732yGonZDSlsZd5vm
ZJ3LHXcm7vw4UNh6pz1OKFWvOX+qZDjmx1Myx2XDcU/VYF+J/9asNwuJ9TjrSK6KIM3IEjuxluTY
8NveN1tHUTsnpVFRBz1hncrb1gfcdybe/Dhh6x312C1Vf+8/V5ENx71Fx8LlhR/t+iBArMdZR3JK
GGnGltgJtSTHht+2vtl6itoxKU2K2vaEdSq3tPw270x8+XGVrXfSY/dU/ViVCnNmg2eH/jMvA8+z
zywERtbjuiOlIM3EEjvRluTYd9zaN5ulqF2Q0qSobU9Yp3Iry2+LzsSXHycwv5Mex0DV3/PnccVw
vBBkBLxFwAhfpRzJGYYcW2I7pq5difEdz7XzzWYpakekNMqKi9r2hHUqV4OadoCGunFn4suPE5gf
99jAfxwvx0LV3+tzHBmOe6qkoSn0SXMIWY+zjuTy/ZaWISeW2C6oa+difced+2bjkg5IadY93D0/
bl83DXWjzsSbHycwP+qxkf846ap7qv5e1Ji5w6QYfbPBEoJ2j71ELPUnjh9Xthnz4xpNMn48hnNs
Moy+2WAJQbvHXiKW+hPHjyvbjPlxjTg/zsV1b5/HOXfINameq3Bx8TnOxTXx53gycXH76O5LJiRI
bIMwBv9xVTHx49oeTip+XMuJCwo+LssMF3fAZcdTKJojo3MNP+4Ga0dBnPPjuIQ91k7nQJ2IjR9X
/dfN+HF2jAzQdZJOJn6cLCicOMLHocxwcQdcdhyFozkxOtfy4y6wdhzEOT9OBsEea6dyoE7Ewo9r
/NdN+HF2jAzQdZwmkx9PBUFufK2COHEVHzfDxR1w2fETjqbhpU3E8OPOsXYcxDk/rg6CPdau5kCd
iIkfR4y4UR68TzdGenSd4vETLZGS8YakzXE9Jy7j4wZCuHgCHKytRgpHszc6d4lyGwWxFwpCSthj
7XQOpROx8uMa/3UDftx6jBCHT9JES+ctnjizcbs5znLiCB9XxeLiyXawpqJZG50zKLcrrF0J4oYf
R82yx9rZHHdj5sd1/us6ftxijDCHj9PJ9FyF5cQRPk6JxcWT7GCNotkanetQbjdYOwrigh9HJWyx
dk0O3IlY+HHGf92IH7caI4yu4zSpSj5BbvnsUI+PM7h4ch2scTR7o3Mdyu0cayddcsyP04OQb1s/
zkE6EQM/zvivG/LjNmOEOXycTprzOBHFieMnqoa4eHIdrHE0e6NznQu3c6yddMkxP05K5Nph7SQH
ZQIeAz/O+q8b8uP0NvoI0ug6TifRHGc58Q3U7ZUJLp5cB2sczbnROWuV7iKI8yK4hD3WjnNQJuCx
8OOs/7ohP854khug6ySd4HLLHbK4eJItx2OO6qaAexLecQlNjgT7j1vw49phnOj8OGdr73EdeLFp
jdX+fVm2J+rupX+5i89xLq57d45z7pBrcj5X4eLic5yLa8LMcScwtY4pj3crSXB7UDvXuKgDwtsN
YW4czIrYtgmY66xdTvhxNzC7nHVS8eMyktwlBlVyvEscGBB98PXiAwPz5K/iWmfjb+RYNtvIHTs+
wpwzZqJpFprJiWLjHJhzxzU4CIKLmtPgOAgbzDyIkUN5gvhxQvYzZujjxX8corW/v//3KZrjAPR3
Sv9AkrktOHUnBBla1pzweEY+Ay2bOj2jVWXQQ3+znAmKZbMN3bHjIsw7YyaaZqG1wrFxDsy5E+dy
+yCkclMaHAdhg5kHMXIoTxA/jnvMmqGPE//x1F+rHJYmcRNc8NwJLIFg8oZVAGR9FKnsCADv2mel
P/e+2S/hrzUZNtvMHTsOQpwzYaJpFlorHJvkUDh3J6Q0zkKKmtLgOAgbzDyIgUN5ovhx3GPWDD3V
/uNQFC2eKv/xtkfOB8HRnQqlc+6k9E8W+s5YpjC8Reels3xg+3n7c3S8Xa0R52zPjbOxiS26A1Ka
yWJJg+Mg2o5aBdE5lCeIH8c9dkjQJ81/XD5rqLR4yvzHm1/pE759eAMAG8pF6NqLP3fVz9/I6yuz
qzo1NWCq2dIde2yiOee7Nnm1sTHn7oCUZrNY0eA4iDaYVRBjh/IE8OO4x87M0Cef/3jaV4+FZ15q
g9fjIbiekaNsV4fhaHTnd5p+pb3mxFSzmTv22IU5Z1tuXBcbc+4OSGk2iwUNjoMwwSyCGDiUJ4gf
Rz12ZoaefP/x1F+PF55/TLkX9zzRXhMG+RfRDXcU3sREv70yenx3d8eRfi3Bg6lmE3fsOH3MZTrh
xtnYxBYdOCKl2Sz51kEMOmoSxMChPEH8OO6xIzP0VPiPw59IPJBcv0PtHM+umocH75kPV4Ps9v3w
6VZ1dnvtURDd8cjK8G92ffzxunZ0u8Ow2Sbu2HEQ4pxVbhzbeeuuN0hslAPbojsgpUkWVDTXjAbH
QXTBTIPoHMoTyI9jsp8KpTlak9B/nPr16GhVp2ck7BnN7IRLnl8D6Z8jMEuDkhYNel5pgBl/Pa8T
JgLct97jaZdGFG5A6WgV3N7piaNalUZ4RrcpKY6sE4mNc/RK51XfoFqDgyC46FkA5hn2AgfRBTMN
Qg9JCLa7vZh0pn2hVEEmCJo1C/cZFsEjLVDD29qpzYN7TIfSHK1isqx2oNCTXIGkRrPlDh0Q24lH
yXXUuuuiDgqyWRLuWJ4gflybifuP2/uPO7D8HoMruEOxJufui0Zc+XyPLZar7PH3H9dm4v7jnB/n
SoE4P87Fxec4Fxef41xciZvjqTEmv1dkNiq5sRY39x+3CqE5SJPNf7x1dmz1mBmUm6PeYxDNT9sK
U9TNFYkOYl+CBr0Rn27Hj9MDiItb8eOAcV5Xu6NS/fjg4HKTy3+8a4/T7rZofwZhZlBujnqPQRp+
2kaYotbS1AkJYl9CYwqu8Ol2/Dg9gLi4FT/OOq9j0VQ/PjioXAr48aR6kGuvVSJlewJAqArK/+/L
2eKDZ5sV0l/8vqMtYsWsLfBnLtFWMeMo6KqsnR1WFmWZGJRboN5jEMNPWwlT1AxNnZAgtiW0oLfM
p9vx4/QAkuKW/LjWeZ1Iw4orB8eJj7s7iQ7lJq8Y3zkeXik7g72q/D/6QdZBkHZi5M1OaXn5tZ79
l7KPHAoK1U1Tf7k86N+2MDhbWTSsl4DbCdLB9c684BBFHZsfucsg9iVo0Fvh0235cZPipvy4RU8J
K44PjiMe340cf5fvIq8nrnN8w/Z/1vyOZf2uUrBoVVYz/KK3ob44s6E+8BEQ3wreWdRal+UrL0WL
dBG9QXlipOenjYUpamc09RiDOCuBQW/Epzvhx/XFzflx856qrDh9cO6CCS/N9fiJv66hpuVt+COg
A+KjlXAZTn7lD+AaPBFI/19WFynpDMoTIoafNp+liKJ2RlOPMYiDEjTojfl0G37csLg5P27eU4oV
xwfHAY+fICXVg1z7G4m1H6JhuP119Mm3qfO9VoNPPcNF+USuNShPkLT8tLkwRe2Iph5rEPsSLAAv
8+nW/LhxcXN+3LSnFCtO3OPtefwJdx6Xzi2/Oy99fG7om1V9UtkwCPJDb2oHerQRhI6vBLf7yKLy
pNXQoNwc9R6LGH7a4gIWW4QTP/IEBrEvoQG9cxGfbs2P09w3KW7Bj+uc1xE/TlhxmjG39XGfeHN8
g3Q33ntmp3d17aU30C34nGcL1wT207eVWd3HxPmP14OSMxkfokX5bGRiUI63x1Ws/3ZC5D6IfQna
FBx5kdv5j9O+4bi4lf+4UTlZ/YN+f1BeV93jHfu439Oy58eHHCDOdP7YUe/JIB0M7mpwDQbV3H8c
X6Cft6hHTic6P277Xf4QcDdXh4bYBS6j4cGLQ7EWR3pw327Lwe6vsapHTvteXDGhx5zz41zJF+fH
ubj4HOfi4nOci8twjttQyN1hOrG6+891VN8Y5LzmpGDsjo3XTX3CY26luf+4lRt6Lr0wifhxsG9g
QLTySzvdj5MfGmVLCkLeTNfsQKhP7trgFjlHQeyN12mHcrTshh/Hy/Q2lh8no69lyjVlSDNQwycP
Px5Z2+kZsZoJ6SR50ihbMhByhY1WPbbt1LJn0DN1m8s2uEXOcRB743XaoRwtu+HH8bKmNww/jkdf
y5Rry+BmoIanwn/890kkyKk5Pij9n+UH+3JaFGScwsejraJyhgo9JQ/buX6w72irKI1aZKtYvU05
XyQBIccUOPbYtpPw7UY/uDPkrg1ukXMSxN7Om3YoV5bd8ONkmemNkUe5jg2ny6BmkIYnUwoSriHI
kzjH51SVw8k6+sFw75urNfi4UP1yQXgZHM35X5W/+h2BRPk7vYeDQs3bU+d977Jh1fFHyDEb7bhm
8ebmxWJ1bEEcI+d0EDs7b9qhXF52xY+byYgDt2TDlWbEMjpjFvKCI4tJ8CGn5njW3xyola5yb/9g
V9k/3gzT+LjY1Hi1tFQ6mjXr1Zm1/idlrZ3iW4furGvX1JhAhByz0S5q/uI7vT0VMQVxgZyTIHZ2
3rRDOVp2y4+bXtMwo09tM2+G+9G51+85vRt786TjWiAtDmvxccW/NT3wuvrFMNydriDkjBKGkBM2
2kXN9XfKdp6PJYgb5BwHsbXzph3K8bILftxMRh7lVmw4aYbr0YmbHkgiQa59Pl5WJyqnxxnK6Qjj
41H5icrt4LMrDc6ewgVmBBOFkGM22nnNaUtiDuIcOSdBHNl50w7l8rJzfty0AQYe5XZsuOznvgRM
ClFzPHQUCGGPP70hHD30RXwbKuPjnqqGKVNmSume95mD6BldmZPVhFYSjZATNprUbFtimdSZw8Vu
2uAeOcdBHNh5Y4dyCHHjZef8uNoLbW+MPMo129h6sJ87GZ1JM8fF5eJ9TdIn2EhBxrtn0G2ogo97
9/TfuvU1OJq/m6759M73Xl9646F25T4raQg5qdlea79ekHH6cIIwdjYIRrTNtVUUyzDojZbd8ON4
me0NzY+j0dcx5XQ9uBmk4RNbGu5QpombvxygmGYH+HjEy3xEJwEhd15zUjB2x0H0PuG5Y2yejh9n
Rt+QH9fmmVT+47Jz9Teu/4I2s7ZxyP7hP2VVF7/KTPrY3cIdP+CLxD9nMpqj9wkfa/N0/uPM6Bv6
j2vzTD7/8Sl33JQX5ozefxVwcY3f8zj/jQTXRJ/jnK3lmkTPVbi4Jv4cd8FaG2RlueUEkNsq9xxz
yYTIeZfNAPKYmxeb/7imCZOOH5ddyEGXDwjPywbZMMkjIDJeU1FzM2rclkaPQZh7tge1AQOB0+C2
02C2buK46xjVtsfaDUDvePPjyNbc0n+cjM5k5cfb8HpbcO7cP/JLydSDtbvVjXCNQs3NqHEMVcdT
mHu2B7VZCJwGtx3K3k0cdx2j2vZYuwHoHW9+HNmaW/qP41FJIT8OUsqPq/IMyfYbnjslmep3BPIa
ldWEGk8Im4zxa3tQm4XAaXDboez9x1HXVVTbDms3AL3jzY8jW3Mb/3FlVBLJj9tYisvQeBKsx9k5
jvhxEJ4+fbp8ygv3zFBOfX03ae8xaQ1nNRBiuxPDJqv4tQ2orYPAaXDbsRz6j2NU2x5r10PdcefH
FVtzQ5ExQ6OSSH7c9l3iwIkDedznOOLHwTFBEI7DDYf+dB785N2RPr8iAGZB4TWclTpWOmo8AWyy
il/bgdosBE6D247l1H9cnlrAKdbOgN5x5sexrblRd8iYETR+0vLj9Tdu3JA/o/dE34ZnpcC0guMg
cknSb8NoDWelpKPGE8AmE+7ZDtTWQeA0uO1UTv3HCaptj7Ubgd5x5sexrbn+BoWMmYrGp44fB6nk
x/W/W/MPX5Uu7+BHx4gfrQEKNSd/IBpqPFFssoxc24LaRhA4DW47klP/cYxq22PtRqB3vPlxgGzN
WVFjhkdl0vLj1AD15cpXJ0YDpqDmyiNWQ2o8IWwy4p7tQW0dBI5hbTcXRvb+40rXCapti7Ubgd7x
5sdzka25hf84GZ1Jy49vwOsbagcuXaLWlY10Vvn+xYQaTwSbjLlne1DbtKSLJwO2buK46wjVdoC1
G4De8ebHka25lf+4Wm6y8uPOpM+qo8YTQG7HXmViMXLnXR6j/7he5vw4vvg+b9ecycePO5M+q44a
TwC5HXuVicXInXdZB3onjh9XZMiPazNPPn6ci2tincc5d8g1ie45ubj4HOfimqRzPBenuZo0Kc7f
5o3KHXt/Yh4B+5wgNv9xfSDn/uO5wCTPJOLHCTneAnmHiLhVxh66fApI3puuoGAVSlYVKsdgMqGo
URoDsm0nzEbbo90Y5XZeggj3xzmkTnLaIvN0nTH4j+PimNWHYvlx3HPWf5wOzQLvk4cfJ+T4qjPS
ABxcuPw9OCcOrVRA8vk5c6e2Lpw7t0vJqkLlGEzGEDNOY0C2bYXYaHu0m6DcjksQ4f44h9RxTntk
nq4zBv9xXByz+rIYfhz3nPUfp0MzwHtK+HFFSaHIja5VsttfDndtPVQyKg1V5K2VCCQfGrqTXjiE
X+yoQuUITMYQM4GZY0C2bYXYaHu0m6DczktgYdDaOaSOcjrAsek6Y/Afx4EIq69Iy48rPdf5j1Oh
nQPvcZWWHyeAeOK4ccM5jsnxVV+rqfuu39sszfGjD/opkJwWBZXLYDKGmAnMHBOybT1xVTbaBu3G
KLfzEppxQKC1Q0gd5XSGY6t1xuQ/btgkmh/HPTfwHydlnQPvcT1BafhxAognjhs3nOOYHM+uOz68
XZrq54PChVpAQHJaClSOLpMJmIwhZpjGhGxbS2Wj7dBujHI7L0Ff9qP+OIXUSU4HOLZaZ0z+43Jx
jcc4ANqhpyH2uyah8b74O8SP/+cqhBwvyYRJdlWn+HP4p49AcloKRq5clCpgMoaYcRoLsm0jwkbb
ot0Y5XZegrrIRqC1U0hdzWmPY1N1xuI/jopj9ByL5sdxz3X+41Ro58B7opUUitzy2eHqNyqKTWYG
xsgJmIwhZhpmdo1s20tBf+3QbhrldlZCFQatHUPqZASWOK4bf3q79B/HxTF6jkQPOeH3Wf9xKrRz
4H0CnsdZFX7tp/K4mIPkKpiMIWYCM8eAbDt4Oiyz0fZoN0a5nZdg++McUicjYItj0xB3DP7jpDhG
z3FDaH4c8/uM/7iGH3cMvE+8Ob5Bd0+/ohjOcQSSA+oXJnRWBCZjiBmnMSDbdsJstC3aTVBuxyX0
/XEBqeMRsMexKYg7Bv9xXBx7jGNR/LjK7zP+43Ro58D7hFA8uUOGok4tP564RsSnfWPix6k4On6c
OQzG/Lgmz6Tix8cohqJOLT+euEbEp31j4sepODp+nDkMxvy4Jg/nx7m44qceUApSy49rMJ5uO1JH
zTADmPBIeFtPTs70mcr9fZKex+qIpNyEBsvVpObNoTK4YbIMitFY1kGLmi0rUQ7Jww8n7SH5N7+Z
2nvOU+LAgPotmvCkDamjZjj1STj6/MDAPARBiT4QSYe8UTT9CXl/9Hn/Bx/8ZjAsPD87PFKWiPEU
OqpkGgqnTHMgkSSvxzUITiGLJQ8cTvUlWqQdYTVVN2kHyiywWgx3jNoEdng7w3SWrQMDecqdZAuF
iBlUIo+OuPO2fyhZ1+O5167lpnKOn11QUdBbo3/M0krzevQKzhBa0DG7+vUTvcqLDR/Jzq4BB329
24PgiE9+yiBUN+32eDxz/KBtGJQ+G0hAN8TGu3QqMM0BuwrmHrnQGN8gJG1Z2zC3IKqm+hIdlSd6
zq9WU3WTZqDMpBYjHaNqAmDNcT+13vv9zpGn5Oc0rZXWlXhmzMjeBsCiY0mbbv8u/5e6OX4bgKtl
a4CwrRoIrZC7SO8WM46CrnX9ZUEQbRXzpBOOsrJvsbiUeuTUVhwQm55eVdZ8Xtro+50grAHphYWZ
oAvRdGJT8S4puSL/VXgbzyfgaVX2xQCdss0Bw1eHyuMdBKeRyoX1Q1eHSaovIe1Ztaj9TBCn1CbN
QJndYarFcMeoTZIu01lA3zz0XuyuddmWlYCy69cFX3F9EqfbiPxf6uZ4ITg8Dw5B05sAbJb+B2dW
fze6POjJBFW+6LR1X6neXgTkFaG/r2ekTh29Jvg1A3oMe7d/6Zfhmf6NHfdtKUM0XR+gvxjxVDUk
oV9Mc8CMAyuLahIT6jKYvVV8OkhSoxzl8ivacUpt0gyUaQBSDHdMs4lZL71Y/udbpcMTKmv42LIS
+TJzS10SZ1vOJwB8kpPCOZ7du+RCeYVyCSJfhvje3NsF+sqafav94Zvrr22sei8sr3h/lP71Fb/R
XN16qs7sOAA/GTNy510tCIJNvzx46tPdI9MMT9mJ//aYbQ4Qlj5zMlH38iL4iffIT2rCODU6e12W
2qSm1CbLgWKKUx2jNrFZ4Bd1P825C6KLFtZbVwLPTwu+E0jibPsP8k+q7jnL3j4C9lOD7fFLgyKN
zDCamEXRfnlFunu5RV/pgXTg3XNg+8UDsI6P94aAdGpY9G89vumNz5YHmfNGcqRrjvc1T+hMgo5m
OqjYta69vx+n+hwZcN71qSm1iQyURQCqGO4YtYnNItQUTQ1drAn23jwjekF50LwSmNdXDya8tM8O
150FnfDnQMTZ8y7AzwlgOk9ZPFfZ4Gmni0E+AmJCWeiaR/4Q3Nt3K1C/RNmgNVJNT3y3dM2BLGWC
YskXAGlqqle+NKoQZsUpyFUX6YEyEVUMd0wtrssiNvnvPHH2IsjIzpZuKIt86LGkQSXSkWxK7q/c
Pkf+SdEc79rREzosXbVtGPF+6SS8lTy/M1Q/TzpyOd8MF4KXj3ZVZgTkFWmsuitz+vFv4zxV0ulh
+swprRufDoBQz5RjcBKHFjTeSe/sOylfBLWD8h093U+F5RJ9TSsT0I9Z/aBvlpqyzZHWgzfjHQSl
2a+cOxra7PPhVF8iu/3M0e7KhQGcnhqowIuagTK711WL4Y6R4gZZlvwsOEs6ImWCIARAvf+U8tNP
g0qAcCjLl9TZdu0hAB66lvQTufrjixBcbfB4zgKwO7PYM1pVtA2AoMfTA8B6T690Flw5qKwImaCo
AxSPVhXjgp3yeR0+IJQKg4pBjwArksrsVnIcgVUXDY5W+QY97dL/cZcgn7wHSco0R14vGoxzEJyO
SOPk6/SQVF9i9CUAFkrhURqSRgctMgNlLKoY7hiuEaq9QZOlR/pMyDpBjkxIOnomlQigGDWz05Mc
ZSsu38CTTFl7eiJgSMMNwRXpf3pby95Ov0r5GKJGpOoum18exOvLBm1zSJroaEPOc7hhstRiOutU
afibataa23oKLz5Sa1qJ8v1G8HudSbrzzB0Ac4eS/V2+Bo7RDfeQwfYh5X9626YOdX3IuCqy7knO
cA6ZpMmJ5ijHkIuGDemX1E0Zy/rDfn3NSOeuv2ZeifKcK21GsqbbUE5SOVBFnMniSqZSwWTxOc6V
fHHfWi4uPse5uPgc5+Lic5yLz3Eursk0x7tTbRiWm8wgZgbeXPf6HBdog3FGp1PjNIO9t7F3Nl7H
ruIJCYLNvWmTb66JMce9GoNxeNBVi3Z7UrBlZwIah723sXc28eJGruIJCYLNvTUm31wT41qFGIxH
W+XfuFXWzg5LZ8wV6gkzugWutUoTIfqXYWUF7DvaKq5QMncvFovi2jjsvY29s4kXN3IVT0QQbO7N
mnxzTaTrcaG6aeovlwf92xYG/WknRt7sVHd8MnXxauCrAyD81mxlBYwuf6f3sJx59pOLprYlqp0a
323KVTxxQbgm8BwX3wreWdRal+UrLwWLVmU1k2txsal8euFt4D8fBIcq0AoA639S1topZwaDd0oT
1Eytd7bqKh7/INjc29Dkm2uiPFeBEHsJgD9zBQfERyupPeUDC9JB9it9kddXohVwu1y5XL8MvO+8
Lu5MTCsZK3DiKp6IINjcmzX55ppIc1z+2Jb/jWzqfK9V3Thv0OO5AMBXD+1+1I9XKC2yf0lUbDKw
As9PWBBs7s2YfHNNpDmeNtoIQsdXgtt9YBDkh94kOzxPrQ7nzgKgMO/7tWQFScoMZsT9JVeK97Zq
BY68uHORq3hCgmBzb8bkm2uizHF4eszqPibOf7welJzJyHi2cE2A/FTfu+fxgoHPI1tyvIKKSZln
LRW9O+P6AwjsvY29s/E6dhVPSBBs7s2afHPdq7Ljx5lftel+9ZYa5ab2h2tcYxT/jQQXn+PJuOfk
4proz1W4uPgc5+Lic9xUwvNi0T37et97uvGTUvcn5+1DudkRALr/6lVlbXfogb+Yeswuu+GKRt0v
tALQcarlHxy2YmbUYczcCLVtyqgmn23jDWviopXcd17dR5+g4IPwrjF9t/JDw+85u8SBAdGHKXSY
J/RzozAE5Zay78Ab90krQXUfrZ4XpLo3PmBRk6ZUy7PSOVjMM+QNhC0DA3gHJslR6HeKmDGybjzi
zkOLM6SsLdl8Qo+raxUWGoyBCX/SZ1CqZc0Jj2fkM0yhS3m6d3UafYWDUe7NHk9oL7oeaNkz6Jm6
jWLHKaXnAxB++uM15jXRpbp+XA/aglMP1hpB4R3vegQMImCSHIV+4vHdmjGyaTziztue+7gOnLV+
QQRX6q7HFTRcZsIxJZ6zxYe4chDZKlZv2wk0/DheO9cPS0l7gfDCuVZltkcqN6wCIOsjaRrIWc/1
R0qvfsPokhaj3HdUR2Xh241+cGeIYseRIlvE71yQJm7l6bygeU1UKeFQnfSv505JpsGPmiKVtSD7
LHrBBSbJcej1+wFoJX+5No1H3LmQ5ksDsx5r9PMpNr7meHj69OlhwonLTDimxD/IOoi4cqHm7anz
vndZ0PDjeG1ELrVMOnude6vEg8CpLER9pMtZpTyevOv3o6uN6bLYOTPjgBd9Vy/e3LxYrDa4tqh5
d86yJgD8VSXHAhY1qRJfV64w+m6WG4SG+EuaShlCkpyELhgOAw+BwGwbL8v7xw3BZYEfcBZgvM3x
Y4IgHCecOGTCVUp8VyniyvveOnRnXTvQ8uNkTS7l7w+CX60G65SLCHUOyFnhBBgeHlam8DkB6j+Y
M6uw85z6koQvvtPbU2EwYw9deaJdCldUWGpRk0470udXBEwKqJ71CFdHoT2j/bgv9o3H3PmmzXV5
J3/89FE+xcbXHK+/ceMG/EBHaDgEyClKHHHl+dgjXcuPoyJyqezWxsjfESf9DPySI5yV0nMPQmUx
pzvvcz8mF8eg/k7ZzvMWPbhsVZNOgWkFx40K5PRT74DAuLpNaOOQmDtf1P/yXy2u2c6n2Pi8HqfQ
cJYSD8tzSrjA7tGulUR3PkiuRPMvmr+Qo2VAlv6K2oPebJJm9RKR205q0so/fNWoQNps2Df0B4hI
chJavM/novGYO494j4nlhXn8Ufq4nOMYDb/dp6HEEVdeOLoyJ6uJ4cepNUiSl3y0t1aaKz3KzVj7
fumGLVRtFH6T4vSPT4WID58pXQfAN5vsWwmyljWEo4eL1X370OdDNDildaNtTSRVrjhMQ2etqAMh
6b4TVo9JchJ6cLof98VB4zF3XtNQAvrE9/lN57ia4/i9yRgNLzmT8T5FiSOu3Ht96Y2H2n1afpxa
k0qFvc0+6ciffgHNhSO1ojhffbOeqTDKvVUUyxqkCkalP5e1Xy/IOH1Y3TeqXKhnh7bf+vlL+XY1
EThc6tUv69Qu6rR2sTgfh8QkOQ79T6vVvmywbTzizltO14M1jd46PsVSLhO2lkLDjSjxiBd+mmv3
aNaaP9G+E88li63Jri3btfm8RcMs9cPP6p3GpLd1PSd9AJxtOuyu8amD6+8BjQu2dshwEU2VjC96
iwO6PfTa2Y3Mr96G3B1xTXZt2f4a04bZ6QWf45j0tmfgBfeFGpeN51N8vJ/HrSTMGb3/qk2WR6/w
oeUaJ+dx/jsgrkl6rcLFNSGfq3BxTe453jHNtcdgd5h1LoeVxFARVK7N/pmWhXP1y5p0Cp8Kk2CO
W/mPAzNO21qn+xnncljJKYuKInILjB5/EKZbXpY0W/7jaSatdQqH42WyTQ+Jc03UOa7zH0dzB00O
Y07bWuksnwIr6WMrooDz7Llz54aAkQEbZrqhngmHC9o98AvEU+SbTsdwOF7GqREkzjVRr1VU/3GF
BZftxGWIHCBOGwHkMkwOpawzfuRwp9a2HKhE+um8A3JFSl6pvLhTjoDxbCn8uUKjb1uwBTlUVmnp
ryvrpIWz33gJn50PwXUHcDhexqkGEueaLNfjiAUXZDtx2YUcKJx2hQKQyzC5klFeZ/zI4U6Nbbla
Jazku3JFSoTqlwvCy+QIKp59aiP6pYKOzqbdwQ+uD0jz9bGO5WjdORyOl1GqgcS5JsscJyw4tBNX
jMUVTvu6ApDLMLmcUVln/ch3MbblapWwkquwImVVbGq8WloqRyB4dmhBA2KcWDqbtiDvaoJfO7at
Z7BWZ3C4uiynFCTONXmeq8gsOLYTR3w2TJEx+W3s5qqsF+n8yFnbcqAh0lUqHXnPXqZO+G3FmClh
6Gzagjz6J6v9kFw594W6/fSvPJ3A4XiZbLPj07km4hxHLLixnXhYtz6k8yNnbMuBDkNHq1HdqbPj
9TpyK6qhszUW5L2PQMDWn/eZd+XCN6jSDuBwvExSO0icayLOccyCK3bit8mPzogxObuu8yPX2pYD
wJqVo1VPVcOUKTPlCAjPDlU+unXWLCWjhs4m7uAQHxcOfxVetWQNDw8XFirXHY7hcLxMUhoS55oM
cxze+iEWXFDsxCEOjp9nIGNywKzr/MjnaGzL1SqZVe+e/lu3viZHQHi2CM5cunTp80YNRUw35Lul
q3t2r3M4HC+TlILEuSakjJms2OBnLXTO1GG9OnY5h8NZf3EVEudKkpLLZBl7wcVmYBbRLEYsq4y7
RVrnjeNWTYvolzXp252v8qmXNCXXC46ztVwT/TzOuUOuSfhchYuLz3EuLj7Hubj4HOfi4nOci4vP
cS4uPse5uPgc5+JznIuLz3EuLj7Hubj4HOfi4nOci4vPcS4uPse5Uq6envE7x7uJD+cMoLXIJMLb
enJypisGm6EU2vKwTTRscvyC5WpS8+ZQGTR5cx33Rl/T9IcPWtRsWYlymB5+OGkH6pvfTOkcR56e
otHr/4Qn8fsHT30Sjj4/MDBPGpUuxYAzki7uACCa/oS8P/q8/4MPfjMYFp6fHR4pS9bYCR1Vcrtx
yjQRWoLK63ENglNoCzrgo1J9iRZpR1hN1U3awTMLrBbDHaM2gR3ezjCdZevAAHq/egt1MA0qkUdH
3HnbP5SsH7PmXruWm8o5Pi0vb9u8r+TlkaPUOludFfg376EFHbOrXz/R+75s6/BIdnYNOOjr3R4E
R3yyTaFQ3bTb4/HM8YO2YVD6bLLepS023qVTgWki2FUw98iFxvgGIWnL2oa5BVE11ZfoqDzRc361
mqqbNINnJrUY6RhVEwBrjvup9d7vd448VScfwErrSjwzZmRvA2DRsaRNt3+X/0vdHB8eHvZd+/nw
sD/aKuZJJ5eudf1lQbBvsbiUOrO3FQfEpqdXlTWflzb6ficIa0B6YWEm6Np7SDmqTcW7pOSK/Ffh
bTwfTE43si8G6JRtIhi+OlQe7yA4jVQurB+6OkxSfQlpz6pF7WeCOKU2aQbPRFQx3DFqE4BGY/R6
3zxkQNa1LtuyElB2/brgK65P4nQbkf9L/fV4dNq6r1RvL4KvOq7yCf19PSN16kg1QQshZCt0t3/p
l+GZ/o0d920pa1QsePo0zsqeqoYUXY4zTQQzDqwsqklMqMtg9lbx6SBJjXJIf2AFakpt0gyeaQBS
DHdMs4lZL71Y/udbpUMWKmv42LIS+dJzS10Sj0rOJwB8kjMO5nj45vprG6veC5c1+1b7vT9K//qK
32iuZD1VZ3YcgJ+CGbnzrhYEwaZfHjz16e6RaYan7NspmeFsE4Gw9JmTifotuAh+4j3yk5owTo3O
XpelNqkptcly8JjiVMeoTWwW6AP105y7ILpoYb11JfCcteA7gSQel/8g/6T8uYo0MYugF+GwfKdy
i76qA+nAu+fA9osHpMWyj/eGgHQaWPRvPb7pjc+WB5lzROqka6L3NU/oTIKOZjqo2LWuvb8fp/oc
GXDe9akptYkMnkUAqhjuGLWJzSLUFE0NXawJ9t48I3pBedC8EpjXVw8mvAznOLyam6csnqts8LTT
+6RDmLXRs0fMkteUV82e2tt3K1C/RNlwJqidACmRrokAlGQmKJZ8AZCmpnrlg07ZCBqnIFddpAfP
RFQx3DG1uC6L2OS/88TZiyAjO1u6oSzyoceSBpVIR7epMamH5XPknxTP8ULw8tGuygzprJfzTemD
9253ZU4/aMMXAdKpYPrMKa0bnw6AUM+UY3AShxY03knv7Dsp32W1g/IdPd1PheUSfU0rk9SPWf2g
b5aask2U1oM34x0EpdmvnDsa2uzz4VRfIrv9zNHuyoUBnJ4aqMCLmsEzu9dVi+GOkeIGWZb8LDhL
OkplgiAEQL0fbjKuBAiHspJr1nvtIQAeupb8S1da7b5B6d9e6Yy3UlroAWC9kAmKOkDxaFWxkiME
OuXzOnxAeFZKKwY9AmiQy+xWchyBtRYNjlZJdSn1JUGCfPIeJCnTRHm9aDDOQXA6sk366Ov0kFRf
YvQlABZK4VEakkYMLTKDZyyqGO4YrlE+ag2aLD3SZ0LWCXK0QmC9WSUCKEbN7EzOYfJkS39sUgI8
yZS1Fxx03mTsOVv2dvpVN0x5gfXnJAaaXZQvfpLFNJGkiY425DxHruHgWRenltRNLU01aw1qRhJe
fKTWtBLlO4/g95J1nHIHwNyhZHvBWZsrDin/0wOyqUNdH9IkmlLKZ0TKpjjbxEROcEdRDHIMuWjY
kH5J3ZSxrD/s19eMdO76a+aVKI8Y0mYk7bDkJPhIGIl7enIlUz0AvkoquedxPse5ki/uW8vFxec4
Fxef41xcfI5z8TnOxTWZ5nh3qt8ln5vMIAa/S+OaEHNcQL91qzDIdTo1L/aLTlss8xQt4oD8WnO8
Dn+jlRFOUJDI8wMy4YFTrokzx705c6e2Lpw7twtvaNlJ9tnTg1Tm+OnuAyvk9HuDymvN8TrwFcz5
sj9BQWo+84wc262mXBPoWmVo6E564dDQEIi2ihlHQVdl7eywdMZcoZ4wo1vgWqs0EaJ/GVZWwL6j
reIKJXP3YrEoro3L/liZyB/5QeESah14rl65kqAgQls5yGo+TFKuiXg9LlQ3Tf3l8qB/28KgP+3E
yJud6o5Ppi5eDXx1AITfmq2sgNHl7/QeljPPfnLR1LZEtTP8zxQFevf80oMJD8I1gee4+FbwzqLW
uixfeSlYtCqrmVyLi03l0wtvA//5IDhUgVYAWP+TstZOOTMYvFOaoGZ2Leigrk3m560IFCUoiLe5
ZmZXZTpJuSbkcxUIsZcA+DNXcEB8tJLaUz6wIB1kv9IXeX0lWgG3y5XL9cvA+87r4s7EtPKUFtLN
Gl7XeyaYoCBrvzP4swO31ZRrIs5x+WNb/jeyqfO9VnXjvEGP5wIAXz20+1E/XqG0SLlpi79CC3SQ
bn7CgnjhD8GK1ZRrAs7xtNFGEDq+EtzuA4MgP/Qm2eF5anU4dxYAhXnfryUrSFJmMIP8djJeyr17
ewq8DfT9D8UnT1mHD7LD8fuVFhNEWu76Ubmack2wOQ5Pj1ndx8T5j9eDkjMZGc8Wrgnsx+dm757H
CwY+D0D2iuIAWUHFpMyzlorenXH9UURkYEHfLfiMun/Q7w+q64dEcW2HP0FBXhHFP9sTUFOue112
/DjzSzfNL7Oc/UwrEcpN7Q/XuMYo/hsJLj7Hk3HPycU10Z+rcHHxOc7Fxee4qYTnxaLwvTpi93Tj
nVwrj2Gv+3wJCyEmfY7LKDah0L2veR7vt81uuKJRN3ye3THNMbsy02nMXHrbFG0+28Yb1sQ1Ls7j
wvPwQXjXmL5b+aHh95xd4sCA6MMUOswT+rlRGIJyS9l34I37pJWguo9WzwtS3RsfsKhJU6rlWekc
LOYZ8gbCloEBvAOT5Cj0O0XMGFk3HnHnocUZUtaWbD7FxtW1CgsNxsCEP+kzKNWy5oTHM/IZptCl
PN27Oo2+wsEo92aPJ7QXnfRb9gx6pm6j2HFK6fkAhJ/+eI15TXSprh/Xg7bg1IO1RlB4x7seAYMI
mCRHoZ94fLdmjGwaj7jztuc+rgNnrV8QwZW663EFDZeZcEyJ52zxIa4cRLaK1dt2Ag0/jtfO9cNS
0l4gvHCuVZntkcoNqwDI+kiaBnLWc/2R0qvfMLqkxSj3HdVRWfh2ox/cGaLYcaTIFvE7F6SJW3k6
L2heE1VKOFQn/eu5U5JpcKURqawF2WfRSy8wSY5Dr98PQCv5y7VpPOLOhTRfGpj1WKP/3psSopWs
9zrNB5IQwmSOh6dPnx4mnLjMhGNK/IOsg4grF2renjrve5cFDT+O10bkUsuks9e5t0o8CJzKQtRH
upxVyuPJu34/utqYLoudMzMOeNF39eLNzYvFaoNri5p35yxrAsBfVXIsYFETdeheV64w+m6WG4SG
+EuaShlCkpyELhgOAw+BwGwbr1y1/3FDcFngB/ciC2DpAevUcXYMtcQphMkcPyYIwnHCiUMmXKXE
d5UirrzvrUN31rUDLT9O1uRS/v4g+NVqsE65iFDngJwVToDh4WFlCp8ToP6DObMKO8+pL0n44ju9
PRUGM/bQlSfapXBFhaUWNem0I31+RcCkgOpZj3B1FNoz2o/7Yt94zJ1v2lyXd/LHTx/llwrj61ql
/saNG/ADHaHhECCnKHHEledjj3QtP46KyKWyWxsjf0fc9TPwS45wVkrPPQiVxZzuvM/9mFwcg/o7
ZTvPW/TgslVNOgWmFRw3KpDTT70DAuPqNqGNQ2LufFH/y3+1uGY7n2Lj83qcQsNZSjwszynhArtH
u1YS3fkguRLNv2j+Qo6WAVn6K2oPerNJmtVLRG47qUkr//BVowJps2Hf0B8gIslJaPE+n4vGY+48
4j0mlhfmhfkcG49zHKPht/s0lDjiygtHV+ZkNTH8OLUGSfKSj/bWSnNFeTd6dvt+6YYtVG0UfpNy
8YRPhYgPnyldB8A3m+xbCbKWNYSjh4vVffvQ50M0OKV1o21NJFWuOExDZ62oAyHpvhNWj0lyEnpw
uh/3xUHjMXde01AC+sT377mbTo+lsYwdTIWLeuximNcw13lDLdrgMZ7j+F3KGA0vOZPxPkWJI67c
e33pjYfafVp+nFqTSoW9zT7pyJ9+Ac2FI7WiOF99s56pMMq9VRTLGqQKRqU/l7VfL8g4fVjdN6pc
qGeHtt/6+Uv5djUROFzq1S/r1C7qtHaxOB+HxCQ5Dv1Pq9W+bLBtPOLOW07XgzWN3rp777RHf1Vg
9K2ElU4NDOAvgeF3EYbvpT/w5xbeOPCrFCdfI+stdnBT6eajk7PxXwOFhhtR4hEv/DTX7tGsNX+i
fSeeSxZbk11btmvzeYuGWeqHn9U7jUlv63pO+gA423TYXeNTB9ePVS2vXVCOLzzQ8+p+7MI/6uzX
OgJScWWOZx3cBowcQh7esylk+ukW+n+uRr5UY/9Cxa61d9K0teOm0s23uB4Hpi/ekKdKxhe9xQHd
Hnrt7EbmV29D7o64Jru2bH+NacPs9ILPcUx62zPwZHShxmXj79kprvmqgP1Wwkbnng6AVe+h0+t/
KzQ2wfnY6geEZVdBdvNlJ1cqrMUOaqqm+YoecD8ILzSNFtj8bfvnJOzB8HOxF/XGVuxD/9jC3mti
vipwc5XzonzRgCbH3//jl38Ry91IxPsD+0x3z68IrHHY/BiYLO+H5NmEaZYrgOte1t3YirXB+YWe
iHlPt/3fshhsGiJfqnDwwNXaYucuGOMc55rY0nxV4O7s1ygVvYvf9Vu6KDraGcNZvOa4kw8bU4sd
ffP5HOfSSvNVgUul44sFNOd/6P5y50vr6x1mzXfafOdz3AWnjdUdZp3LYSUxVKQ8rrCWczg81yCd
wic3PkNSXxXQ3y840eP7g0LNo37Q9XQYHrDQRqN5mNsH+kwP5sGb/7mnJ+xoNrAWO0pTSfON5riV
/zgw47StdbqfcS6HlZyyqCgit8Do8QdhuuVlSbPlgWgmrXUKh+Nlsk0PiU9y0V8VUN8vOFHZ2fL7
TkOc+P+DRcX5uw3OycK1sujyz5lfSQf8/kb7SHqLHdxU3HxV95MJt/uRh8RXfjf1oQ8j2slV+q6c
Lvx89z+4Ha2lU49J/1EbYCW6inAESXvyH3rordb/0quv6sK/tJ5Z9VOlrsPPvPD234Tg8J1aVozy
dm0//lLg0P9+c9XLvzQ4xR//5NafosJ4GactL3e3es9E9v/FX/yST29lIpzJfwheR5+8Lh2QByT1
Oi+7P/+h916Vkt+/Co/lrXeNqv+DVOV1swpOOgwoBfrgmGYLbipuvuG1iuo/rrDgsp24DJEDxGkj
gFyGyeWnRPI640cOd2pty4FKpJ/OOyBXpOSVyos75QgYz5bCnys0+rYFW5DLn6alpb+urJMWzn7j
JXxyOATXHcDheBmnGkicCx+FeBQdQy1jayO7y9B/XGbBBdlOXHYhBwqnXaEA5DJMrmSU1xk/crhT
Y1uuVgkr+a5ckRKh+uWC8DI5gopnn9qInt/r6GzaHfzgeunTKPJYx3K07hwOx8so1UDiXBNSRv7j
mAWHduKKsbjCaV9XAHIZJpczKuusH/kuxrZcrRJWchVWpKyKTY1XS0vlCATPDi3A11IsnU1bkHc1
wa8d29Yz3zQ5g8PVZTmlIHGue1aho67mOGLBsZ04/mL1MjEmv42/jFXWi3R+5KxtOdAQ6SqVjm6M
qa9uhbZifJvC0Nm0BXn0T1b7Ibly7gt1++lfeTqBw/Ey2WbHp08uQdZJDN57oUa2u5vjiAU3thMP
69aHdH7kjG050GHoaDWqO3V2vF5HbkU1dLbGgrz3EfhYy5/3mXflwjeo0g7gcLxMUjtIfLLJN3Xu
XCcgRleRm82GO52GchInLd3VHMcsuGInfrtPrQcZk7PrOj9yrW05AKxZOVr1VDVMmTJTjoDw7FDl
o1tnzVIyauhs4g4OH9oKh78Kr1qyhoeHCwuV6w7HcDheJikNiXPB+3bpli2ULmYEQRf8jGzdCU+4
O6RZVX0gIxzdih7aRsrO5AXlTWAfzIuK4M3ivCmnxHnwEYS8s6u6S5wdlHe6DwUvC+DL1PA+UpUS
Xtns4noc3vohFlxQ7MQhDo6fZyBjcsCs6/zI52hsy9UqmVXvnv5bt74mR0B4tgjOXLp06fNGDUVM
N3xoK13ds3udw+F4maQUJM4lDe6UWVPA7bapP64DhYelSbuusOXPOkeuS3Os/kcP+Y+8Pfe2fC7I
PuC7vU3e1LJn6i9qwqgI3pz/5K3N+U8eA2gnqF87e1uDstN1KND6THDqvwKyT61KDo82W/7dGmmu
JxbN1SzOtawytggWeqXBsmlz9cuaNFTs4YLjIE0JeSjapX+rGjxni0czpZEVsgZDhdLW1qICnFHa
DzeNZq6f2ws6cRG8uX2hdEjW450h3yDcox1kp6GkSuR/0T61KiU82mxx/Iy/y4/tyeaQZnHIssq4
Pzt1DofjZU36TJCfwmVJc6UfXkDAm/fVh3MPVxCvG3jFu+bJQfpXOnDThv0D8wHARchm6aN2KtkJ
PP6xhFIOLdpHVZVObXb37PDelHfVmIp/yK/Gqadbi2o88N6/sO/ff14Ob6+Isl/r7We+aW+DH6AB
XIToMrVzrKH60V2eoQYnzxzniu80h9RJdvtHX/V7mw+FhYN5yjlgRrgQT3FROcl6m18+CqJhXARv
BsxOTRl3obzNp4+CHs0+Orx2s5Ee4IeTS/eZuG9t7SN/LJ0+S0D5YbAWFICiY8os+i5clFmLwg8L
lG+yN7UuBxmdflQEb0bfKis7cb1wZ8B9KFhJIDyb2keFX6vZbCj+PiCuiS5+rcLF5zgXF5/jXFx8
jnNx8TnOxcXnOBcXn+NcXHyOc/E5zsXF5zgXF5/jXFzjS/8/02sU1kRi1BQAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-11-08 21:39:31 -0800" MODIFIED_BY="James M Wright" NO="2" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Antihypertensive drug therapy vs control in very elderly 80 years or older, outcome: 2.1 Total mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtMAAAFQCAMAAABK5gLoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-11-08 21:40:27 -0800" MODIFIED_BY="James M Wright" NO="3" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Antihypertensive drug therapy vs control in elderly with ISH, outcome: 3.1 Total mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtMAAAEACAMAAABGaAofAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="cardiovascular mortality elderly May17th.bmp.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-11-01 11:19:46 -0700" MODIFIED_BY="Vijaya M Musini" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cardiovascular mortality in elderly patients with hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAty0lEQVR42u3dr5bkWB3A8RYIxAoE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</FILE>
</FIGURE>
<FIGURE FILENAME="Non-cardiovascular mortality elderly may 17th.bmp.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-11-01 11:20:11 -0700" MODIFIED_BY="Vijaya M Musini" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Non-cardiovascular mortality in elderly patients with hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAArB0lEQVR42u3dPbLrxrWA0VuOXZ6B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</FILE>
</FIGURE>
<FIGURE FILENAME="CVS mortality  in ISH may 24th 2009.bmp.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-11-01 11:21:07 -0700" MODIFIED_BY="Vijaya M Musini" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cardiovascular mortality in elderly patients with ISH</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAfHUlEQVR42u3drbLk1rmA4Q0MDeYC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</FILE>
</FIGURE>
<FIGURE FILENAME="CVS mortality in VE May 26th 2009.bmp.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2010-11-01 11:21:19 -0700" MODIFIED_BY="Vijaya M Musini" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cardiovascular mortality in the very elderly patients</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAom0lEQVR42u3dr7L0WLnA4S2ogqIQ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</FILE>
</FIGURE>
<FIGURE FILENAME="cerebrovascular mortality elderly May17th.bmp.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-11-01 11:21:37 -0700" MODIFIED_BY="Vijaya M Musini" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cerebrovascular mortality in elderly patients with hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAtxklEQVR42u3dr5IkWd344RZIxF4A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</FILE>
</FIGURE>
<FIGURE FILENAME="cerebrovascular Mortality ISH elderly may 17th.bmp.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-11-01 11:22:10 -0700" MODIFIED_BY="Vijaya M Musini" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>cerebrovascular mortality in elderly patients with isolated systolic hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAfhElEQVR42u3dq44cV7uA4QG5higg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</FILE>
</FIGURE>
<FIGURE FILENAME="cerebrovascular M in very elderly may 17th.bmp.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2010-11-01 11:22:44 -0700" MODIFIED_BY="Vijaya M Musini" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cerebrovascular mortality in the very elderly patients with hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAoIklEQVR42u3dr7LsWP3w4S0QVEGh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</FILE>
</FIGURE>
<FIGURE FILENAME="CHD mortality elderly May17th.bmp.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2010-11-01 11:23:00 -0700" MODIFIED_BY="Vijaya M Musini" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Coronary heart disease mortality in elderly patients with hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAq3klEQVR42u3dzZHr1rWA0R544IEH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</FILE>
</FIGURE>
<FIGURE FILENAME="CHD mortality in very elderly may 17th.bmp.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2010-11-01 11:23:43 -0700" MODIFIED_BY="Vijaya M Musini" NO="12" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Coronary heart disease mortality in the very elderly</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAm0ElEQVR42u3dr7PtVt3A4SMQCAQC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</FILE>
</FIGURE>
<FIGURE FILENAME="CHD mortality in ISH May 26th 2009.bmp.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2010-11-01 11:24:02 -0700" MODIFIED_BY="Vijaya M Musini" NO="13" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>CHD mortality in elderly patients with isolated systolic hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAfQklEQVR42u3drbIc1d7A4S0iEIhI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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2010-11-08 21:38:58 -0800" MODIFIED_BY="James M Wright" NO="14" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antihypertensive drug therapy vs control in elderly 60 years or older, outcome: 1.2 Cardiovascular mortality and morbidity.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuMAAAGgCAMAAAA3h5nJAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="cerebrovascular M M elderly may 17th.bmp.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2010-11-01 11:27:59 -0700" MODIFIED_BY="Vijaya M Musini" NO="15" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cerebrovascular mortality and morbidity in elderly patients with hypertension </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAuyUlEQVR42u3dP5LkSNnA4TYwMNbg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</FILE>
</FIGURE>
<FIGURE FILENAME="CHD M$M elderly May17th.bmp.png" FILE_TYPE="PNG" ID="FIG-16" MODIFIED="2010-11-01 11:28:06 -0700" MODIFIED_BY="Vijaya M Musini" NO="16" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Coronary heart disease mortality and morbidity in elderly patients with hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAArK0lEQVR42u3dPZLkWLmA4TIwMMbA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-17" MODIFIED="2010-11-08 21:40:04 -0800" MODIFIED_BY="James M Wright" NO="17" REF_ID="CMP-002.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Antihypertensive drug therapy vs control in very elderly 80 years or older, outcome: 2.2 Cardiovascular mortality and morbidity.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtMAAAFACAMAAABJMABzAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-18" MODIFIED="2010-11-08 21:41:03 -0800" MODIFIED_BY="James M Wright" NO="18" REF_ID="CMP-003.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Antihypertensive drug therapy vs control in elderly with ISH, outcome: 3.2 Cardiovascular morbidity and mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtMAAAEACAMAAABGaAofAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="cerebrovascular M M in very elderly may 17th.bmp.png" FILE_TYPE="PNG" ID="FIG-19" MODIFIED="2010-11-01 12:17:27 -0700" MODIFIED_BY="Vijaya M Musini" NO="19" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cerebrovascular mortality and morbidity in the very elderly patients with hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAm6UlEQVR42u3dr5Lk1tnA4QEBBgYB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</FILE>
</FIGURE>
<FIGURE FILENAME="CHD M M in very elderly may 17th.bmp.png" FILE_TYPE="PNG" ID="FIG-20" MODIFIED="2010-11-01 12:18:16 -0700" MODIFIED_BY="Vijaya M Musini" NO="20" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Coronary heart disease mortality and morbidity in the very elderly with hypertension</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAkxElEQVR42u3dL5cs1bnA4RGIiJDF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</FILE>
</FIGURE>
<FIGURE FILENAME="cerebrovascualr mortality iand morbidity n ISH may 24th 2009.bmp.png" FILE_TYPE="PNG" ID="FIG-21" MODIFIED="2010-11-01 12:18:57 -0700" MODIFIED_BY="Vijaya M Musini" NO="21" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cerebrovascular mortality and morbidity in elderly patients with ISH</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAfDklEQVR42u3drZIk15mA4YYGBgMN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</FILE>
</FIGURE>
<FIGURE FILENAME="CHD mortality and morbidity in ISH may 24th 2009.bmp.png" FILE_TYPE="PNG" ID="FIG-22" MODIFIED="2010-11-01 12:18:57 -0700" MODIFIED_BY="Vijaya M Musini" NO="22" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>CHD mortality and morbidity in elderly patients with ISH</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAJfCAIAAAArZrYPAAAfN0lEQVR42u3drbIc5dqA4SWQiBwA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-23" MODIFIED="2010-11-01 12:21:10 -0700" MODIFIED_BY="Vijaya M Musini" NO="23" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antihypertensive drug therapy vs control in elderly 60 years or older, outcome: 1.3 Withdrawal due to adverse effects.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtMAAACwCAMAAAD61RLeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-24" MODIFIED="2010-11-01 11:31:10 -0700" MODIFIED_BY="Vijaya M Musini" NO="24" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary of each included trial</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAQ8AAAK0CAIAAACSqC9CAABPEklEQVR42u29zav0ypbmJ97zn/TI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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-25" MODIFIED="2010-11-01 12:21:10 -0700" MODIFIED_BY="Vijaya M Musini" NO="25" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: Each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfsAAADOCAMAAAAOlVtKAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-08-11 15:49:32 -0700" MODIFIED_BY="Ciprian D Jauca">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2009-08-11 15:49:32 -0700" MODIFIED_BY="Ciprian D Jauca" NO="1">
<TITLE>Comment on the conclusion</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-08-11 15:49:32 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>While reading your interesting review in the Cochrane Library: "Pharmacotherapy for hypertension in the elderly", we were particularly interested in a statement made in the Main results of the abstract:" The average prevalence of cardiovascular risk factors, cardiovascular disease, and competing co-morbid diseases was lower among trial participants than the general population of hypertensive elderly persons." We would very much like to know how you came to that conclusion. After carefully reading the full review, we were not able to find this statement mentioned in any other part of the review. Could you please provide how you validated this statement and what references were used to validate this statement?</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2009-08-11 15:49:00 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>We have deleted that statement in the current/updated version of this review.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Saba T.A. and Berger Ch. <BR/>Fifth year Pharmacy Students<BR/>Department of pharmacology <BR/>University of Lausanne <BR/>Switzerland <BR/>We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of our criticisms.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2009-08-11 15:48:08 -0700" MODIFIED_BY="Ciprian D Jauca" NO="2">
<TITLE MODIFIED="2008-11-12 14:42:09 -0800" MODIFIED_BY="Ciprian D Jauca">Conclusions are flawed</TITLE>
<DATE_SUBMITTED>
<DATE DAY="28" MONTH="10" YEAR="2008"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-07-12 12:00:52 -0700" MODIFIED_BY="Vijaya M Musini">
<P>As stated in the title and objectives: The purpose of this SR was to provide a comprehensive overview of trial evidence regarding benefits of "anti-hypertensive drug" therapy in elders.<BR/>This systematic review can be criticized mainly because it includes the HDFP trial (in which patients were randomized to two different treatment strategies, i.e. stepped care vs. referred care. In other words, in this trial not only the type of pharmacological agents were different in both groups, but also non-pharmacological interventions. Thus, it is not possible to be certain if the difference in outcomes was due to pharmacological or to non-pharmacological interventions) and CASTEL trial (similar design as that of HDFP) and pooled these trials along with true placebo control trials. Thus, when calculating total mortality, the weight given to those two trials in combination is even greater than that given to the biggest placebo-control trial, SHEP trial. If those two trials were removed the benefit disappears. Therefore, the conclusions of this systematic review are flawed.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2009-08-11 15:48:08 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>We have excluded HDFP 1982 trial in the current/updated version of this review.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2008-11-12 14:44:43 -0800" MODIFIED_BY="Ciprian D Jauca">
<P>Marco Perez<BR/>Occupation MD/research<BR/>Department of Anesthesiology, Pharmacology &amp; Therapeutics<BR/>University of British Columbia<BR/>Vancouver, BC Canada<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2009-08-11 13:38:19 -0700" MODIFIED_BY="Ciprian D Jauca">
<APPENDIX ID="APP-01" MODIFIED="2009-08-11 13:38:19 -0700" MODIFIED_BY="Ciprian D Jauca" NO="1">
<TITLE MODIFIED="2009-08-11 13:38:16 -0700" MODIFIED_BY="Ciprian D Jauca">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-11 13:38:19 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>1 randomized controlled trial.pt.<BR/>2 controlled clinical trial.pt.<BR/>3 randomized controlled trials/<BR/>4 random allocation/<BR/>5 double blind method/<BR/>6 single-blind method/<BR/>7 or/1-6<BR/>8 animal/ not human/<BR/>9 7 not 8<BR/>10 clinical trial.pt.<BR/>11 exp clinical trials/<BR/>12 (clin$ adj25 trial$).ti,ab.<BR/>13 ((singl$ or doubl$ or treb$) adj25 (blind$ or mask$)).ti,ab.<BR/>14 placebos/<BR/>15 placebo$.ti,ab.<BR/>16 random$.ti,ab.<BR/>17 research design/<BR/>18 or/10-17<BR/>19 18 not 8<BR/>20 19 not 9<BR/>21 comparative study/<BR/>22 exp evaluation studies/<BR/>23 follow up studies/<BR/>24 prospective studies/<BR/>25 (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>26 or/21-25<BR/>27 26 not 8<BR/>28 27 not (9 or 20)<BR/>29 9 or 20 or 28<BR/>30 exp antihypertensive agents/<BR/>31 exp diuretics/<BR/>32 exp adrenergic alpha-antagonists/<BR/>33 exp adrenergic beta-antagonists/<BR/>34 exp ace inhibitors/<BR/>35 exp calcium channel blockers/<BR/>36 exp vasodilator agents/<BR/>37 losartan.tw.<BR/>39 or/30-37<BR/>40 39 and hypertension/<BR/>41 40 or hypertension/dt<BR/>42 41 and 29</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>